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Abstract 
 
In 2005 Ünver and Kaya reported that ethanolic extraction of the dried and powdered total 
plant material derived from Galanthus gracilis, a Turkish member of the Amaryllidaceae 
family, lead to the isolation of gracilamine and to which the unprecedented structure 1.1 
was assigned on the basis of extensive NMR spectroscopic and mass spectrometric 
analyses. This compound represents the first example of a pentacyclic dinitrogenous 
alkaloid isolated from the Amaryllidaceae family. It embodies five rings and seven 
stereocentres. The ethyl ester moiety associated with compound 1.1 is almost certainly an 
artifact of the isolation process, the naturally occurring alkaloid presumably being either 
another ester or the corresponding free acid. This rather complex structure together with the 
author’s previous [BSc(Hons.)] studies made its total synthesis a topic of considerable 
interest. 
 
 
Chapter One provides a brief introduction to the isolation, structural elucidation, proposed 
biogenesis, and previous total syntheses of gracilamine. It also details earlier relevant work 
carried out by the author. 
 
Chapter Two details a model study involving a Pd-catalysed intramolecular Alder-ene 
(IMAE) reaction that delivers a substrate used for testing the crucial intramolecular 
[3+2]cycloaddition process. By such means the basic framework, 2.24, of gracilamine was 
established. 
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Chapter Three outlines the difficulties encountered in efforts to extend the above-
mentioned model studies in establishing a total synthesis of gracilamine. Despite this, one 
of these “difficulties” could be parlayed in the establishment of a ten-step total synthesis of 
the racemic modification of the alkaloid (±)-3-O-demethylmacronine (1.68).  
 
 
 
Chapter Four details the completion of a total synthesis of gracilamine. The final route 
proceeded in just eleven steps and so representing the shortest route to the title alkaloid 
reported thus far in this active area of research. 
 
 
 
Chapter Five presents the experimental procedures and data underpinning all of the work 
and conclusions detailed in Chapters Two, Three and Four. 
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1. Chapter One: Introduction 
 
 
1.1.1 ISO LATIO N AND PRO PO SED BIO G ENESIS  O F GRACILAM INE  
 
In 2005 Ünver and Kaya1 reported isolating the alkaloid gracilamine (1.1) from the plant 
galanthus gracilis. The compound was obtained as a colourless, amorphous solid and its 
structure defined as shown in Figure 1.1. As such this compound represents the first 
example of a pentacyclic dinitrogenous alkaloid isolated from the Amaryllidaceae family. 
During the course of the extraction and isolation of gracilamine (1.1), 5.25 kg of dried and 
powered total plant material was extracted using 100 L of ethanol for 40 h at room 
temperature. As such, the ethyl ester moiety associated with compound 1.1 is almost 
certainly an artifact of the isolation process, the natural occurring alkaloid presumably 
being either another ester or the corresponding free acid. The structure of compound 1.1 
was initially investigated using 1H NMR spectroscopy. Two singlets appearing at δ 6.86 
ppm and 6.68 ppm in the derived spectrum are attributed to the 1,4-related aromatic protons 
while the two mutually coupled doublets (J = 1.1 Hz) at δ 5.95 ppm and 5.93 ppm are 
attributed to the geminally related and diastereotopic protons of the methylenedioxy unit. 
These signals helped to establish the substitution pattern of the aromatic ring. The 
resonances in the aliphatic region indicated the presence of six methane protons, five 
methylene units and four methyl groups with the lowest field of this last group of 
resonances suggesting the presence of a N-methyl residue. In the 13C NMR spectrum one of 
the most prominent signals was a carbonyl carbon resonance appearing at δ 175.8 ppm. 
This, when considered alongside the appearance of a strong carbonyl stretching band at 
1715 cm−1 in the IR spectrum, suggested the presence of an ester group. After detailed 
analysis involving ESI-MS, CI-MS, IR, UV and 2D NMR spectrometric and spectroscopic 
studies, structure 1.1 was proposed for gracilamine although the stereochemistry of the 2°-
hydroxyl group remain undefined at that point. In 2012, Ma and co-workers2 reported the 
first total synthesis of (±)-gracilamine and so establishing the illustrated β-configuration of 
	 2 
this group. 
  
                                         
 
 
 
 
 
 
 
 
Figure 1.1: The Flowers of the Plant Galanthus gracilis and the Structure of the Derived Alkaloid 
Gracilamine (1.1). 
 
A part of the process of elucidating the structure of gracilamine, Ünver and Kaya proposed 
the pathway shown in Figure 1.2 for its biogenesis. This starts with the fragmentation of 
the tazattine 1.2 and thus forming the isomeric aldehyde 1.3 that itself engages in a Schiff 
base condensation reaction with the amino acid lysine 1.4 to give imine 1.5. Re-
organization of this last species would give rise to an azomethine ylide 1.6 that could then 
engage in a facially selective [3+2]cycloaddition reaction with the double bond of the 
pendant hexahydroindole moiety and thus forming the carboxylic acid corresponding to 
gracilamine (1.1). The validity of the latter elements of this proposal is supported by the 
elegant work of Ma and co-workers2 who developed a biomimetic synthesis of this alkaloid 
framework. Details of this work are presented below. 
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Figure 1.2: A Possible Biogenetic Pathway Leading to Gracilamine (1.1).  
______________________________________________________ 
 
1.1.2.  TH E BIO LO G ICAL PRO PERTIES O F TH E AM ARYLLIDACEAE  
ALK ALO IDS 
 
Plants from the Amaryllidaceae family include ca. 65 genera and about 860 species. They 
are among the top twenty of the most widely applied families of medicinal plant.3 A large 
number of pharmacologically active compounds have been derived from this family 
including alkaloids, phenols, lectins and peptides.  To date around 500 structurally diverse 
alkaloids have been isolated from plants of the Amaryllidaceae family and many of them 
have shown interesting biological activities including anti-tumour, anti-viral, and anti-
inflammatory properties. Others have been shown to display immunostimulatory and 
acetylcholinesterase inhibitory activities.3 Such is their potency and efficacy that some of 
these alkaloids have been approved for clinical use (Figure 1.3). Perhaps most notably, 
galanthamine (1.7), a particularly well-known alkaloid of this class, has been employed in a 
range of countries for the treatment of Alzheimer’s disease. It shows long-acting, selective, 
reversible and competitive acetylcholinesterase inhibitory activity that lasts even after 
termination of treatment.4 Another well-known Amaryllidaceae alkaloid is pancratistatin 
ON
O A
E
C F
O A
E
CHO
A
E
HO2C NH2
6a
1.2 1.3
1.4
E
1.1 1.5
N
N
O H O
C
C
N
O
HO2C
N
AC
N
O
HO2C
HN
A
E
C
1.6
enzymatic 
rearrangement
[3+2] cycloaddition
O
O
O
O
O
O
O
O
O
O
PG PG
PG
PGPG
	 4 
(1.8). This exhibits potent apoptotic activity against cancer cells without being cytotoxic to 
healthy ones.5 In order to improve its aqueous solubility and transport to tumours (where it 
exerts anti-angiogenic effects) this has been converted into a 3,4-cyclic phosphate 
derivative that acts as a prodrug.6   Lycorine (1.9), homelycorine (1.10), trisphaeridine 
(1.11) and haemanthamine (1.12) have each been subjected to in vitro evaluation of their 
capacities to inhibit the growth of HIV-1 within the MT4 human T cell line and thus shown 
to possess high anti-retroviral activities (IC50 = 0.4-7.3 µg mL-1) as well as low therapeutic 
indices (TI50 = 1.3-1.9).3 As the first example of pentacyclic dinitrogenous alkaloid, the 
biological activities of gracilamine (1.1) would be very interesting to determine. To date 
this has not been possible because of its limited availability from natural sources. As such, 
and given its novel structural features, gracilamine (1.1) represents a very interesting target 
for total synthesis.  
______________________________________________________ 
 
 
Figure 1.3: Examples of Pharmacologically Active Amaryllidaceae Alkaloids.  
______________________________________________________ 
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1.2.1.  TH E FIRST TO TAL SYNTH ESIS  O F (±)-GRACILAM INE 
(2012) 
 
In 2012 Ma and co-workers2 reported the first total synthesis of the racemic modification of 
gracilamine that cleverly exploited the biogenetic proposals of Ünver and Kaya. As shown in 
Scheme 1.1, their route started with tyramine (1.13) and piperonal (1.14) and, following 
Node’s procedure, derivative 1.15 was generated in 87% yield over 3 steps.7 Luche-type 
reduction of compound 1.15 (to give the corresponding methylamine) and a further 
reduction with LiAlH4 followed by protection of the ensuing alcohol with TBDPSCl then 
delivered silyl ether 1.16. The seven-membered ring associated with compound 1.16 was 
cleaved with TrocCl/TEA and the resulting benzyl chloride immediately treated with 
AgNO3 in aqueous acetone to provide the corresponding benzyl alcohol 1.17 that was 
obtained in 68% yield over the two steps involved. Oxidation of compound 1.17 with the 
Dess–Martin-periodinane then furnished aldehyde 1.18, the key substrate required for 
setting up the biomimetic and intramolecular [3+2]cycloaddition reaction. 
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Scheme 1.1:  Ma’s Synthesis Part 1- 
Formation of the Precursor for the Intramolecular [3+2]Cycloaddition Reaction. 
______________________________________________________ 
 
In order to test the key step of Ünver and Kaya’s biosynthetic hypothesis (Scheme 1.2), 
condensation of aldehyde 1.18 with L-leucine ethyl ester hydrochloride salt was carried out 
and so producing the imine 1.19 required for the intramolecular [3+2]cycloaddition 
reaction.8 In the event, on heating compound 1.19 under reflux in toluene then adducts 1.20 
and 1.21 were formed in 66% combined yield with the major one, 1.21, shown to be that 
incorporating the required ABDE ring system of gracilamine. This impressive 
transformation has thus resulted in the assembly of two new rings and four stereocenters in 
a single chemical event. An intramolecular hetero-Michael addition reaction was then 
employed to establish the C-ring. Thus, two-fold deprotection of compound 1.21 using 
Zn/AcOH and TBAF afforded the corresponding amino alcohol that was subject to a Swern 
oxidation using (CF3CO)2O and DMSO and so producing the enone 1.22 (60%) embodying 
a trifluoroacetamide unit. Cleavage of the latter moiety using NaOEt in ethanol then 
delivered the cyclization product 1.23 in 64% yield. Finally, stereoselective reduction of 
the E-ring carbonyl group served to introduce the required β-configured hydroxyl group 
and, thereby, (±)-gracilamine (85%). The structure of this product was confirmed by single-
crystal X-ray analysis. Since all of the other spectral data obtained on this synthetically 
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derived material matched those reported for the “natural” product, the relative 
configuration of gracilamine was determined to be as shown in structure 1.1.  
 
Overall, Ma and co-workers achieved the first total synthesis of (±)-gracilamine (1.1) in 17 
linear steps and 4.5% overall yield.  The successful implementation of the biomimetic 
intramolecular [3+2]cycloaddition reaction strongly supports Ünver and Kaya’s proposals 
concerning the biogenesis of the gracilamine framework. 
______________________________________________________ 
 
 
Scheme 1.2: Ma’s Synthesis Part 2-Completion of Gracilamine (1.1). 
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1.2.2.  TH E SECO ND TO TAL SYNTH ESIS  O F (±)-GRACILAM INE 
(2014) 
 
In 2014 Gao and co-workers9 detailed an AE → AEB → AEBC → AEBCD ring assembly 
process involving photo-Nazarov, intramolecular hetero-Michael, and intramolecular 
Mannich reactions as key events in their synthesis of gracilamine 1.1.  
Their synthesis began with the construction of the AEBC ring skeleton (Scheme 1.3). The 
starting bromoenol triflate 1.24 was prepared using a reported three-step process10 and 
Stille coupling of this with tributyl(vinyl)stannane (1.25) followed by a two-step reaction 
sequence involving hydroboration-oxidation then protection furnished compound 1.26 in 
74% yield. Treatment of this last compound with t-BuLi followed by reaction of the lithio-
species so formed with the Weinreb amide 1.27 generated the enone 1.28 (63%), the 
substrate for the key Nazarov reaction. In the fully optimized photo-Nazarov process,11 a 
solution of compound 1.28 in dichloroethane (DCE) was irradiated with 300 nm 
wavelength light for 1.5 hours at room temperature to generate compound 1.29 (80%) 
containing the B-ring of gracilamine. In order to construct the D ring, compound 1.29 was 
converted into congener 1.30 (84%) via a deprotection and mesylation sequence. By 
applying the Saegusa-Ito oxidation condition12 to this last compound a chromatographically 
separable mixture of enones 1.31 and 1.32 was obtained in 78% combined yield. The 
unwanted regioisomer 1.31 could be easily converted into “starting material” 1.30 in 85% 
yield by treatment with NaI and conc. HCl. After protection, amination, and 1,4-addition of 
compound 1.32, ring C was successfully installed and thereby producing compound 1.33 in 
82% overall yield. Selective protection of the E-ring carbonyl group of compound 1.33 
then gave compound 1.34 in 94% yield. 
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Scheme 1.3: Gao’s Synthesis Part 1- Assembling the ABCE Rings of Gracilamine (1.1). 
______________________________________________________ 
 
Gao’s assembly of the D ring associated the gracilamine skeleton is shown in Scheme 1.4 
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corresponding O-methyl oxime that was itself hydrogenated to give amine 1.35 (d.r. = 5:1 
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cation formation (to produce 1.39) and, finally, an intramolecular Mannich annulation 
reaction that completed formation of the D ring. Reduction of the carbonyl group within 
cycloadduct 1.40 using sodium borohydride in tetrahydrofuran/water afforded a 
chromatographically separable mixture of the racemic modification of gracilamine 1.1 
(47%) and the lactone 1.41 (35%), the latter presumably arising through cyclisation of the 
α-epimer at C6. The structures of both products were confirmed by single-crystal X-ray 
analyses while the spectral data derived from the former product matched those reported by 
Ma and co-workers.2 
______________________________________________________ 
 
 
Scheme 1.4: Completion of the Synthesis of (±)-Gracilamine (1.1) by Gao and Co-workers. 
______________________________________________________ 
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1.2.3 YU’S  FO RM AL SYNTH ESIS  O F (±)-GRACILAM INE (2016) 
 
In 2016 Yu and co-workers reported a formal total synthesis of the title compound.13  They 
assembled the target in an enantioselective fashion using a Rh(I)-catalyzed 
[3+2+1]cycloaddition reaction14 to obtain an AEB-containing system associated with Gao’s 
synthesis. So, starting with the known bromide 1.42 15  this was treated with ethylene 
dibromide and lithium amide in dichloroethane16 and the cyclopropane 1.43 was thereby 
formed in 71% yield (Scheme 1.5). Reduction of the associated nitrile group using DIBAl-
H followed by aqueous work-up then provided the corresponding aldehyde that was 
converted into vinyl cyclopropane 1.44 (89%) under standard Wittig conditions. In order to 
introduce the propargyl moiety required for a Rh(I)-catalyzed [3+2+1]cycloaddition 
reaction, the bromo moiety was firstly subject to a cyanation reaction and the product 
nitrile reduced to the corresponding aldehyde 1.45 (76%). This last compound was engaged 
in a Grignard addition with ethynylmagnesium bromide and the hydroxyl group associated 
with the resulting propargylic alcohol then protected as a TBS-ether to give the target 
substrate 1.46 in 78% yield over the two steps involved.  
 
The key [3+2+1]cycloaddition was performed in the presence of 5 mol % of rhodium 
catalyst under an atmosphere of CO and N2 and so delivering the desired 5/6 ring-fused 
product 1.47 in 55% yield and as a 3:1 admixture with its diastereoisomer.i The preferential 
formation of compound 1.47 may result from the repulsion between the OTBS group and 
the vinyl moiety in the transition state leading to its isomer. The carbonyl group associated 
with enone 1.47 was reduced with lithium aluminum hydride and the resulting allylic 
alcohol treated with TBSOTf and 2,6-lutidine to provide the corresponding TBS-ether 1.48 
in 78% yield and as a ca. 16:1 mixture of C6-epimers. The exocyclic double bond within 
product 1.48 was subjected to a hydroboration-oxidation reaction using 9-BBN17 and so 
giving the corresponding primary alcohol. The associated endocyclic double bond was then 
hydrogenated using dihydrogen and Pt/C and thus affording compound 1.49 in 50% overall 
yield. This primary alcohol was then protected as the corresponding acetate and the two 
associated TBS ethers were cleaved with TBAF to afford diol 1.50 in 91% yield (over two 
																																								 																				 	
i	See the red highlight frame in Scheme 1.5.	
	 12 
steps). Diol 1.50 was oxidized with the Dess-Martin periodinane to form the corresponding 
diketone that was treated with potassium carbonate so as to generate compound 1.51 in 
59% yield (over 2 steps). The NMR spectral data acquired on this last compound matched 
those report for the same intermediate associated with Gao’s synthesis.9 As such a formal 
total synthesis of (±)-gracilamine (1.1) had been achieved.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 13 
 
 
Scheme 1.5: Yu’s Formal Synthesis of (±)-Gracilamine (1.1) Through the Acquisition of a Key 
Intermediate, 1.51, Associated with Gao’s Work.  
______________________________________________________ 
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Yu and co-workers13 were able to modify their route so as to make the same key 
intermediate in an enantioselective manner (Scheme 1.6). Thus, the previously synthesized 
and racemic propargyl alcohol 1.52 was oxidized to ketone 1.53 that then was reduced 
using the (S)-form of the CBS (Corey-Bakshi-Shibata) reagent 18  in conjunction with 
BH3•Me2S and so producing the alcohol (−)-1.52 in 98% ee. TBS-protection of this alcohol 
and engagement of the product ether (+)-1.46 in the previously performed 
[3+2+1]cycloaddition reaction gave a mixture of the (−)-trans-1.47 and (+)-cis-1.47 forms 
of the product 2-cyclohexen-1-one in a combined yield of 50%. Both of these could be 
carried forward in the production of the chiral non-racemic diketone 1.51. However, this 
second facet of the Yu group’s work is of only limited utility because it wasn’t carried 
forward to the relevant form of gracilamine and so the absolute configuration of the 
alkaloid remained undefined at this stage.    
______________________________________________________ 
 
 
Scheme 1.6: Yu’s Formal Synthesis Towards Enantiomer Pure Gracilamine (1.1). 
_____________________________________________________ 
 
O
O
OH
O
O
O
O
O
OHIBX
EtOAc
reflux
O
O
OTBS
O
O
OTBS
O
5 mol% [Rh(CO2)Cl]2
toluene
80 °C
[3+2+1] reaction
CO (0.2 atm)
O
O
OTBS
O
+
1.52 1.53 (−)−1.52
(+)−1.46(−)−trans−1.47 (+)−cis−1.47
88%
N B
O
CH3
Ph Ph
H
(S)-2-methyl-CBS
oxazoborolidine
BH3•Me2Stoluene
−30 °C 93%, 98.2% ee
77%
(−)−trans−1.47 : (+)−cis−1.47 = 3:1
37.5% 12.5%
TBSOTf
2,6-lutidine
DCM
0 °C
	 15 
1.2.4 SNYDER’S FO RM AL SYNTH ESIS  O F (±)-GRACILAM INE 
(2016)  
 
In 2016, Snyder and co-workers19 reported an elegant route to a methylene-bridged C3a-
arylated hexahydroindole embodying the AEBC-framework of (±)-gracilamine and which 
could be elaborated to an advanced intermediate associated with Gao’s total synthesis. The 
key step in this synthesis was an intramolecular Diels-Alder reaction involving a pyrone as 
the diene moiety. Thus, as shown in Scheme 1.7, the synthesis started with 4,6-
dichloropyrone (1.54) that could be readily prepared in three steps on a multigram scale.20 
Following a six-step21 sequence, an amine-containing linkage between the pyrone and AB 
ring system of the target was installed to afford compound 1.55. This was then heated at 
170 °C in toluene under microwave irradiation for 12 hours before being treated with silica 
gel in chloroform at room temperature. Under such conditions, an intermolecular pyrone-
based Diels-Alder reaction ensued and this was followed by a cycloreversion reaction 
involving the loss of CO2 and then a hydrolysis to afford tetracycle 1.57 (83%) embodying 
the AEBC-ring system of target (±)-1.1. Reduction of compound 1.57 with SmI2 and 
HMPA22 then delivered, via intermediates 1.58 and 1.59, alcohol 1.60 embodying the full 
carbocyclic framework of the target alkaloid. Salmond-type oxidation23 of alcohol 1.60 
then gave diketone 1.61 (20% overall from ketone 1.57) and the application of a one-pot 
Teoc deprotection and methylation24 reaction sequence to this last compound provided 
congener 1.33 (85%), an advanced intermediate associated with Gao’s synthesis of 
gracilamine. In an overall sense, then, the authors were able to complete a total synthesis of 
gracilamine (1.1) in 14 steps from the commercially available pyrone 1.54.  
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Scheme 1.7:  Synder’s Formal Synthesis of (±)-Gracilamine (1.1) Through the Acquisition of a Key 
Intermediate, 1.33, Associated with Gao’s Work. 
______________________________________________________ 
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1.2.5 ADRIO’S  ASYM M ETRIC SYNTH ESIS  O F TH E ABD-CO RE O F 
(±)-GRACILAM INE (2015) 
 
In 2015 by Adrio and co-workers25 reported a rather concise synthesis of a 1,2,3,3a,4,8b-
hexahydroindeno[1,2-b]pyrrole that embodies key elements of the ABD-ring system of (±)-
gracilamine (1.1). The key step in their work was the 1,3-dipolar cycloaddition of an 
azomethine ylide to an activated olefin. 26  Thus, as shown in Scheme 1.8, a 
[3+2]cycloaddition reaction between imino-ester 1.62 and diene 1.63 using copper and 
ligand 1.64 as a catalyst source led to the endo-configured pyrrolidine 1.65 which was 
obtained in 80% yield and 90% ee. Protection of the amine residue within this adduct as its 
Cbz derivative and engagement of this in a 5-exo-trig radical cyclization process using 
tributyltin hydride/2,2’-azobis(iso-butyronitrile) led to the tetracyclic derivative 1.66 in 
53% overall yield and as 1:1 mixture of diastereoisomers. By such direct means a suitably 
functionalized form of the ABD-ring system of gracilamine was assembled. 
______________________________________________________ 
 
 
Scheme 1.8: Adrio’s Enantioselective Preparation of the ABD-Core of the Alkaloid (±)-Gracilamine (1.1). 
______________________________________________________ 
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1.2.6 SUM M ARY O F PREVIO US TO TAL SYNTH ESES/FO RM AL 
TO TAL SYNTH ESES O F GARCILAM INE 
 
A summary of all the above-mentioned approaches to gracilamine (1.1) is presented in 
Figure 1.4.  Thus, as noted earlier, in 2012 Ma and co-workers2 reported that a spiro-ring 
fused cyclohexa-1,4-diene containing a tethered Schiff-base engaged in a thermally-
induced and stereoselective intramolecular [3+2]cycloaddition reaction and so giving 
compound 1.19 that incorporates the ABDE-ring system of gracilamine (1.1). An 
intramolecular hetero-Michael addition reaction was then employed to establish the final C-
ring.  In 2014 Gao and co-workers9 detailed an AE → AEB → AEBC → AEBCD ring-
assembly process involving photo-Nazarov, intramolecular hetero-Michael, and 
intramolecular Mannich reactions as key events in their synthesis of the target natural 
product. One year later, Adrio and co-workers25 reported a three-step and asymmetric 
synthesis of a 1,2,3,3a,4,8b-hexahydroindeno[1,2-b]pyrrole (1.66) that embodies key 
elements of the ABD-core of gracilamine but have not reported, at least to date, taking this 
work any further. A formal total synthesis of gracilamine was realized by Yu and co-
workers14 who assembled, in an enantioselective fashion using a Rh(I)-catalyzed 
[3+2+1]cycloaddition reaction, an AEB-containing system (compound 1.51) associated 
with Gao’s synthesis. Finally, and very recently, Snyder and co workers19 described a 
pyrone-based intramolecular Diels−Alder route to a methylene-bridged C3a-arylated 
hexahydroindole containing the AEBC-framework of (±)-gracilamine (compound 1.33) and 
that could be elaborated to an advanced intermediate associated with Gao’s total synthesis. 
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Figure 1.4: Outline of Approaches to the Synthesis of Gracilamine (1.1) Carried Out by the Groups of Ma, 
Gao, Adrio, Yu, and Synder. 
______________________________________________________ 
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The work that is described in the body of this thesis was directed towards establishing a 
total synthesis of gracilamine using the methodology that has been developed within the 
Banwell Group and involving a Pd(II)-catalysed IMAE reaction as the key step to prepare 
the C3a-arylhexahydroindole unit 1.67. Compound 1.67 was then to be employed as the 
substrate in a process mimicking the proposed biosynthetic pathway described above {and 
involving an intramolecular [3+2]cycloaddition reaction} so as to assemble the remaining 
parts of the molecular framework associated with gracilamine (1.1).  
 
Accordingly, the first part of the work reported in the remaining chapters was directed 
towards constructing, using model systems, the ABCDE ring system of gracilamine by 
using the [3+2]cycloaddition process and the second was to be focused on constructing the 
fully functionalized framework of gracilamine if the initial (model) studies were successful. 
Accordingly, Chapter Two details the author’s work involved in conducting a relevant 
“model study” while the extension of these to (±)-gracilamine (1.1) is presented in Chapters 
Three and Four. Also detailed in Chapter Three is the exploitation of some unexpected 
cyclisation reactions encountered during these studies in the synthesis of the racemic 
modification of the natural product 3-O-demethyl-macronine (1.68). The remaining parts of 
this Chapter (One) highlight the previous, relevant work undertaken by the author. 
______________________________________________________ 
 
 
Figure 1.5: Structure of Gracilamine 1.1, 3-O-Demethylmacronine (1.68) and the C3a-
Arylhexahydroindole Unit 1.67. 
______________________________________________________  
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In 2010, the author co-published27 details of a total synthesis of haemultine that emerged 
from her studies for the BSc(Hons.) degree (Scheme 1.9). So, using established 
methodolodgy, 28  the ring-fused gem-dibromocyclopropane 1.69 was subjected to an 
electrocyclic ring-opening/nucleophilic trapping sequence that led to the 
cyclohexenylamine29 1.70 in three steps.  Suzuki–Miyaura cross-coupling30 of compound 
1.70 with the commercially available aryl boronic acid 1.71 then gave the arylated 
cyclohexene 1.72 that was treated with sodium hydride then 1-bromo-2-butyne and thus 
affording the compound 1.73 required for the pivotal IMAE reaction. In the event, 
subjecting this last compound to reaction with Pd(OAc)2 and the strongly σ-donating and 
bidentate ligand N,N’-bis(benzylidene)ethylenediamine (BBEDA) gave the required and 
previously reported28 cis-C3a-arylhexahydroindole 1.75 in 94% yield. Selective oxidative 
cleavage of the exocyclic double bond associated with diene 1.75 using	 potassium 
osmate(VI) dihydrate and N-methylmorpholine N-oxide (NMO) in the presence of citric 
acid and then treatment of the resulting mixture of diastereoisomeric diols with 
phenylliodonium diacetate gave ketone 1.76 in 38% yield. Simple manipulations of this 
ketone then provided the aminoalchol 1.77 that was subjected to a Pictet-Spengler reaction 
and thus affording the racemic modification of the structure, 1.78, assigned to the natural 
product heamultine. Given that compounds 1.75, 1.76, and 1.77 associated with this 
reaction sequence all possess the same ACE core as encountered in gracilamine, the 
adaptation of these protocols to the assembly of this more complex natural product became 
the major objective of the author’s PhD studies. 
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Scheme 1.9: Total Synthesis of Haemultine. 
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Chapter Two: A Model Study Exploring the Pd-Catalysed 
IMAE Reaction and Testing the Intramolecular 
[3+2]Cycloaddition Process 
	
 
Banwell and co-workers28, 31 have reported, that the Pd(II)-catalyzed intramolecular Alder-
ene (IMAE) reaction of propargylated 1-amino-2-aryl-2-cyclohexenes allows for the 
generation of C3a-arylated hexahydroindoles 1.67 and subsequently deployed this and 
closely related processes in the synthesis of a range of natural products and natural product 
scaffolds.27, 32 
 
 
 
The basic reaction pathway associated with the synthesis of C3a-arylated hexahydroindoles 
via such an IMAE process is shown in Figure 1.6. In principle, the IMAE reaction may be 
promoted thermally or by using a transition metal such as palladium (in a lower-valent 
state).33 By such means, an N-protected and propargylated 1-amino-2-aryl-2-cyclohexene 
of the general form 2.1 is converted into a cis-3a-arylhydroindole 2.2 (corresponding to a 
protected form of 1.67) incorporating a ∆4-double bond as well as an exocyclic one at C-3. 
Provided the latter alkene can be oxidatively cleaved in a selective manner, this unit should 
serve as an intermediate in the synthesis of gracilamine (1.1). Given the geometrical 
requirements for the IMAE reaction, (Figure 1.6) the nature of the protecting group, P, at 
the nitrogen in substrate 2.1 is almost certain to be crucial to success. In particular, this 
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group must allow the nitrogen-based substituents to assume a tetrahedral geometry and, 
thereby, the alkyne to interact in the necessary fashion with the endocyclic double bond and 
the associated allylic methylene unit (of the substrate undergoing the IMAE reaction). 
Based on previous studies by Banwell and co-workers,28 the tosyl and nosyl moieties were 
chosen as the preferred protecting groups in the author’s work detailed below.   
 
 
 
Figure 1.6: Proposed Synthesis of C3a-Arylated Hexahydroindoles via an IMAE Reaction. 
(M = Pd[0]) 
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iodocyclohex-2-en-1-ol (2.7) serving as the starting material for the preparation of allylic 
amine 2.6. In this retrosynthetic plan, the IMAE and intramolecular [3+2]cycloaddition 
reactions were considered to be the key steps. 
_______________________________________________________ 
 
 
Scheme 1.10: Retrosynthetic Analysis of (±)-Gracilamine (1.1). 
_______________________________________________________ 
 
 
The preparation of a suitable C3a-arylhexahydroindole is shown in Scheme 1.11 and began 
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ensuing amine with nosyl chloride (NsCl) then gave sulfonamide 2.9 (82%).	 The nosyl 
group was chosen because of the likelihood of the associated nitrogen assuming a geometry 
that would allow for the desired IMAE to take place and, of course, because of its likely 
ready removal towards the end of the synthesis.28 
 
The cross-coupling partner 6-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)benzo[d][1,3]dioxole-
5-carboxylate required for Suzuki-Miyaura cross-coupling with iodide 2.9 was prepared 
following a previously reported procedure.36 Thus, and as shown in Scheme 1.11, piperonal 
(2.10) was treated with molecular bromine and iron filings in glacial acetic acid and the 
aryl bromide 2.1137 (87%) thereby formed in a regioselective manner. The aldehyde moiety 
associated with the latter compound was oxidized to the corresponding carboxylic acid 
using sodium chlorite and this treated with methanol in the presence of sulfuric acid.38 As a 
result, the methyl benzoate 2.12 was formed (93%) and upon subjecting this to a Miyaura 
borylation reaction using bis(neopentylglycolato)diboron in the presence of potassium 
acetate and catalytic amounts of PdCl2(dppf)•CH2Cl2 the required bis-ester 2.13 was 
obtained in 88% yield. 
 
The cross-coupling of compounds 2.9 and 2.13 under standard Suzuki−Miyaura conditions 
provided the previously reported28 and arylated cyclohexene 2.14 in 79% yield. 
Propargylation at the nitrogen within compound 2.14 was readily achieved by successive 
treatment of it with sodium hydride then 1-bromo-2-butyne and so producing compound 
2.15 (87%),28 the substrate required for the pivotal IMAE reaction. 
 
With compound 2.15 in hand it was immediately subjected to the conditions used by Trost 
and Pedregal 39  for effecting IMAE reactions. Specifically, then, it was reacted with 
Pd(OAc)2 and N,N’-bis(benzylidene)ethylenediamine (BBEDA) in refluxing toluene. As a 
result the hexahydroindole 2.16 was obtained in 68% yield after chromatographic 
purification.28 
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Scheme 1.11: The Synthetic Route Leading to the C3a-Arylated Hexahydroindole 2.16. 
_______________________________________________________ 
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With the successful assembly of the AEC ring system of gracilamine (as embodied in 
compound 2.16), the next step was to prepare of the aldehyde required for participation in 
Schiff-base condensation reaction and thus providing the substrate necessary for examining 
the intramolecular and biomimetic [3+2]cycloaddition reaction.   
 
As shown in Scheme 1.12, the required manipulation of ester 2.16 so as to generate the 
corresponding aldehyde was a very straightforward matter. This simply involved exposing 
a dichloromethane solution of the former compound to DIBAl-H at –78 °C and then 
oxidizing the product alcohol to aldehyde 2.17 (83%) using the Dess−Martin periodinane 
(DMP). By such means and over the two steps involved, compound 2.17 was obtained in 
83% yield. All of the spectral data acquired for this product were consistent with the 
assigned structure but this was finally confirmed by a single-crystal X-ray analysis. The 
derived ORTEP is shown in Figure 1.7 and other details of this analysis are presented in 
the Experimental Section (Chapter 5). 
_______________________________________________________ 
 
 
Scheme 1.12: Formation of Aldehyde 2.17 via Reduction of Ester 2.16. 
_______________________________________________________ 
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Figure 1.7: ORTEP Derived from the Single-Crystal X-ray Analysis of Compound 2.17. 
 
Given the presence of a hydroxyl group on ring E of gracilamine (1.1) efforts were made, at 
this point, to effect the allylic oxidation of compounds 2.16 and 2.17 using selenium 
dioxide (Scheme 1.13).40 However, upon exposure of either ester 2.16 or aldehyde 2.17 to 
the relevant conditions, none of the hoped-for oxidation products 2.18-2.21 was observed. 
Since combinations of manganese triacetate, tert-butylhydroperoxide and molecular 
oxygen have been reported, by Shing et al,41  to effect allylic oxidations, this reagent 
combination was examined but also to no avail. Decomposition was observed in every 
instance.  
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Scheme 1.13: Reagents and Conditions (a) Various Conditions, Including SeO2; Mn3(OAc)9,t-BuOOH, O2. 
_______________________________________________________ 
	
Despite these failures, compound 2.17 could still be used to study the viability (or 
otherwise) of the pivotal intramolecular [3+2]cycloaddition reaction. Details of the 
outcomes of the author’s efforts in this area are detailed in the following section. 	
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support for the illustrated structures followed from single-crystal X-ray analyses of each of 
them. The resulting ORTEPs are presented in Figures 1.8 and 1.9. 
_______________________________________________________ 
 
 
Scheme 1.14: Testing the Pivotal Intramolecular [3+2]Cycloaddition Reaction. 
_______________________________________________________ 
	
In both of the products, two rings and four stereocenters were generated. Compound 2.24 is 
formed as a consequence of azomethine ylide addition onto the endocyclic double bond and 
so resulting in the assembly of the full complement of rings associated with gracilamine 
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Figure 1.8: ORTEP Derived from the Single-Crystal X-ray Analysis of Compound 2.24.	
	 33 
 
 
Figure 1.9: ORTEP Derived from the Single-Crystal X-ray Analysis of Compound 2.25. 
	
The presence of an exocyclic double bond within C3a-arylated hexahydroindoles prepared 
by the route just described is an inevitable consequence of the use of the IMAE reaction to 
prepare such systems,28, 31 and the model study clearly indicates that it participates in [3 + 
2]cycloaddition reactions when the ylide is appended to the C3a aryl unit. Based on such 
observations, the excision of this group, as well as the introduction of the E-ring hydroxyl 
group of gracilamine (1.1) became the major concerns associated with the campaign 
leading to this target alkaloid. Details of the relevant studies are presented in the following 
chapters. 
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Chapter Three: Initial Studies on the "Real" System and the 
Challenges So Revealed  
 
 
One aspect of the work described in the preceding chapter was the failure to install the 
hydroxyl group associated with the E-ring of gracilamine at a late stage in the reaction 
sequence. This chapter details studies on the alternate ways investigated by the author in 
her efforts to complete a synthesis of gracilamine. The basic approach involved 
incorporating the hydroxyl functional group from the very beginning of the synthesis. Such 
an approach was inspired by the total synthesis of hamayne reported in 2011 by Banwell 
and co-workers32a) (Scheme 1.15). In this work, they started with the known42 and readily 
obtained	 tert-butyldimethylsilyl (TBS) ether 3.1, this compound being subjected	 to a ring-
closing metathesis (RCM) reaction43 using Grubbs’ first-generation catalyst.44 The ensuing 
cyclopentene was reacted with dibromocarbene generated under the Makosza conditions45 
from bromoform and sodium hydroxide in the presence of the phase-transfer catalyst 
triethylbenzylammonium chloride (TEBAC). As a result a ca. 5:1 mixture of two 
diastereoisomeric cyclopropanes of the general form 3.2 was produced with the major one 
being readily obtained in 75% yield after flash chromatography. Compound 3.2 was 
subjected to thermally induced electrocyclic ring-opening in refluxing chlorobenzene and 
upon treatment of the ensuing 2,3-dibromocyclohexane with sodium azide in N,N-
dimethylformamide the allylic azide 3.3 was obtained in 86% yield with ca. 6% of the 
corresponding and chromatographically inseparable trans-isomer accompanying it. Azide 
3.3 was treated with triphenylphosphine in methanol/water and the resulting primary amine 
reacted with nosyl chloride to give the sulfonamide 3.4 in 83% yield. Suzuki-Miyaura 
cross-coupling of compound 3.4 with commercially available boronic acid 1.71 then gave 
the arylated cyclohexane 3.5 (78%) that was N-propargylated using 1-bromo-2-butyne in 
the presence of sodium hydride. This produced, in 96% yield, the substrate, 3.6, required 
for the pivotal IMAE reaction. In the event, microwave irradiation of a benzene solution of 
alkyne 3.6 containing Pd(OAc)2 and BBEDA afforded, via the anticipated IMAE process, 
the cyclisation product 3.7 and selective reaction of this product under Upjohn conditions46 
	 35 
resulted in regioselective dihydroxylation of the more substituted double bond within diene 
3.7. Treatment of the ensuing diols with phenyliodonium diacetate in dichloromethane then 
gave ketone 3.8 in 53% yield. Subsequent deprotection, reduction and Pictet-Spengler 
cyclisation reactions followed by a saponification then delivered hamayne (3.9) in 57% 
overall yield.  
_______________________________________________________ 
 
 
Scheme 1.15: Total Synthesis of Hamayne by Banwell et al.	
______________________________________________________ 
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The synthesis of a C3a-arylhexahydroindole carrying an E-ring hydroxyl group and 
potentially suitable for elaboration to gracilamine is shown in Scheme 1.16. Thus, the 
previously	 reported32a) 6,6-dibromobicyclo[3.1.0]hexan-3-ol derivative 3.2 was converted, 
by established methods, into the Ts-N-protected or Ns-N-protected allylic amines 3.10 
(76%) and 3.4 (72%), respectively. Suzuki−Miyaura cross coupling of these last 
compounds with boronate ester 2.1336 then gave the corresponding arylated cyclohexene 
3.11 and 3.12, and these, in turn, were engaged in an N-propargylation reaction of the same 
type as used in the model study. By such means the N-linked 1,6-enynes 3.13 (89%) and 
3.14 (91%), respectively, were obtained.  
 
Compounds 3.13 and 3.14 were engaged, separately, in the required IMAE reaction using 
Pd(OAc)2 and BBEDA in refluxing toluene. When the nosyl-protected analogue 3.14 was 
reacted under these conditions, the cis-3a-arylhydroindole 3.17 was obtained in 73% and 
this was accompanied by small amounts of uncharacterised material. A less satisfying 
outcome involved the tosyl-protected analogue 3.13 as substrate and with the desired C3a-
arylhexahydroindole 3.16 now being obtained in just 47% yield under the same conditions. 
This was because it was accompanied by its cyclopropane-annulated isomer 3.15 (38%), 
the	structure of which was confirmed by single-crystal X-ray analysis (Figure 1.10).  
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Scheme 1.16: Synthesis of the C3a-Arylhexahydroindole Bearing an E-Ring Hydroxyl Group.  
_______________________________________________________ 
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Figure 1.10: ORTEP Derived from the Single-Crystal X-ray Analysis of Compound 3.15. 
 
Presumably, the cyclopropane-annulated hexahydroindole 3.15 arises through participation 
of the initially formed (and desired) cis-3a-arylhydroindole in a secondary IMAE reaction 
involving the ethylidene and endocyclic alkene units. Attempts to suppress this secondary 
process by using milder reaction conditions have, thus far, been ineffective. 
 
Compounds 3.16 and 3.17 closely resemble the cis-3a-arylhydroindole unit discussed in 
previous chapter, differing only in that they incorporate a TBS ether in ring E. Importantly, 
this ether group is configured correctly for elaboration to gracilamine. Since the TBS ether 
is an electron-withdrawing group it was expected to deactivate the nearby cyclohexene 
double bond toward electrophilic attack. Moreover, the bulkiness of this ether should also 
provide a steric impediment to such attack. As a result, reasonably selective 
dihydroxylation reactions were observed upon treating these compounds with potassium 
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osmate(VI) dihydrate and N-methylmorpholine N-oxide in presence of citric acid. 
Oxidative cleavage of the corresponding diols using iodobenzene diacetate47 then gave 
ketones 3.18 (58%) and 3.19 (56%), respectively.   
 
Since the exocyclic double bond could be selectively removed using oxidative cleavage 
protocols, complete deletion of the ketone group within compounds 3.18 or 3.19 was now 
necessary in order to complete the total synthesis of gracilamine. Efforts towards such ends 
are detailed in the following section. 
 
 
3.3.1 A TW O-STEP APPRO ACH 
 
In the author’s first attempt to remove the ketone residues within the polyfunctionalised 
compounds 3.18 and 3.19 protocols involving mild reaction conditions were sought. As 
such, ones involving thioketal intermediates were investigated.48 Two different forms of 
these, namely 1,3-dithiane and 1,3-dithiolanes were studied first. However, despite 
investigating a range of different reaction conditions, neither of these derivatives could be 
formed. Subjecting compounds 3.18 and 3.19 to Wolff-Kishner reduction conditions,49, 50 
(requiring highly basic conditions) or a Clemmensen reduction (involving the use of acidic 
conditions)51 also failed to deliver any useful outcomes (Scheme 1.17). 
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Scheme 1.17: Summary of the Various Attempts Made to De-Oxygenate Ketones 3.18 and 3.19. 
______________________________________________________ 
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On the basis that the presence of the sulfonamide residues within compounds 3.18 and 3.19 
might be adversely affecting the attempted deoxygenation processes (as described 
immediately above) efforts were made to remove these. Accordingly, and as shown in 
Scheme 1.18, compound 3.17 was treated with p-chlorobenzenethiol and cesium carbonate 
in N,N-dimethylformamide at ambient temperatures, conditions defined by Fukuyama for 
the cleavage of nosylates.52 In the present case, however, this not only resulted in removal 
of the sulfonamide residue (presumably leading to intermediate 3.21) but also  in a 
(subsequent) lactamisation reaction involving the pendant ester residue and thus affording 
compound 3.20 (79%), the structure of which was confirmed by single-crystal X-ray 
analysis. (Figure 1.11) 
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Scheme 1.18: Manipulation of Compound 3.17 Leading to Lactams 3.20 and 3.22. 
_______________________________________________________ 
	
	
	
Figure 1.11: ORTEP Derived from the Single-Crystal X-ray Analysis of Compound 3.20. 
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Compound 3.20 was subjected to oxidative cleavage of its exocyclic double bond through a 
selective dihydroxylation reaction employing the conditions mentioned earlier and 
involving potassium osmate (VI) dihydrate and N-methylmorpholine N-oxide in presence 
of citric acid. The cis-vicinal diol so-formed was itself treated with iodosobenzene diacetate 
and by such means ketone 3.22 was obtained in 51% yield over the two steps involved. 
Further to the commentary provided above, the Wolff-Kishner, thioketal 
formation/cleavage and Clemmensen reduction protocols were applied to compound 3.22. 
Unfortunately, in each instance no recognizable product was obtained.  
 
3.3.3 A TH REE-STEP APPRO ACH   
 
Given the difficulties encountered in the removing the ketone residue using two-step 
protocols as detailed above, a three-step, Barton-McCombie-based deoxygenation protocol 
was investigated as outlined in Scheme 1.19. Thus, it was expected that if ketone 3.18 were 
reduced to the corresponding alcohol 3.24 then this could, in turn, be converted into the 
corresponding methyl xanthate 3.25. Barton-McCombie deoxygenation of this last 
compound using tri-n-butyltin hydride would then be expected to afford target compound 
3.26. 
_______________________________________________________ 
 
 
Scheme 1.19: A Possible Three-step Means of Deoxygenating Ketone 3.18 and Leading to Compound 3.26. 
_______________________________________________________ 
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In the event, upon treating compound 3.18 with sodium borohydride in methanol (Scheme 
1.20) the ketone carbonyl moiety was reduced in a stereoselective manner but the alcohol 
so-formed reacted with the pendant methyl ester residue to form lactone 3.27 in 86% yield. 
The structure of this product was initially established using the usual range of spectroscopic 
techniques but finally confirmed by single-crystal X-ray analysis (Figure 1.40). Since the 
tetracyclic framework of compound 3.27 is related to that seen in the natural product 3-O-
demethylmacronine (1.68). As such this alkaloid was targeted for synthesis as detailed 
below.  
______________________________________________________ 
 
 
Scheme 1.20: The Reductive Conversion of Ketone 3.18 into Lactone 3.27 and the Resemblance of the 
Latter to the Alkaloid 3-O-Demethylmacronine (1.68).   
______________________________________________________ 
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Figure 1.12: ORTEP Derived from the Single-Crystal X-ray Analysis of Compound 3.27. 
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As described above, the alcohol and amine groups derived from reduction or deprotection 
of compounds 3.18 and 3.17 have a high propensity to interact with the pendant ester 
moiety. In order to prevent such processes from interfering with the desired deoxygenation 
process, ester 3.17 was reduced (Scheme 1.21), using DIBAl-H, to the corresponding 
alcohol 3.28 and this was immediately protected, through reaction with chloromethyl 
methyl ether, as the MOM ether (94%). Oxidative cleavage of the exocyclic double bond 
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associated with the methoxymethyl ether 3.29 under the same Upjohn dihydroxylation 
conditions46 and then treatment of the resulting diols with iodobenzene diacetate afforded 
ketone 3.30 in 54% yield. Product ketone 3.30 was then reduced, in a stereoselective 
manner, to the corresponding alcohol using sodium borohydride in methanol, and this was 
itself converted into the methyl xanthate 3.31 (86%). However, subjection of this last 
compound to Barton−McCombie deoxygenation under a range of different conditions 
failed to generate the hoped-for compound 3.32.  
 
 
 
 
Scheme 1.21: A Further Attempt to Remove the Exocyclic Olefin Moiety Associated with Compound 3.17. 
______________________________________________________ 
 
Given the failures detailed above and in order to derive some benefit from the extensive 
efforts of the author in this area, attention turned to exploiting the lactonisation process just 
described in developing a synthesis of the macronine type alkaloids including compound 
3.22.  
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In 1964, Hauth and Stauffacher reported53 the isolation of the alkaloid macronine (3.33) 
(Figure 1.13) from the plant Crinum macrantherum Engl. (Amaryllidaceae). The 
assignment of its full structure, by Wildman and co-workers,54 followed shortly thereafter. 
The latter group noted that compound 3.33 represents the first example of a lactonic 
Amaryllidaceae alkaloid possessing the tazettine ring system.  
 
 
 
Figure 1.13: Structures of the Alkaloid Macronine (3.33) and Its 3-O-Demethylcongener (1.68). 
 
They also revealed that the strained lactam 3.34 (Scheme 1.22) incorporated within the 
haemanthidine alkaloid framework rearranges to give N-demethylmacronine 3.35 in 
aqueous buffer at pH 6.80 and that the latter compound undergoes reductive methylation, in 
the presence of formaldehyde and sodium borohydride, to give alkaloid 3.33. Whether or 
not rearrangements such as 3.34 → 3.35 have biosynthetic relevance remains unclear.  
______________________________________________________ 
 
 
Scheme 1.22: Literature Transformation Leading to Macronine (3.33). 
______________________________________________________ 
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In 1999, Hesse and co-workers55 described the isolation of 3-O-demethylmacronine (1.68) 
from a Galanthus species of plants of Turkish origin and the illustrated structure was 
established using conventional NMR spectroscopic methods. The same group also 
determined that the compound does not arise through demethylation of congener 3.33 
during the isolation process. Accordingly, 3-O-demethylmacronine (1.68) is considered to 
be a naturally occurring alkaloid.  
 
Thus far, no biological evaluation of compound 1.68 has been reported. Furthermore, while 
macronine (3.33) has been isolated from a range of plant sources since 1964,56 studies of its 
potential therapeutic properties appear to have been confined to ones utilising crude 
extracts of the producing plants and thus suggesting that it may possess, at a minimum, 
useful antibacterial and/or antifungal properties.56 d,e)  
 
In 1976, Tsuda et al.57 reported a ca. 14-step synthesis of (±)-macronine (Scheme 1.23) 
that exploited, as a late-stage transformation, a rearrangement reaction of the type described 
by Wildman. Thus, treatment of compound 3.36 with (PhSe)2 and N-bromoacetamide58 in 
methanol followed by oxidation of the resulting methoxy-selenide 3.37 with 3% H2O2 in 
tetrahydrofuran gave, after thermally-induced elimination of the phenylselenoxide so-
formed, the allyl methyl ether 3.38. This last compound was converted into the imino-ether 
3.39 on treatment with triethyloxonium tetrafluoroborate and reduction of this with sodium 
borohydride /SnCl4•2Et2O complex59 gave the free amine 3.40 that was formylated using 
the mixed anhydride HCOOAc in the presence of pyridine and the resulting formamide 
treated with POCl3. Basification of the ensuing reaction mixture with dilute NH4OH then 
gave the cyclized product 3.41. Oxidation of compound 3.41 with manganese dioxide 
produced the corresponding lactam 3.42 and after hydrolysis with K2CO3, the free hydroxyl 
group was revealed and thus triggering the rearrangement reaction described above and 
producing, after acidic work-up, lactone 3.35. Reductive methylation of this last compound 
under standard conditions then gave the natural product 3.32 (60% from 3.42). 
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Scheme 1.23: The Synthesis of Macronine by Tsuda and Co-workers. 
______________________________________________________ 
 
No other relevant work on alkaloids 1.68 or 3.33 has been reported in the intervening 
period and nor do there appear to have been any studies on the stereochemical requirements 
(if any) of this pivotal and potentially versatile rearrangement process. In addition to 
developing a novel synthesis of this natural product, it was also the aim of the author’s 
work to undertake a detailed study of the rearrangement reaction.  
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3.5.1 ATTEM PTING  TO  SELECTIVELY REDUCE TH E KETO NE 3.18 
 
As detailed above, lactone 3.27 was formed after reducing ketone 3.18 with sodium 
borohydride. Product 3.27 possesses the same skeletal framework as macronine type 
alkaloids 1.12 and 3.33. The main difference between compound 3.27 and the target 
alkaloids is the opposing stereochemistry at C6a. Accordingly, the first requirement 
associated with any successful total synthesis of 3-O-demethylmacronine (1.68) is the need 
to establish the necessary C6a stereochemistry and efforts to do so involved subjecting 
ketone to reaction with a range of reducing reagents as shown in. Figure 1.24. 
______________________________________________________ 
 
 
Figure 1.24： Outcomes of Treating Ketone 3.18 with Different Reducing Reagents. 
______________________________________________________ 
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When compound 3.18 was treated with a bulky reducing agent such as DIBAl-H, in 
tetrahydrofuran, hydride was added to the ester first and the oxyanion produced as the 
result of the hydride addition cyclized onto the adjacent carbonyl and the net result was the 
formation of compound 3.43 in 72% yield. In contrast, when compound 3.18 was treated 
with L-selectride in methanol then the acyl imine 3.44 was obtained as a result of an E1cb 
reaction. Reduction of compound 3.44 was also investigated using sodium borohydride but 
this only resulted in the formation of the corresponding amine, the structure of which was 
confirmed through X-ray analysis of the corresponding and readily derived borane adduct 
3.45 (Figure 1.14). 
 
 
 
Figure 1.14: ORTEP Derived from the Single-Crystal X-ray Analysis of Compound 3.45. 
 
3.5.2 AN ALTERNATE APPRO ACH  INVO LVING  REDUCTIO N O F TH E 
KETO-LACTAM  3.22 
 
Another possible approach to solving the C6a stereochemistry “problem” described above 
would be to effect the stereocontrolled reduction of the keto-lactam 3.22. This compound 
displays a lactam carbonyl absorption band at 1700 cm−1 in the infrared spectrum, while, in 
the 13C NMR spectrum of this same material, the associated carbon resonates at δ 179.8 
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ppm. These values stand as testimony to the strained nature of this nitrogen-containing ring 
system (the equivalent values for δ-valerolactam are ca. 1672 cm−1 and δ 169.1ppm, 
respectively60) and as such the correctly configured alcohol derivative would appear to be 
primed to engage in the lactam to lactone rearrangement leading to the macronine 
framework. In the event, when a methanolic solution of compound 3.22 maintained at 0 °C 
was treated with sodium borohydride, non-stereoselective reduction of the associated 
ketone residue took place to afford a chromatographically separable mixture of compounds 
3.46 and 3.47 (Scheme 1.25). Since each of these reduction products was obtained as an 
interconverting mixture of epimers/anomers, they were subjected, as a mixture and without 
extensive	 spectroscopic characterisation, to oxidation with manganese dioxide and thereby 
affording the chromatographically separable lactone 3.48 (45% from 3.22) and lactam 3.49 
(29% from 3.22), respectively. The structure of the latter product was confirmed by single-
crystal X-ray analysisii. (Figure 1.15) 
_______________________________________________________ 
 
 
Scheme 1.25: Chemical Manipulation of Compound 3.22 Leading to Lactone 3.48 and Lactam 3.49. 
 
																																								 																				 	
ii	 The X-ray structure of compound 3.49 was proved by Mr Xiang Ma 
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Figure 1.15: ORTEP Derived from the Single-Crystal X-ray Analysis of Compound 3.49. 
(Proved by Xiang Ma) 
 
Presumably compound 3.46 arises through initial reduction of the ketone carbonyl residue 
within precursor 3.22 such that the hydroxyl group within the resulting alcohol sits, as is 
evident from inspection of molecular models, directly above the lactam carbonyl moiety 
and can thus approach the latter along a Bürgi−Dunitz trajectory61 and so facilitating its 
conversion into the isomeric lactone that is itself reduced to the observed mixture of lactols 
3.46. In contrast, the epimeric alcohol arising from reduction of the ketone residue within 
compound 3.22 is unable to readily engage in a lactam-to-lactone isomerisation process and 
so the residual (and strained) lactam carbonyl group is reduced directly to give compound 
3.47.  
 
3.5.3 CO M PLETING  TO TAL SYNTH ESES O F TH E (±)-3-O-
DEM ETH YLM ACRO NINE (1.68) AND ITS C6A-EPIM ER  
 
Because of time constraints, the work detailed from this point was undertaken by the 
author’s colleague Mr Xiang Ma but is presented here for the sake of completeness. In 
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order to define a possible pathway for achieving a total synthesis of (±)-3-O-
demethylmacronine (1.68) and so as to conserve material, the completion of the assembly 
of its C6a-epimer was first investigated. The ultimately straightforward synthetic pathway 
used to convert lactone 3.48 into compound 3.51, the C6a-epimer of 3-O-demethyl-
macronine, is shown in Scheme 1.26. Thus, treatment of silyl ether 3.48 with HF•pyridine 
in tetrahydrofuran at ambient temperatures for 1 h gave the expected allylic alcohol 3.50 in 
99% yield and when this was treated with potassium hydride and methyl iodide in 
tetrahydrofuran at 0 °C for 0.5 h, the anticipated 3°-amine 3.51 was obtained in near 
quantitative yield. Interestingly, in the second step of this reaction sequence, no product 
arising from O-methylation of the allyic alcohol moiety was observed. The 1H and 13C 
NMR spectral data acquired on compound 3.51 were in complete accord with the assigned 
structure and quite distinct from those recorded for the natural product 3-O-
demethylmacronine 1.68.  
_______________________________________________________ 
 
 
Scheme 1.26: Conversion of Lactone 3.48 into the C6a-Epimer, 3.51, of (±)-3-O-Demethylmacronine. 
_______________________________________________________ 
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The equivalent route used in completing the total synthesis of target 1.68 is shown in 
Scheme 1.27. This involved, as a pivotal step, the p-toluenesulfonic acid acid-promoted 
conversion of the haemanthidine-based hydroxylactam 3.49 into the lactone 3.52 (48%). 
Accompanying this process was the cleavage of the silyl ether associated with the starting 
material. The precise pathway by which this rearrangement takes place remains unclear. 
However, given the likely abnormally basic nature of the nitrogen associated with the 
bridged lactam62 in substrate 3.49, protonation at this centre, followed by cleavage of the 
N–C=O single bond then reaction of the resulting acylium ion with the pendant hydroxyl 
group, would afford the observed lactone 3.52. Reductive N-methylation of compound 3.52 
using sodium cyanoborohydride and formaldehyde in acetic acid at ambient temperatures 
then gave (±)-3-O-demethylmacronine (1.68) in 89% yield. Interestingly, attempts to effect 
the O-methylation of the last compound under a range of conditions63 failed to generate 
(±)-macronine (3.33). While the origins of this situation are not clear, the likely close 
spatial arrangement of the hydroxyl and amine groups within compound (±)-1.68 could be 
responsible.  
______________________________________________________ 
 
 
Scheme 1.27: Completion of the Total Synthesis of (±)-3-O-Demethylmacronine (1.68). 
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All the spectral data acquired on compound 1.68 were in complete accord with the assigned 
structure, while the 1H and 13C NMR spectra recorded on the synthetic material matched 
those reported by Hesse55 for the natural product (Table 1). 
 
Table 1: Tabular Comparison of the 13C NMR Chemical Shifts 
Recorded for Compound 1.68 with Those Reported for the Natural 
Product 3-O-Demethylmacronine 
 
13C NMR Data for 
Compound 1.68 
(δC)a
	
13C NMR Data for 3-O-
Demethylmacronine 
(δC)b	
Δδ 
167.2 167.3 –0.1 
154.3 154.4 –0.1 
148.9 149.0 –0.1 
143.1 143.1 0 
133.1 133.2 –0.1 
127.2 127.3 –0.1 
119.4 119.5 –0.1 
111.3 111.5 –0.2 
104.9 105.0 –0.1 
103.9 104.0 –0.1 
82.0 82.2 –0.2 
65.6 65.7 –0.1 
64.4 64.6 –0.2 
53.7 53.8 –0.1 
47.5 47.7 –0.2 
42.9 43.0 –0.1 
31.1 31.3 –0.2 
 
a recorded in CD3OD at 100 MHz;  
b data obtained from Hesse,55 spectrum recorded in CD3OD at 150 MHz 
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This Chapter has detailed attempts by the author to establish a new route to the complex 
alkaloid gracilamine (1.1) that acknowledges the presence of the hydroxyl group on the E-
ring. In the course of this work the formation of lactam 3.20 and lactone 3.27 were 
observed and given the relevance of the structure of the latter to the alkaloid 3-O-demethyl-
macronine (1.68) the development of a synthesis of this novel natural product was pursued. 
So, the previously reported cycloalkenyl bromide 3.3 (Scheme 1.28) was converted over 
four steps into the strained lactam 3.20. This was itself transformed into congener 3.49, 
embedded within which is a C12-hydroxylated haemanthidine framework that could be 
engaged in a rearrangement reaction to generate the tetracyclic skeleton of the alkaloid (±)-
3-O-demethylmacronine (1.68). Evidence has been presented to show that this 
rearrangement proceeds regardless of the stereochemistry at C-12 although the reaction 
pathways involved are quite different in each instance. While the biosynthetic relevance (or 
otherwise) of such reactions remain to be determined, this process should enable the 
preparation of various compounds possessing a range of molecular frameworks of 
biological interest.  
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Scheme 1.28: Overview of the Total Synthesis of (±)-3-O-Demethylmacronine (1.68) Realised by the 
Author and Her Co-worker. 
_______________________________________________________  
 
In summary, then, a ten-step synthesis of (±)-3-O-demethylmacronine (1.68) from readily 
available materials is reported, as is a synthesis of its C6a-epimer using related chemistry.  
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Chapter Four: Completion of a Total Synthesis of (±)-
Gracilamine (1.1)  
 
 
Chapter 2 detailed a model study that resulted in a successful, biomimetic means for 
assembling the polycyclic framework of gracilamine (1.1). The pivotal steps were, as 
shown in Scheme 1.29, a Schiff base condensation reaction between aldehyde 2.17 and 
ethyl L-leucinate followed by engagement of the ensuing imine 2.22 in an intramolecular 
[3+2]cycloaddition reaction and thereby forming, in essentially equal amounts, the 
chromatographically separable cycloadducts 2.24 and 2.25. The first and desired adduct 
arises from addition of the ylide to the cyclohexanyl double bond within compound 2.17, 
while the second derives from analogous addition to the exocyclic olefinic residue within 
this same substrate. 
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Scheme 1.29: Summary of the Key Steps Associated with Work Described in Chapter Two.  
_______________________________________________________ 
 
Chapter 3 describes the author’s efforts to apply these results to the synthesis of 
gracilamine itself by acknowledging the presence of the E-ring hydroxyl group in the 
natural product. As part of these investigations efforts were made to the remove the 
exocyclic olefin associated with compounds 3.16 and 3.17. While this proved difficult, 
because of the intervention of unanticipated lactamization reactions, the opportunity arose 
to effect a total synthesis of the natural product (±)-3-O-demethylmacronine (1.68) by the 
pathway shown in Scheme 1.30.  
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Scheme 1.30: A Summary of the Work Described in Chapter 3. 
_______________________________________________________ 
 
This Chapter details the author’s identification of protocols for the successful deletion of 
the exocyclic double bond within compound 3.16 and, thereby, the completion of a total 
synthesis of (±)-gracilamine. As revealed below, the key to success was delaying the 
deletion of the exocyclic olefin associated with the IMAE product 3.16 until after the 
relevant [3+2]cycloaddition reaction had been carried out. Unsurprisingly, the “penalty” 
associated with adopting this approach was that a competing [3+2]cycloaddition reaction 
involving the exocyclic olefin had to be tolerated. 
 
 
The previously reported sulfonamide 3.16 was carried forward to gracilamine (1.1) by the 
reaction pathway shown in Scheme 1.31. So, as previously described, the ester residue 
within compound 3.16 was converted, over two steps, into aldehyde 4.1 (87%) that was 
itself subjected to reaction with ethyl L-leucinate and so affording the expected Schiff base. 
Without exhaustive characterization, this base was subjected to thermolysis in refluxing 
toluene and, as a result, the anticipated and chromatographically separable mixture of the 
[3+2] cycloadducts 4.3 (38%) and 4.4 (36%) was obtained. All the spectroscopic and 
analytical data obtained on these cycloadducts were consistent with the assigned structures. 
In particular, a one-proton olefinic signal, appearing at δ 5.05 (m, 1H), was observed in the 
1H NMR spectrum of compound 4.3 (Figure 1.16), while in the analogous spectrum of 
congener 4.4 two mutually coupled olefinic proton resonances were observed at δ 5.77 (d, J 
= 10.2 Hz, 1H) and 5.20 (d, J = 10.2 Hz, 1H). 
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Scheme 1.31: Synthesis of Aldehyde 4.1 and Its Engagement in a Schiff-Base 
Condensation/[3+2]Cycloaddition Reaction Sequence Leading to Compounds 4.3 and Isomer 4.4.	
______________________________________________________ 
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Figure 1.16: The 400 MHz 1H NMR Spectra of Compounds 4.3 and 4.4 (recorded in CDCl3) Highlighting 
the Olefinic Resonances Allowing for the Ready Assignment of Their Structures. 
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Compound 4.3 embodies the full pentacyclic ring system of gracilamine (1.1) and the 
associated exocyclic olefin was readily and efficiently converted into the corresponding 
ketone 4.5 (79%) through dihydroxylation of the first compound followed by iodobenzene 
diacetate-mediated oxidative cleavage of the product diol.32a) In order to completely 
remove the ketone moiety, a three-step and Barton-McCombie-based deoxygenation 
protocol was then used.64 Thus, ketone 4.5 was first reduced, in a stereoselective manner, to 
the corresponding alcohol 4.6 (89%) using sodium borohydride in methanol. The structures 
of compounds 4.5 and 4.6 followed from the derived NMR, MS, and IR spectral data but 
were confirmed by single-crystal X-ray analyses on each of them. The resulting ORTEPs 
are shown in Figures 1.17 and 1.18, respectively, while further details of these analyses are 
presented in the Experimental Section.  
 
Treatment of alcohol 4.6 with sodium hydride, carbon disulfide, and methyl iodide in 
tetrahydrofuran led to the formation of the methyl xanthate 4.7 (92%) (Scheme 1.32) and 
subjection of a refluxing benzene solution of this to reaction with tri-n-butyltin hydride and 
azobisisobutyronitrile then afforded the desired perhydroindole 4.8 in 74% yield. 
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Scheme 1.32: Deletion of the Exocyclic Double Bond Accomplished. 
______________________________________________________ 
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Figure 1.17: ORTEP Derived from the Single-Crystal X-ray Analysis of Compound 4.5. 
 
 
 
Figure 1.18: ORTEP Derived from the Single-Crystal X-ray Analysis of Compound 4.6. 
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The completion of the author’s by now long-sought-after total synthesis of (±)-gracilamine 
(1.1) is shown in Scheme 1.33. Thus, treatment of the compound 4.8 with magnesium in 
methanol under sonication led to cleavage of the sulfonamide residue and subjection of the 
resulting amine to reaction with 3 M aqueous hydrochloric acid effected cleavage of the 
TBS-ether and thus generating norgracilamine 4.9 in 75% yield. Eschweiler-Clarke-type 
methylation of compound 4.9 using formaldehyde and sodium cyanoborohydride then gave 
(±)-gracilamine (1.1) itself in 63% yield. The assignment of structure (±)-1.1 to this end 
product followed from the usual acquisition of NMR, MS, and IR spectral data but was 
subsequently confirmed by single-crystal X-ray analysis (see Figure 1.19 and the 
Experimental Section for details). Furthermore, all of the 1H and 13C NMR spectral data 
obtained on the synthetically derived sample of (±)-gracilamine were in complete 
agreement (see Table 2) with those reported by both Ma2 and Gao9 for their materials, and 
with those reported by Ünver and Kaya1 for the naturally-derived compound. 
______________________________________________________ 
 
Scheme 1.33: Completion of a Total Synthesis of (±)-Gracilamine (1.1).  
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Figure 1.19: ORTEP Derived from the Single-Crystal X-ray Analysis of Compound (±)-1.1. 
______________________________________________________ 
 
Table 2: Comparison of the 13C NMR Spectral Data Reported by Ma2 and Gao9 for Gracilamine with the 
Equivalent Data Recorded for Compound (±)-1.1 Prepared by the Present Route 
 
δC 
(ex. Ma)a 
δC 
(ex. Gao)b 
δC 
(ex. Present Route)c 
Δδ 
δC(PRd) –δC(Gao) 
175.8 175.9 175.8 –0.1 
150.2 150.1 150.1 0 
149.3 149.1 149.1 0 
143.8 (broadened) 144.7 144.4 –0.3 
136.5 136.3 136.4 +0.1 
106.0 105.7 105.8 +0.1 
103.6 103.8 103.7 –0.1 
102.8 102.7 102.7 0 
74.1 74.3 74.2 –0.1 
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71.3 71.2 71.2 0 
67.7 67.7 67.7 0 
66.4 66.5 66.5 0 
62.2 62.1 62.1 0 
58.5 58.8 58.8 0 
55.7 56.9 56.5 (broadened) –0.4 
55.6 55.6 55.6 0 
54.6 54.7 54.7 0 
48.1 47.4 47.7 +0.3 
45.0 45.5 45.3 –0.2 
40.8 40.8 40.8 0 
34.4 (broadened) 35.9 35.5 (broadened) –0.4 
26.4 26.3 26.3 0 
24.8 24.9 24.9 0 
23.7 23.5 23.6 +0.1 
14.2 14.1 14.1 0 
 
(a Spectrum recorded in CD3OD at 100 MHz; b Spectrum recorded in CD3OD at 100 MHz; c Spectrum 
recorded in CD3OD at 175 MHz; d PR = present route.) 
 
 
As summarised in Scheme 1.31, the present work has provided a new route to (±)-
gracilamine (1.1) starting from the previously reported and ring-fused gem-
dibromocyclopropane 3.2. Key transformations leading from this “starting material” to 
compound 4.1 included thermally-induced electrocyclic ring-opening and Pd[0]-catalyzed 
intramolecular alder-ene reaction (IMAE) reactions. The illustrated azomethine ylide 4.2, 
obtained through a Schiff-base condensation of the corresponding aldehyde 4.1 embodying 
C3a-arylhexahydroindole, with ethyl L-lucinate, was engaged in a thermally-induced and 
stereoselective (but not regioselective) intramolecular [3+2]cycloaddition reaction 
mimicking the proposed biogenesisv of the pentacyclic framework of compound 1.1. The 
	 69 
pentacyclic framework 4.3 so-formed was then elaborated, over a further eight steps, into 
the racemic modification of the alkaloid derivative gracilamine (1.1). 
Compared with previous syntheses,2, 9, 19, 13 this route only required eleven steps to 
assemble the complete polycyclic framework of the target alkaloid.  
______________________________________________________ 
 
 
Figure 1.20: Summary the Author’s Total Synthesis of (±)-Gracilamine (1.1). 
______________________________________________________ 
 
 
 
 
 
 
 
 
 
N
NHH
H
EtO2C
O
O
HO
(±)-1.1
N
NHH
H
EtO2C
Ts O
O
TBSO
4.3
N
O
OTs
EtO2C
NTBSO
4.2
N
O
OTs
CHOTBSO
Br Br
OTBS
4.13.2
9 steps Schiff base condensation
intramolecular
azomethine ylide 
cycloaddition
8 steps
	 70 
Chapter Five: Experimental Procedures Associated with the 
Work Described in Chapter Two to Four 
	
	
Starting materials and reagents were generally available from Sigma-Aldrich, Merck, TCI, 
AK Scientific, Stem and were used as supplied or, occasionally, recrystallised or distilled. 
Drying agents and other inorganic salts were purchased from the AJAX, BDH or Unilab 
Chemical Companies. Tetrahydrofuran, dichloromethane, N,N-dimethylformamide, diethyl 
ether, hexane and toluene were dried using a Glass Contour™ solvent purification system 
that is based upon a technology originally described by Grubbs et al.65  
 
Glassware was soaked in a base bath (pyroneg in water) before being rinsed with distilled 
water then acetone before being oven-dried at 120 °C. Assembled apparatus was evacuated 
(<0.1 mm Hg) and flushed three times with dry nitrogen prior to use. All reaction mixtures 
were manipulated under nitrogen using standard schlenk techniques and, unless otherwise 
specified, stirred magnetically.  
 
Ambient temperature was assumed to be ca. 22 °C. Temperatures higher than ambient were 
attained using thermostated oil baths. To attain temperatures lower than ambient, a cooled, 
water-circulating bath (0 to 10 °C) or relevant cryostats (ice/water, 0 °C; dry-ice/acetone, 
−78 °C) were used. 
 
Organic solutions (extracts) obtained from the work-up of reaction mixtures were dried 
with sodium sulfate (Na2SO4) or magnesium sulfate (MgSO4) before being filtered and 
concentrated under reduced pressure on a rotary evaporator with water bath temperature 
generally not exceeding 40 °C unless otherwise specified.  
 
Analytical thin layer chromatography (TLC) was performed on aluminum-backed 0.2 mm 
thick silica gel 60 F254 plates as supplied by Merck. Eluted plates were visualized using a 
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254 nm UV lamp and/or by treatment with a suitable dip followed by heating. These dips 
included: a) potassium permanganate: potassium carbonate: 5% sodium hydroxide aqueous 
solution: water (3g : 20g : 5 mL : 300mL); b) anisaldehyde : sulfuric acid (conc.) : ethanol 
(3 mL : 4.5 mL : 200 mL); c) vanillin : sulfuric acid (conc.) : ethanol : water (18g : 3 mL : 
285 mL : 15 mL). Flash chromatographic separations were carried out following protocols 
defined by Still et al.66 with silica gel 60 (40–63 µm) as the stationary phase and using the 
AR- or HPLC-grade solvents indicated. 
 
Unless otherwise specified, proton (1H) and carbon (13C) NMR spectra were recorded at 18 
°C in base-filtered CDCl3 on a Varian spectrometer operating at 400 MHz for proton and 
101 MHz for carbon nuclei. For 1H NMR spectra, signals arising from the residual protio-
forms of the solvent were used as the internal standards. Chemical shifts are recorded as δ 
values in parts per million (ppm). 1H NMR data are recorded as follows: chemical shift (δ) 
[multiplicity, coupling constant(s) J (Hz), relative integral] where multiplicity is defined as: 
s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet or combinations of the above. 
The signal due to residual CHCl3 appearing at δH 7.26 and the central resonance of the 
CDCl3 “triplet” appearing at δC 77.16 were used to reference 1H and proton-decoupled 13C 
NMR spectra, respectively. For 13C NMR spectra, the data are given as: chemical shift (δ).  
 
Infrared spectra (νmax) were sometimes recorded on a Perkin–Elmer 1800 Series FTIR 
Spectrometer with the samples being presented as thin films on KBr plates. Samples 
analyzed by attenuated total reflectance (ATR) IR spectroscopy were prepared by allowing 
a CDCl3 solution of these to evaporate on the sampling plate before the spectrum was 
acquired. 
 
Mass spectrometry was performed by the Australian National University’s Mass 
Spectrometric Services Unit located in the Research School of Chemistry, Canberra, 
Australia. Low-resolution ESI mass spectra were recorded on a single-quadrupole liquid 
chromatograph−mass spectrometer, while high-resolution measurements were conducted 
on a time-of-flight instrument. Low- and high-resolution electron impact (EI) mass spectra 
were recorded on a magnetic-sector machine. 
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Melting points were recorded on an Optimelt™ automated melting point system and are 
uncorrected. 
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(±)-6-Azido-1-iodocyclohex-1-ene [(±)-2.8] 
 
 
 
Step i: A magnetically stirred solution of 2-iodocyclohex-2-enol (2.7)67 (1.00 g, 4.46 mmol) 
in dichloromethane (30.0 mL) maintained at 0 °C was treated with triethylamine (1.20 mL, 
8.92 mmol) then methanesulfonyl chloride (620 mg, 5.41 mmol). The ensuing mixture was 
stirred at 22 °C for 2 h before being diluted with ethyl acetate (100 mL) then water (50.0 
mL). The separated aqueous phase was extracted with ethyl acetate (2 × 50.0 mL) and the 
combined organic phases then dried (MgSO4), filtered and concentrated under reduced 
pressure. The ensuing light-brown oil was subjected, without purification, to step ii of the 
reaction sequence as detailed immediately below. 
 
Step ii: The light-brown oil obtained from step i was dissolved in N,N-dimethylformamide 
(30.0 mL) and the resulting solution treated, at 22 °C, with sodium azide (435 mg, 6.69 
mmol) then allowed to stir at 80 °C for 2 h before being cooled then diluted with ethyl 
acetate (30.0 mL) and water (30.0 mL). The separated organic phase was washed with 
water (4 × 30.0 mL) and brine (1 × 30.0 mL) then dried (MgSO4), filtered and concentrated 
under reduced pressure to give a light-yellow oil. Subjection of this material to flash 
chromatography (silica gel, 4:1 v/v hexane/ethyl acetate) and concentration of the 
appropriate fractions (Rf = 0.7 in 3:1 v/v hexane/ethyl acetate) gave azide 2.8 (922 mg, 
83%) as clear, colourless oil. 
 
1H NMR (400 MHz, CDCl3) δH	 6.64 (t, J = 4.4 Hz, 1H), 3.98 (m, 1H), 2.22-2.06 (complex 
m, 2H), 2.06-1.94 (complex m, 2H), 1.78-1.69 (complex m, 2H); 
13C NMR (100 MHz, CDCl3) δC 143.1, 94.6, 64.7, 30.7, 29.2, 17.4; 
IR (KBr) νmax 2925, 2852, 2097, 1626, 1441, 1244, 990, 803 cm–1; 
OH
I
N3
I
1) MsCl, TEA
DCM, rt, 2h
2) NaN3, DMFreflux, 2 h
83%2.7 2.8
DDDD
DDDDD
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MS (EI, 70 eV) m/z 249 (M+•, 83%), 207 (50), 206 (100), 205 (65), 79 (82); 
HRMS (EI) Calculated for C6H8IN3: 248.9763. Found: 248.9775. 
 
(±)-N-(2-Iodocyclohex-2-en-1-yl)-2-nitrobenzenesulfonamide [(±)-2.9] 
 
 
 
Step i: A magnetically stirred solution of compound 2.8 (2.00 g, 8.03 mmol) in 
methanol/water (100 mL of a 95:5 v/v mixture) was treated with triphenylphosphine (3.67 
g, 14.5 mmol) and the ensuing mixture stirred at 22 °C overnight. After this time the 
reaction mixture was diluted with ethyl acetate (100 mL) then water (50.0 mL) and the 
separated aqueous phase extracted with ethyl acetate (2 × 50.0 mL). The combined organic 
phases were dried (MgSO4), filtered then concentrated under reduced pressure. The yellow 
oil thus obtained was subjected to flash chromatography (silica gel, 4:1 v/v hexane/ethyl 
acetate) to give, after concentration of the relevant fractions (Rf = 0.3 in 4:1 v/v 
hexane/ethyl acetate), a clear, colourless oil. This material, assumed to contain the 
anticipated 1°-amine, was subjected, without purification, to step ii of the reaction sequence 
as detailed immediately below. 
 
Step ii: The clear, colourless oil obtained from step i was dissolved in dry dichloromethane 
(30.0 mL) and the resulting solution cooled to 0 °C then treated with triethylamine (1.29 
mL, 9.64 mmol) and nosyl chloride (1.84 g, 9.64 mmol). The ensuing mixture was stirred 
at 0 °C for 2 h then diluted with dichloromethane (20.0 mL) and water (20.0 mL). The 
separated aqueous phase was extracted with dichloromethane (2 × 20.0 mL) and the 
combined organic phases washed with brine (1 × 50.0 mL) before being dried (MgSO4), 
filtered and concentrated under reduced pressure. Subjection of the resulting light-yellow 
oil to flash chromatography (silica gel, 4:1 v/v hexane/ethyl acetate) gave, after 
concentration of the appropriate fractions (Rf = 0.7 in 4:1 v/v hexane/ethyl acetate), 
DDDD
DDDDD
N3
I
1) Ph3P, H2O/MeOH rt, overnight
2) NsCl, TEA, DCM
0 °C, 2 h
2.8 2.9
82%
I
NH
Ns
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compound 2.9 (2.69 g, 82%) as white, crystalline solid, m.p. = 125-127 °C. 
 
1H NMR (400 MHz, CDCl3) δH	 8.17 (m, 1H), 7.93 (m, 1H), 7.74 (m, 2H), 6.54 (t, J = 4.4 
Hz, 1H), 5.61 (d, J = 6.8 Hz, 1H), 4.07 (broadened s, 1H), 2.21-2.01 (complex m, 3H), 
1.96-1.88 (complex m, 1H), 1.76-1.69 (complex m, 2H); 
13C NMR (100 MHz, CDCl3) δC 148.0, 144.5, 134.7, 133.7, 133.1, 130.9, 125.7, 94.6, 59.4, 
32.7, 29.3, 16.2; 
IR (KBr) νmax 3348, 3096, 2937, 1537, 1442, 1406, 1356, 1167, 1059, 732 cm–1; 
MS (ESI, +ve) m/z 431 [(M+Na)+, 100%], 264 (95), 224 (80); 
HRMS (ESI, +ve) (M + Na)+, Calculated for C12H13IN2NaO4S: 430.9539. Found: 
430.9535. 
 
(±)- (S)-Methyl 6-(6-(2-Nitrophenylsulfonamido)cyclohex-1-en-1-
yl)benzo[d][1,3]dioxole-5-carboxylate [(±)-2.14] 
 
 
 
A magnetically stirred solution of compound 2.9 (3.50 g, 8.58 mmol), methyl 6-(5,5-
dimethyl-1,3,2-dioxaborinan-2-yl)benzo[d][1,3]dioxole-5-carboxylate (2.13)36 (2.74 g, 17.2 
mmol), PdCl2dppf•CH2Cl2 (314 mg, 0.429 mmol) and triethylamine (1.39 mL, 10.3 mmol) 
in tetrahydrofuran/water (120 mL of a 9:1 v/v mixture) was purged with nitrogen for 0.25 h 
then heated under reflux for 3 h before being cooled, quenched with water (50.0 mL) and 
then extracted with ethyl acetate (3 × 50.0 mL). The combined organic layers were washed 
with brine (1 × 50.0 mL) then dried (MgSO4), filtered and concentrated under reduced 
pressure. The ensuing brown oil was subjected to flash chromatography (silica, 4:1 v/v 
hexane/ethyl acetate) to afford, after concentration of the appropriate fractions (Rf = 0.6 in 
DDDD
DDDDDDDDD
DDDDD
NH
O
O
CO2Me
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2.9 79%
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7:3 v/v hexane/ethyl acetate), compound 2.14 (3.12 g, 79%) as white, crystalline solid. The 
spectral and physical data derived from this material matched those reported previously.28 
 
(±)-6-((3aR,7aS,Z)-3-Ethylidene-1-((2-nitrophenyl)sulfonyl)-2,3,3a,6 
,7,7a-hexahydro-1H-indol-3a-yl)benzo[d][1,3]dioxole-5-carbaldehyde [(±)-2.17] 
 
 
Step i: A magnetically stirred solution of compound 2.1628 (400 mg, 0.780 mmol, prepared 
over three previously defined28 steps from sulfonamide 2.9) in dichloromethane (25.0 mL) 
maintained under nitrogen was cooled to −78 °C then treated, dropwise, with DIBAl-H 
(3.12 mL of a 1 M solution in tetrahydrofuran, 3.12 mmol). The ensuing mixture was 
stirred at −78 °C for 5 h then quenched with tartaric acid (20.0 mL of a 1 M aqueous 
solution) and after stirring for 0.5 h the separated aqueous phase was extracted with 
dichloromethane (2 × 30.0 mL). The combined organic phases were then dried (MgSO4) 
before being filtered then concentrated under reduced pressure. The clear, colourless oil 
thus obtained was subjected to flash chromatography (silica gel, 4:1 v/v hexane/ethyl 
acetate) to give, after concentration of the relevant fractions (Rf = 0.4 in 7:3 v/v 
hexane/ethyl acetate), a white, crystalline solid. This material, assumed to be the 
anticipated benzyl alcohol, was subjected, without purification, to step ii of the reaction 
sequence as detailed immediately below. 
 
Step ii: The crystalline solid obtained from step i was dissolved in dry dichloromethane 
(20.0 mL) and the resulting solution cooled to 0 °C then treated with the Dess-Martin 
periodinane (345 mg, 0.940 mmol). The ensuing mixture was stirred at 0 °C for 1 h then 
treated with brine (10.0 mL). The separated aqueous phase was extracted with 
dichloromethane (2 × 20.0 mL) and the combined organic phases dried (Na2SO4), filtered 
and concentrated under reduced pressure. The light-brown oil thus obtained was subjected 
to flash chromatography (silica gel, 4:1 v/v hexane/ethyl acetate) to afford, after 
DDDD
DDDDDN
O
ONs
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    DCM
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concentration of the appropriate fractions (Rf = 0.6 in 7:3 v/v hexane/ethyl acetate), 
compound 2.17 (312 mg, 83%) as a white, crystalline solid, m.p. = 175-176 °C. 
 
1H NMR (700 MHz, CDCl3) δH δ 9.96 (s, 1H), 7.79 (m, 1H), 7.63 (t, J = 7.2 Hz, 1H), 7.54 
(t, J = 7.2 Hz, 1H), 7.48 (m, 1H), 7.22 (s, 1H), 6.85 (s, 1H), 5.98 (ABq, J = 17.6 Hz, 2H), 
5.92 (m, 1H), 5.60 (m, 1H), 5.23 (m, 1H), 4.46 (d, J = 14.9 Hz, 1H), 4.35-4.27 (complex 
m, 2H), 2.35-2.28 (complex m, 1H), 2.20-2.11 (complex m, 1H), 2.05 (m, 1H), 1.83 (m, 
1H), 1.68 (d, J = 6.7 Hz, 3H); 
13C NMR (175 MHz, CDCl3) δC 188.8, 151.5, 148.1, 147.1, 143.1, 142.4, 133.4, 131.5, 
131.3, 130.5, 128.8, 127.4, 124.0, 110.8, 109.8, 102.2, 67.3, 55.2, 49.8, 22.9, 14.8, 14.3 
(two signals obscured or overlapping); 
IR (KBr) νmax 2919, 2814, 1673, 1610, 1544, 1505, 1482, 1372, 1355, 1256, 1166, 1127, 
1069, 1037, 910, 729 cm–1; 
MS (ESI, +ve) m/z 505 [(M+Na)+, 100%]; 
HRMS (ESI, +ve) (M + Na)+, Calculated for C24H22N2NaO7S: 505.1045. Found: 505.1046. 
 
(±)-Ethyl (3aS,5aS,6R,7aS,12bR,Z)-1-Ethylidene-6-isobutyl-3-((2-
nitrophenyl)sulfonyl)-2,3,3a,4,5,5a,5a1,6,7,7a-decahydro-1H-
[1,3]dioxolo[4',5':5,6]indeno[1,2,3-cd]pyrrole [3,2-e]isoindole-6-carboxylate (2.24) and 
Ethyl (4aS,6aS,7R,8R,9aR,14bR)-8-Iso-butyl-7-methyl-5-((2-nitrophenyl)sulfonyl)-
4,4a,5,6,7,8,9,9a-octahydro-3H-[1,3]dioxolo[4',5':5,6]pyrrolo[3',2':2,3]indeno[2,1-
c]indole-8-carboxylate [(±)-2.25] 
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A magnetically stirred solution of compound 2.17 (250 mg, 0.520 mmol) in 
dichloromethane (20.0 mL) maintained under a nitrogen atmosphere at 22 °C was treated, 
successively, with L-Leu-OEt•HCl (300 mg, 1.53 mmol), triethylamine (221 µL, 1.53 
mmol) and anhydrous MgSO4 (300 mg, 7.82 mmol). The resulting mixture was stirred at 
22 °C for 72 h then concentrated under reduced pressure. The residue thus obtained was 
treated with toluene (20 mL) and the ensuing solution heated under reflux for 24 h then 
cooled and concentrated under reduced pressure. The brown oil thus obtained was 
subjected to flash chromatography (silica gel, 9:1 v/v hexane/ethyl acetate) to afford two 
fractions, A and B. 
 
Concentration of fraction A (Rf = 0.7 in 3:1 v/v hexane/ethyl acetate) compound 2.24 (116 
mg, 36%) as white solid, m.p. = 191-193 °C. 
 
1H NMR (400 MHz, CDCl3)	 δH	 8.03 (dd, J = 7.7 and 1.6 Hz, 1H), 7.75-7.59 (complex m, 
3H), 6.74 (s, 1H), 5.96 (s, 1H), 5.84 (s, 2H), 5.05 (m, 1H), 4.60 (d, J = 8.8 Hz, 1H), 4.51 
(d, J = 15.5 Hz, 1H), 4.20 (d, J = 15.5 Hz, 1H), 4.15 (m, 2H), 3.84 (dd, J = 10.5 and 5.9 
Hz, 1H), 3.21 (t, J = 8.9 Hz, 1H), 2.24-2.11 (complex m, 2H), 2.08 (m, 1H), 1.87-1.77 
(complex m, 2H), 1.69 (m, 1H), 1.58 (d, J = 6.9 Hz, 3H), 1.47 (m, 1H), 1.32 (m, 1H), 1.25 
(t, J = 7.1 Hz, 3H), 0.99 (d, J = 6.2 Hz, 3H), 0.82 (d, J = 6.2 Hz, 3H), 0.78 (m, 1H) (signal 
due to N-H group proton not observed); 
13C NMR (100 MHz, CDCl3) δC 174.0, 148.8, 148.2, 147.7, 145.7, 143.4, 134.3, 133.9, 
133.0, 131.8, 130.8, 124.2, 118.5, 104.4, 103.0, 101.4, 76.4, 67.5, 67.2, 61.1, 58.5, 54.4, 
49.5, 48.9, 44.1, 28.6, 25.1, 24.6, 22.5, 22.0, 14.8, 14.3; 
IR (KBr) νmax 3400, 2924, 2028, 1727, 1546, 1477, 1371, 1262, 1164, 1039 cm–1; 
MS (ESI, +ve) m/z 624 [(M+H)+, 100%]; 
HRMS (ESI, +ve) (M + H)+, Calculated for C32H38N3O8S: 624.2380. Found: 624.2383. 
 
Concentration of fraction B (Rf = 0.8 in 3:1 v/v hexane/ethyl acetate) gave compound 2.25 
(103 mg, 32%) as white, crystalline solid, m.p. = 189-191 °C. 
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1H NMR (400 MHz, CDCl3) δH 7.56 (m, 2H), 7.46-7.36 (complex m, 2H), 6.47 (s, 1H), 
6.33 (s, 1H), 5.96 (m, 1H), δ 5.92 (d, J = 1.3 Hz, 1H), 5.86 (d, J = 1.3 Hz, 1H), 5.30 (d, J = 
10.1 Hz, 1H), 4.12 (q, J = 10.1 Hz, 2H), 4.08 (s, 1H), 3.95 (dd, J = 10.5 and 4.2 Hz, 1H), 
3.81 (m, 2H), 2.18 (m, 2H), 1.97 (m, 2H), 1.82 (m, 1H), 1.73 (m, 2H), 1.30 (dd, J = 13.8 
and 4.4 Hz, 1H), 1.25 (t, J = 7.1 Hz, 3H), 1.03 (d, J = 6.5 Hz, 6H), 0.80 (d, J = 6.5 Hz, 3H) 
(signal due to N-H group proton not observed); 
13C NMR (100 MHz, CDCl3) δC	 175.4, 159.9, 148.5, 147.9, 140.2, 135.4, 133.0, 132.9, 
131.2, 130.0, 129.2, 128.9, 123.7, 104.9, 104.6, 101.4, 74.9, 73.0, 67.6, 65.7, 62.4, 61.3, 
53.2, 48.1, 39.6, 26.3, 24.8, 22.6, 22.5, 14.2, 11.3 (one resonance obscured or overlapping); 
IR (KBr) νmax 3405, 2958, 2028, 1723, 1545, 1477, 1372, 1252, 1165, 1128, 1038, 939, 
852, 800 cm–1; 
MS (ESI, +ve) m/z 624 [(M+H)+, 100%]; 
HRMS (ESI, +ve) (M + H)+, Calculated for C32H38N3O8S: 624.2380. Found: 624.2377. 
 
 
(±)-N-((1S,5S)-2-Bromo-5-((tert-butyldimethylsilyl)oxy)cyclohex-2-en-1-yl)-4-
methylbenzenesulfonamide [(±)-3.10] 
 
 
 
Step i: A magnetically stirred solution of 3.332a) (2.00 g, 6.04 mmol) in methanol/water (100 
mL of a 95:5 v/v mixture) was treated with triphenylphosphine (3.06 g, 12.1 mmol) and the 
ensuing mixture stirred at 22 °C overnight then diluted with ethyl acetate (100 mL) and 
water (50.0 mL). The separated aqueous phase was extracted with ethyl acetate (2 × 50.0 
mL) and the combined organic phases dried (MgSO4), filtered and concentrated under 
reduced pressure. The brown oil thus obtained was subjected to flash chromatography 
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(silica gel, 4:1 v/v hexane/ethyl acetate) to give, after concentration of the relevant fractions 
(Rf = 0.4 in 7:3 v/v hexane/ethyl acetate), a clear, colourless oil. This material, assumed to 
contain the anticipated 1° amine, was subjected, without purification, to step ii of the 
reaction sequence as detailed immediately below. 
 
Step ii: The oil obtained from step i was dissolved in dry dichloromethane (20.0 mL) and 
the resulting solution cooled to 0 °C then treated with triethylamine (2.43 mL, 18.1 mmol) 
and tosyl chloride (1.40 g, 7.34 mmol). The ensuing mixture was stirred at 0 °C for 2 h then 
diluted with dichloromethane (20.0 mL) and water (20.0 mL). The separated aqueous phase 
was extracted with dichloromethane (2 × 20.0 mL) and the combined organic phases then 
washed with brine (1 × 50.0 mL) before being dried (MgSO4), filtered and concentrated 
under reduced pressure. Subjection of the resulting light-yellow oil to flash 
chromatography (silica, 7:1 v/v hexane/ethyl acetate) gave, after concentration of the 
appropriate fractions (Rf = 0.5 in 4:1 v/v hexane/ethyl acetate), compound 3.10 (2.59 g, 
89%) as white, crystalline solid, m.p. = 153-155 °C. 
 
1H NMR (400 MHz, CDCl3) δH 7.80 (d, J = 8.2 Hz, 2H), 7.28 (d, J = 8.2 Hz, 2H), 6.03 (t, 
J = 4.2 Hz, 1H), 5.77 (d, J = 9.7 Hz, 1H), 4.20 (m, 1H), 4.03 (broadened t, J = 7.8 Hz, 1H), 
2.42 (s, 3H), 2.21 (m, 2H), 2.05 (m, 1H), 1.90 (m, 1H), 0.91 (s, 9H), 0.09 (s, 3H), 0.08 (s, 
3H); 
13C NMR (100 MHz, CDCl3)	 δC 143.3, 138.5, 129.5, 128.7, 127.6, 121.9, 64.8, 54.0, 37.0, 
36.0, 26.1, 21.7, 18.2, –4.8, –4.9 (four signal obscured or overlapping); 
 IR (KBr) νmax 3332, 2954, 2929, 2857, 1649, 1598, 1471, 1410, 1338, 1281, 1258, 1160, 
1093, 1058, 1019, 952, 905, 853, 837 cm–1; 
MS (ESI, +ve) m/z 484 and 482 [(M+Na)+, 100 and 85%]; 
HRMS (ESI, +ve) (M + Na)+, Calculated for C19H3081BrNNaO3SSi: 484.0776. Found: 
484.0772. 
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(±)-Methyl 6-((4S,6S)-4-((tert-Butyldimethylsilyl)oxy)-6-(4-
methylphenylsulfonamido)cyclohex-1-en-1-yl)benzo[d][1,3]dioxole-5-carboxylate [(±)-
3.11] 
 
 
 
A magnetically stirred solution of compound 3.10 (2.05 g, 4.47 mmol), methyl 6-(5,5-
dimethyl-1,3,2-dioxaborinan-2-yl)benzo[d][1,3]dioxole-5-carboxylate (2.13)36 (2.74 g, 8.94 
mmol), PdCl2(dppf)•CH2Cl2 (256 mg, 0.310 mmol), potassium acetate (438 mg, 4.47 
mmol) and cesium carbonate (1.46 mg, 4.47 mmol) in tetrahydrofuran/water (100 mL of a 
9:1 v/v mixture) was flushed, at 22 °C, with nitrogen for 0.25 h then heated under reflux for 
3 h before being cooled, quenched with water (50.0 mL) and extracted with ethyl acetate (3 
× 50.0 mL). The combined organic layers were washed with brine (1 × 50.0 mL) then dried 
(MgSO4), filtered and concentrated under reduced pressure. The ensuing light-yellow oil 
was subjected to flash chromatography (silica gel, 9:1→ 4:1 v/v hexane/ethyl acetate) to 
afford, after concentration of the appropriate fractions (Rf = 0.7 in 7:3 v/v hexane/ethyl 
acetate), compound 3.11 (2.07 g, 83%) as white, crystalline solid, m.p. = 161-163 °C. 
 
1H NMR (400 MHz, CDCl3) δH	 7.40 (d, J = 8.0 Hz, 2H), 7.18 (s, 1H), 7.05 (d, J = 8.0 Hz, 
2H), 6.38 (s, 1H), 6.04-5.96 (complex m, 3H), 5.36 (t, J = 3.4 Hz, 1H), 4.20 (m, 1H), 4.13 
(m, 1H), 3.79 (s, 3H), 2.37 (s, 3H), 2.32 (m, 1H), 2.19 (m, 1H), 2.10-1.99 (complex m, 2H), 
0.94 (s, 9H), 0.13 (s, 3H), 0.11 (s, 3H); 
13C NMR (100 MHz, CDCl3) δC 166.9, 150.2, 146.6, 142.4, 139.6, 138.4, 129.1, 126.9, 
124.0, 122.4, 111.6, 109.9, 101.9, 66.1, 52.2, 51.2, 37.2, 34.4, 26.1, 21.6, 18.2, –4.6, –4.7 
(five signal obscured or overlapping); 
IR (KBr) νmax 3361, 2953, 2927, 2856, 1714, 1614, 1505, 1485, 1435, 1371, 1335, 1252, 
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1157, 1124, 1092, 1038, 836 cm–1; 
MS (ESI, +ve) m/z 582 [(M+Na)+, 100%], 560 (20); 
HRMS (ESI, +ve) (M + Na)+, Calculated for C28H37NNaO7SSi: 582.1958. Found: 
582.1968. 
 
(±)-Methyl 6-((4S,6S)-rel-4- ((tert-Butyldimethylsilyl)oxy)-6-((4-
nitrophenyl)sulfonamido)-cyclohex-1-en-1-yl)benzo[d][1,3]dioxole-5-carboxylate [(±)-
3.12] 
 
 
 
A magnetically stirred solution of compound 3.432a) (1.96 g, 4.00 mmol), compound 2.13 
(1.75 g, 6.00 mmol), PdCl2(dppf)•CH2Cl2 (164 mg, 0.220 mmol), potassium acetate (1.25 
g, 12.7 mmol) and cesium carbonate (1.30 g, 4.00 mmol) in tetrahydrofuran /water (30.0 
mL of a 9:1 v/v mixture) was degassed in a sonicator for 0.33 h and then a nitrogen 
atmosphere was established. The ensuing mixture was heated under reflux for 3 h before 
being cooled, quenched with water (100 mL) and extracted with ethyl acetate (3 × 100 
mL). The combined organic layers were washed with brine (1 × 150 mL) then dried 
(MgSO4), filtered and concentrated under reduced pressure. The light-yellow oil thus 
obtained was subjected to flash chromatography (silica gel, 10:0 → 7:3 v/v hexane/ethyl 
acetate) to afford, after concentration of the appropriate fractions (Rf = 0.7 in 7:3 v/v 
hexane/ethyl acetate), compound 3.12 (1.94 g, 83%) as a white, crystalline solid, m.p. = 
175-177 °C.		
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1H NMR (400 MHz, CDCl3) δH 7.66 (d, J = 7.9 Hz, 2H), 7.52 (t, J = 7.6 Hz, 1H), 7.45 (m, 
1H), 7.09 (s, 1H), 6.58 (m, 1H), 6.31 (s, 1H), 5.88 (s, 1H), 5.86 (s, 1H), 5.40 (s, 1H), 4.49 
(m, 1H), 4.23 (s, 1H), 4.13 (m, 1H), 3.85 (s, 3H), 2.36 (m, 1H), 2.27 (m, 1H), 2.19 (m, 1H), 
0.95 (s, 9H), 0.16 (s, 3H), 0.15 (s, 3H); 
13C NMR (100 MHz, CDCl3) δC 166.8, 149.7, 147.0, 146.6, 138.8, 135.6, 132.5, 131.9, 
129.7, 124.8, 124.6, 122.7, 110.8, 109.7, 101.7, 65.9, 53.1, 52.3, 39.3, 34.7, 26.0, 18.3, −
4.7, −4.7 (three signals obscured or overlapping); 
IR (KBr) vmax 3374, 2928, 2856, 1712, 1541, 1486, 1437, 1407, 1368, 1253, 1165, 1124, 
1038, 853, 836, 780 cm−1; 
MS (ESI, +ve) m/z 613 [(M+Na)+, 100%]; 
HRMS (ESI, +ve) (M+Na)+, Calculated for C27H34N2NaO9SSi: 613.1652. Found: 613.1652. 
	
(±)-Methyl 6-((4S,6S)-6-(N-(But-2-yn-1-yl)-4-methylphenylsulfonamido)-4-((tert-
butyldimethylsilyl)oxy)cyclohex-1-en-1-yl)benzo[d][1,3]dioxole-5-carboxylate [(±)-
3.13] 
 
 
 
A magnetically stirred solution of compound 3.11 (2.30 g, 4.11 mmol) in N,N-
dimethylformamide (30.0 mL) maintained under a nitrogen atmosphere at 0 °C was treated 
with sodium hydride (197 mg of a 60% suspension in oil, 4.93 mmol). After 0.33 h the 
reaction mixture was treated with 1-bromobut-2-yne 68  (720 µL, 8.22 mmol) and the 
mixture thus obtained allowed to warm to 22 °C, stirred at this temperature for 3 h then 
quenched with water (40.0 mL) (CAUTION: possibility for evolution of hydrogen gas) 
before being diluted with ethyl acetate (50.0 mL). The separated aqueous layer was 
extracted with ethyl acetate (3 × 20.0 mL) and the combined organic layers washed with 
water (5 × 20.0 mL) then brine (1 × 40.0 mL) before being dried (MgSO4), filtered and 
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concentrated under reduced pressure. The resulting light-yellow oil was subjected to flash 
chromatography (silica gel, 9:1 → 4:1 v/v hexane/ethyl acetate) to afford, after 
concentration of the appropriate fractions (Rf = 0.7 in 7:3 v/v hexane/ethyl acetate), 
compound 3.13 (2.24 g, 89%) as a white, crystalline solid, m.p. = 172-174 °C. 
 
1H NMR (400 MHz, CDCl3) δH 7.68 (d, J = 8.2 Hz, 2H), 7.33 (s, 1H), 7.19 (d, J = 8.2 Hz, 
2H), 6.66 (s, 1H), 6.01 (s, 2H), 5.64 (m, 1H), 5.20 (m, 1H), 3.93 (m, 2H), 3.84 (s, 3H), 3.73 
(m, 1H), 2.40 (s, 3H), 2.37 (m, 1H), 2.09 (m, 1H), 1.97 (m, 1H), 1.76 (m, 1H), 1.64 (t, J = 
2.3 Hz, 3H), 0.85 (s, 9H), 0.02 (s, 3H), 0.00 (s, 3H); 
13C NMR (100 MHz, CDCl3) δC 166.8, 150.2, 146.7, 142.9, 139.9, 138.3, 138.0, 129.1, 
128.8, 127.9, 123.0, 111.0, 110.4, 102.0, 80.7, 75.3, 67.2, 57.3, 52.1, 37.2, 35.8, 34.2, 26.0, 
21.6, 18.2, 3.6, –4.4, –4.5 (four signals obscured or overlapping); 
IR (KBr) νmax 2953, 2928, 2856, 1721, 1612, 1505, 1486, 1435, 1367, 1339, 1248, 1163, 
1123, 1104, 1091, 1036, 836 cm–1; 
MS (ESI, +ve) m/z 634 [(M+Na)+, 100%]; 
HRMS (ESI, +ve) (M + Na)+, Calculated for C32H41NNaO7SSi: 634.2271. Found: 
634.2272. 
 
(±)-Methyl 6-((4S,6S)-6-(N-(But-2-yn-1-yl)-2-nitrophenylsulfonamido)-4-((tert-
butyldimethylsilyl)oxy)cyclohex-1-en-1-yl)benzo[d][1,3]dioxole-5-carboxylate [(±)-
3.14] 
 
 
 
A magnetically stirred solution of compound 3.12 (3.29 g, 5.57 mmol) in N,N-
dimethylformamide (50.0 mL) maintained under a nitrogen atmosphere at 0 °C was treated 
with sodium hydride (267 mg of a 60% suspension in oil, 6.68 mmol). After 0.33 h the 
reaction mixture was treated with 1-bromobut-2-yne (976 µL, 11.1 mmol). The mixture 
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thus obtained was allowed to warm to 22 °C then heated to 60 °C and stirred at this 
temperature for 3 h before being cooled then quenched with ice-water (40.0 mL) 
(CAUTION: possibility for evolution of hydrogen gas) and diluted with ethyl acetate (50.0 
mL). The separated aqueous layer was extracted with ethyl acetate (3 × 50.0 mL) and the 
combined organic layers washed with water (5 × 40.0 mL) then brine (1 × 100 mL) before 
being dried (MgSO4), filtered and concentrated under reduced pressure. The resulting light-
yellow oil was subjected to flash chromatography (silica gel, 10:0 → 7:3 v/v hexane/ethyl 
acetate) to afford, after concentration of the appropriate fractions (Rf = 0.7 in 7:3 v/v 
hexane/ethyl acetate), compound 3.14 (3.33 g, 93%) as a light-yellow solid, m.p. = 189-191 
°C.  
 
1H NMR (400 MHz, CDCl3) δH 8.02 (d, J = 7.9 Hz, 1H), 7.61 (m, 1H), 7.52 (m, 1H), 7.49 
(dd, J = 7.9 and 1.4 Hz, 1H), 7.22 (s, 1H), 6.61 (s, 1H), 5.96 (s, 2H), 5.66 (m, 1H), 5.30 (m, 
1H), 4.14-4.01 (complex m, 2H), 3.86 (broad s, 1H), 3.80 (s, 3H), 2.42 (m, 1H), 2.24-2.06 
(complex m, 3H), 1.61 (s, 3H), 0.86 (s, 9H), 0.07 (s, 3H), 0.04 (s, 3H); 
13C NMR (100 MHz, CDCl3) δC 166.6, 150.2, 148.1, 146.7, 139.0, 137.4, 133.9, 133.3, 
131.7, 130.8, 129.5, 123.5, 123.0, 110.8, 110.2, 101.9, 81.2, 75.1, 67.0, 58.3, 52.0, 37.8, 
35.8, 34.6, 25.9, 18.1, 3.5, −4.5, −4.5 (two signals obscured or overlapping); 
IR (KBr) vmax 2953, 2929, 2895, 2856, 1720, 1545, 1485, 1436, 1371, 1249, 1169, 1123, 
1102, 1035, 861, 836, 777 cm−1;  
MS (ESI, +ve) m/z 665 [(M+Na)+, 100%];  
HRMS (ESI, +ve) (M+Na)+, Calculated for C31H38N2NaO9SSi: 665.1964. Found: 665.1965. 
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(±)-Methyl 6-((2a1R,2bS,4S,5aS)-4-((tert-Butyldimethylsilyl)oxy)-1-tosyl-2a-
vinyloctahydro-1H-cyclopropa[cd]indol-2a1-yl)benzo[d][1,3]dioxole-5-carboxylate 
[(±)-3.15] and (±)-Methyl 6-((3aR,6R,7aS,Z)-6-((tert-Butyldimethylsilyl)oxy)-3-
ethylidene-1-tosyl-2,3,3a,6,7,7a-hexahydro-1H-indol-3a-yl)benzo[d][1,3]dioxole-5-
carboxylate [(±)-3.16] 
 
 
A magnetically stirred solution of compound 3.13 (1.56 g, 2.55 mmol) in toluene (40.0 mL) 
containing Pd(OAc)2 (115 mg, 0.510 mmol) and BBEDA (125 mg, 0.510 mmol) was 
flushed with nitrogen for 0.25 h then heated under reflux 5 h. The cooled reaction mixture 
was concentrated under reduced pressure and the residue thus obtained subjected to flash 
chromatography (silica gel, 9:1 → 4:1 v/v hexane/ethyl acetate) to afford two fractions, A 
and B.  
 
Concentration of fraction A (Rf = 0.8 in 7:3 v/v hexane/ethyl acetate) gave compound 3.15 
(592 mg, 38%) as white, crystalline solid, m.p. = 171-173 °C.  
 
1H NMR (400 MHz, CDCl3)	 δH	 7.84 (d, J = 8.3 Hz, 2H), 7.37 (s, 1H), 7.26 (partially 
obscured d, J = 8.3 Hz, 2H), 6.65 (s, 1H), 6.02 (s, 2H), 5.07 (m, 1H), 4.84 (s, 1H), 4.81 (d, 
J = 6.8 Hz, 1H), 4.44 (broad s, 1H), 4.12 (m, 1H), 4.09 (d, J = 8.8 Hz, 1H), 3.72 (s, 3H), 
3.25 (d, J = 8.8 Hz, 1H), 2.40 (s, 3H), 2.25 (dd, J = 15.5 and 4.3 Hz, 1H), 2.11-1.96 
(complex m, 2H), 1.46-1.33 (complex m, 2H), 0.92 (s, 9H), 0.09 (s, 6H); 
13C NMR (100 MHz, CDCl3) δC 165.9, 150.6, 147.0, 142.8, 136.9, 136.6, 134.2, 129.3, 
127.9, 125.3, 113.7, 112.3, 111.1, 102.0, 66.6, 63.2, 52.4, 50.3, 41.5, 39.5, 34.7, 27.0, 25.9, 
25.2, 21.5, 18.1, –4.5, –4.6 (four signals obscured or overlapping); 
IR (KBr) νmax 2952, 2856, 1729, 1616, 1505, 1488, 1435, 1378, 1338, 1257, 1162, 1098, 
1037, 932, 836, 777, 662 cm–1; 
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MS (ESI, +ve) m/z 634 [(M+Na)+, 100%]; 
HRMS (ESI, +ve) (M + Na)+, calculated for C32H41NNaO7SSi: 634.2271. Found: 
634.2272. 
 
Concentration of fraction B (Rf = 0.7 in 7:3 v/v hexane/ethyl acetate) gave compound 3.16 
(730 mg, 47%) as white, crystalline solid, m.p. = 165-167 °C. 
 
1H NMR (400 MHz, CDCl3) δH 7.45 (d, J = 8.2 Hz, 2H), 6.97 (d, J = 8.2 Hz, 2H), 6.71 (s, 
1H), 6.10 (s, 1H), 5.94 (d, J = 1.3 Hz, 1H), 5.81 (d, J = 1.3 Hz, 1H), 5.62 (d, J = 10.1 Hz, 
1H), 5.46 (dd, J = 10.1 and 2.1 Hz, 1H), 5.35 (m, 1H), 5.12 (dd, J = 12.4 and 4.7 Hz, 1H), 
4.57 (m, 1H), 4.34 (d, J = 14.8 Hz, 1H), 4.00 (d, J = 14.8 Hz, 1H), 3.73 (s, 3H), 2.33 (m, 
1H), 2.32 (s, 3H), 1.71-1.60 (complex m, 4H), 0.92 (s, 9H), 0.13 (s, 3H), 0.12 (s, 3H); 
13C NMR (100 MHz, CDCl3) δC 169.4, 148.2, 145.8, 142.3, 141.9, 138.3, 136.0, 132.4, 
129.1, 129.0, 126.8, 126.7, 123.2, 109.5, 109.1, 101.7, 67.4, 65.2, 54.3, 52.5, 48.9, 39.7, 
26.1, 21.4, 18.4, 14.9, –4.4, –4.6 (four signals obscured or overlapping); 
IR (KBr) νmax 2952, 2928, 2857, 1725, 1619, 1599, 1506, 1487, 1434, 1346, 1246, 1159, 
1084, 1040, 932, 875, 835, 779, 665 cm–1; 
MS (ESI, +ve) m/z 634 [(M+Na)+, 100%]; 
HRMS (ESI, +ve) (M + Na)+, calculated for C32H41NNaO7SSi: 634.2271. Found: 
634.2272.  
 
(±)-Methyl 6-((3aR,6R,7aS,Z)-6-((tert-Butyldimethylsilyl)oxy)-3-ethylidene-1-((2-
nitrophenyl)sulfonyl)-2,3,3a,6,7,7a-hexahydro-1H-indol-3a-yl)benzo[d][1,3]dioxole-5-
carboxylate [(±)-3.17] 
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A magnetically stirred solution of compound 3.14 (500 mg, 0.780 mmol) in toluene (10.0 
mL) containing Pd(OAc)2 (35.0 mg, 0.160 mmol) and BBEDA (38.0 mg, 0.160 mmol) was 
degased in a sonicator for 0.5 h then heated under reflux for 16 h. The cooled reaction 
mixture was concentrated under reduced pressure and the residue thus obtained subjected to 
flash chromatography (silica gel, 10:0 → 7:3 v/v hexane/ethyl acetate) to afford, after 
concentration of the appropriate fractions (Rf = 0.7 in 7:3 v/v hexane/ethyl acetate), 
compound 3.17 (370 mg, 73%) as a light-yellow solid, m.p. = 175-177 °C.  
 
1H NMR (400 MHz, CDCl3) δH 7.68 (d, J = 8.1 Hz, 1H), 7.43 (t, J = 7.7 Hz, 1H), 7.36 (d, J 
= 8.1 Hz, 1H), 7.21 (t, J = 7.7 Hz, 1H), 6.63 (s, 1H), 6.45 (s, 1H), 5.85 (s, 1H), 5.80 (s, 1H), 
5.65 (d, J = 10.2 Hz, 1H), 5.55 (d, J = 10.2 Hz, 1H), 5.37 (m, 1H), 5.13 (m, 1H), 4.65 (d, J 
= 15.6 Hz, 1H), 4.63-4.55 (complex m, 1H), 4.34 (d, J = 15.6 Hz, 1H), 3.73 (s, 3H), 2.31 
(m, 1H), 1.74 (m, 3H), 1.54 (s, 1H), 0.92 (s, 9H), 0.14 (s, 3H), 0.13 (s, 3H); 
13C NMR (100 MHz, CDCl3) δC 169.7, 147.9, 147.4, 145.9, 141.9, 137.9, 132.9, 132.4, 
132.1, 131.3, 130.0, 128.9, 126.7, 123.1, 122.9, 109.7, 109.1, 101.7, 67.3, 65.8, 54.3, 52.6, 
48.8, 38.5, 26.1, 18.4, 15.0, −4.4, −4.6 (two signals obscured or overlapping); 
IR (KBr) vmax 2952, 2929, 2857, 1722, 1543, 1487, 1435, 1371, 1356, 1247, 1164, 1119, 
1071, 1040, 909, 852, 835, 776, 728 cm−1; 
MS (ESI, +ve) m/z 665 [(M+Na)+, 100%]; 
HRMS (ESI, +ve) (M+Na)+, calculated for C31H38N2NaO9SSi: 665.1967. Found: 665.1965. 
 
(±)-Methyl 6-((3aS,6R,7aS)-6-((tert-Butyldimethylsilyl)oxy)-3-oxo-1-tosyl-2,3,3a,6,7,7a-
hexahydro-1H-indol-3a-yl)benzo[d][1,3]dioxole-5-carboxylate [(±)-3.18] 
 
 
 
Step i: A magnetically stirred solution of compound 3.16 (400 mg, 0.650 mmol) in 
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acetonitrile/water (5.00 mL of a 4:1 v/v mixture) maintained at 22 °C was treated with citric 
acid (379 mg, 1.95 mmol), N-methylmorpholine N-oxide (235 mg, 1.37 mmol) and 
potassium osmate dihydrate (25.1 mg, 0.0670 mmol). 69  The ensuing mixture, which 
developed a green coloration within a few minutes, was stirred vigorously at 22 °C for 30 h 
then diluted with ethyl acetate (10 mL) and hydrochloric acid(10 mL of a 1 M aqueous 
solution). The separated aqueous phase was extracted with ethyl acetate (2 × 10.0 mL) and 
the combined organic phases were washed with brine (1 × 20.0 mL) then dried (MgSO4), 
filtered and concentrated under reduced pressure. The resulting light-brown oil was 
dissolved in a minimum volume of dichloromethane and the resulting solution treated with 
TLC-grade silica gel (100 mg) before being concentrated under reduced pressure. The free-
flowing solid thus obtained was loaded onto the top of a short plug of TLC-grade silica gel 
that was then rinsed with hexane/ethyl acetate (200 mL of a 2:1 v/v mixture). The filtrate 
was concentrated under reduced pressure and the crude diol (now free from osmium-
containing impurities) was subjected to step ii of the reaction sequence as described 
immediately below. 
 
Step ii: The crude diol obtained as described above was dissolved in dichloromethane (5.00 
mL) and the solution thus obtained treated with iodobenzene diacetate (240 mg, 0.750 
mmol). The ensuing mixture was vigorously stirred at 22 °C for 2 h then treated with TLC-
grade silica (100 mg) and concentrated under reduced pressure. The resulting free-flowing 
solid was subject to flash chromatography (silica, dry loading, 9:1 → 7:3 v/v hexane/ethyl 
acetate) to afford, after concentration of the appropriate fractions (Rf = 0.6 in 7:3 v/v 
hexane/ethyl acetate), compound 3.18 (226 mg, 58%) as a white glass. 
 
1H NMR (400 MHz, CDCl3) δH 7.57 (d, J = 8.2 Hz, 2H), 7.09 (d, J = 8.1 Hz, 2H), 6.61 (s, 
1H), 6.24 (dd, J = 10.0, 4.6 Hz, 1H), 5.84 (s, 2H), 5.20 (d, J = 10.0 Hz, 1H), 5.12 (s, 1H), 
4.23 (t, J = 4.8 Hz, 1H), 4.03 (s, 1H), 3.88-3.74 (complex m, 2H), 3.13 (s, 1H), 2.87 (dd, J 
= 15.2, 3.6 Hz, 1H), 2.22 (s, 2H), 1.51-1.43 (complex m, 1H), 1.10 (s, 3H), 0.82 (s, 9H), 
0.03 (s, 3H), 0.00 (s, 3H); 
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13C NMR (100 MHz, CDCl3) δC 204.8, 166.0, 151.4, 147.2, 142.8, 136.3, 135.6, 134.5, 
129.3, 128.5, 126.0, 120.6, 111.8, 111.7, 102.4, 62.0, 61.7, 60.1, 55.0, 53.5, 51.7, 31.3, 
26.2, 18.5, –4.5, –4.6 (four signals obscured or overlapping); 
IR (KBr) vmax 2926, 1755, 1714, 1541, 1487, 1437, 1369, 1356, 1247, 1164, 1119, 1071, 
1040, 909, 852, 835, 776, 728 cm−1; 
MS (ESI, +ve) m/z 600 [(M+H)+, 100%]; 
HRMS (ESI, +ve) (M+H)+, calculated for C30H38NO8SSi: 600.2087. Found: 600.2090. 
 
(±)-Methyl 6-((3aS,6R,7aS)-6-((tert-Butyldimethylsilyl)oxy)-1-((2-
nitrophenyl)sulfonyl)-3-oxo-2,3,3a,6,7,7a-hexahydro-1H-indol-3a-
yl)benzo[d][1,3]dioxole-5-carboxylate [(±)-3.19] 
 
 
 
Step i: A magnetically stirred solution of compound 3.17 (325 mg, 0.510 mmol) in 
acetonitrile/water (5 mL of a 4:1 v/v mixture) maintained at 22 °C was treated with citric 
acid (297 mg, 1.53 mmol), N-methylmorpholine N-oxide (190 mg, 1.00 mmol) and 
potassium osmate dihydrate (19.5 mg, 0.0520 mmol). The ensuing mixture, which 
developed a green coloration within a few minutes, was stirred vigorously at 22 °C for 30 h 
then diluted with ethyl acetate (10.0 mL) and hydrochloric acid (10.0 mL of a 1 M aqueous 
solution). The separated aqueous phase was extracted with ethyl acetate (2 × 10.0 mL) and 
the combined organic phases were washed with brine (1 × 20.0 mL) then dried (MgSO4), 
filtered and concentrated under reduced pressure. The resulting light-brown oil was 
dissolved in a minimum volume of dichloromethane and the resulting solution treated with 
TLC-grade silica gel (100 mg) before being concentrated under reduced pressure. The free-
flowing solid thus obtained was loaded onto the top of a short plug of TLC-grade silica gel 
that was then rinsed with hexane/ethyl acetate (200 mL of a 1:2 v/v mixture). The filtrate 
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was concentrated under reduced pressure and the crude diol (now free from osmium-
containing impurities) was subjected to step ii of the reaction sequence as described 
immediately below. 
 
Step ii: The crude diol obtained as described above was dissolved in dichloromethane (5.00 
mL) and the solution thus obtained treated with iodobenzene diacetate (190 mg, 0.590 
mmol). The ensuing mixture was vigorously stirred at 22 °C for 2 h then treated with TLC-
grade silica (100 mg) and concentrated under reduced pressure. The resulting free-flowing 
solid was subject to flash chromatography (silica, dry loading, 9:1 → 7:3 v/v hexane/ethyl 
acetate) to afford, after concentration of the appropriate fractions (Rf = 0.6 in 7:3 v/v 
hexane/ethyl acetate), compound 3.19 (186 mg, 56%) as light yellow oil. 
 
1H NMR (400 MHz, CDCl3) δH 8.05 (m, 1H), 7.64 (m, 2H), 7.54-7.48 (complex m, 1H), 
7.44 (d, J = 0.7 Hz, 1H), 6.80 (d, J = 0.7 Hz, 1H), 6.43 (dd, J = 10.0, 5.0 Hz, 1H), 6.03 (m, 
2H), 5.43 (m, 1H), 4.72 (t, J = 3.5 Hz, 1H), 4.38 (t, J = 4.9 Hz, 1H), 4.17 (m, 2H), 3.25 (s, 
3H), 2.89 (d, J = 14.7 Hz, 1H), 1.69-1.62 (complex m, 1H), 0.95 (s, 9H), 0.15 (s, 3H), 0.13 
(s, 3H); 
13C NMR (100 MHz, CDCl3) δC 204.0, 166.6, 151.6, 149.1, 147.3, 136.2, 135.9, 132.9, 
132.0, 131.5, 130.9, 126.2, 123.6, 120.5, 111.9, 111.7, 102.5, 62.0, 61.9, 59.8, 54.7, 52.0, 
31.3, 26.2, 18.5, –4.5, –4.7 (two signals obscured or overlapping); 
IR (KBr) vmax 2928, 2855, 1958, 1755, 1710, 1617, 1546, 1507, 1489, 1436, 1365, 1258, 
1170, 1082, 837, 776, 593 cm−1; 
MS (ESI, +ve) m/z 632 [(M+H)+, 100%]; 
HRMS (ESI, +ve) (M+H)+, calculated for C29H35N2O10SSi: 631.1782. Found: 631.1782. 
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(±)-(3R,5S,11bR,E)-3-((tert-Butyldimethylsilyl)oxy)-12-ethylidene-4,4a-dihydro-5,11b-
ethano[1,3]dioxolo[4,5-j]phenanthridin-6(3H)-one [(±)-3.20] 
 
 
 
A magnetically stirred solution of compound 3.17 (224 mg, 0.350 mmol) in dry N,N-
dimethylformamide (10.0 mL) containing cesium carbonate (516 mg, 1.58 mmol) and 4-
chlorothiophenol (211 mg, 1.46 mmol) was stirred at 22 °C for 1 h then quenched with 
NH4Cl (10.0 mL of a saturated aqueous solution) and extracted with dichloromethane (3 × 
20.0 mL). The combined organic layers were washed with brine (1 × 50.0 mL) before being 
dried (MgSO4), filtered and concentrated under reduced pressure. The oily residue thus 
obtained was subjected to flash chromatography (silica gel, 10:0 → 4:1 v/v hexane/ethyl 
acetate) to afford, after concentration of the appropriate fractions (Rf = 0.7 in 4:1 v/v 
hexane/ethyl acetate), a white powder than upon recrystallization 
(methanol/dichloromethane/hexane) gave compound 3.20 (118 mg, 79%) as a white, 
crystalline solid, m.p. = 165-167 °C.  
 
1H NMR (400 MHz, CDCl3) δH 7.44 (s, 1H), 6.81 (s, 1H), 6.32 (dd, J = 10.2 and 2.3 Hz, 
1H), 6.00 (dd, J = 6.2 and 1.1 Hz, 2H), 5.80 (d, J = 10.2, 1H), 5.33 (m, 1H), 4.37 (m, 1H), 
4.06 (d, J = 16.5 Hz, 1H), 3.54 (m, 2H), 1.97 (m, 1H), 1.58 (m, 1H), 1.51 (d, J = 6.9 Hz, 
3H), 0.89 (s, 9H), 0.08 (s, 3H), 0.07 (s, 3H);	
13C NMR (100 MHz, CDCl3) δC 181.5, 152.8, 147.9, 146.7, 144.1, 134.7, 124.5, 121.6, 
119.5, 110.1, 102.4, 102.1, 68.4, 68.0, 51.8, 49.2, 33.9, 26.0, 18.4, 15.3, −4.4, −4.7 (two 
signals obscured or overlapping);	
IR (KBr) vmax 2953, 2921, 2851, 1720, 1615, 1503, 1485, 1422, 1366, 1249, 1118, 1095, 
1038, 932, 888, 873, 779 cm−1;		
MS (ESI, +ve) m/z 426 [(M+H)+, 100%];	
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HRMS (ESI, +ve) (M+H)+, calculated for C24H32NO4Si: 426.2101, Found: 426.2099. 
 
(±)- (3R,5S,11bS)-3-((tert-Butyldimethylsilyl)oxy)-4,4a-dihydro-5,11b-
ethano[1,3]dioxolo[4,5-j]phenanthridine-6,12(3H)-dione [(±)-3.22] 
 
	
 
Step i: A magnetically stirred solution of compound 3.20 (800 mg, 1.86 mmol) in 
acetonitrile/water (100 mL of a 4:1 v/v mixture) maintained at 22 °C was treated with citric 
acid (393 mg, 2.05 mmol), N-methylmorpholine N-oxide (656 mg, 3.84 mmol) and 
potassium osmate dihydrate (70.0 mg, 0.190 mmol).69 The ensuing mixture was stirred 
vigorously at 22 °C for 18 h before being diluted with ethyl acetate (50.0 mL) and water 
(50.0 mL). The separated aqueous phase was extracted with ethyl acetate (2 × 100 mL) and 
the combined organic phases then washed with brine (1 × 100 mL) before being dried 
(MgSO4), filtered and concentrated under reduced pressure. The resulting light-brown oil 
was used immediately in the next step as detailed immediately below. 
 
Step ii: A solution of the oil obtained as described above, in step i, in dichloromethane 
(10.0 mL) was treated with iodobenzene diacetate (663 mg, 2.05 mmol). The ensuing 
mixture was stirred vigorously at 22 °C for 2 h before being treated with TLC-grade silica 
gel (500 mg) then concentrated under reduced pressure. The resulting free-flowing solid 
was subjected to flash chromatography (silica gel, 10:0 → 4:1 v/v hexane/ethyl acetate) and 
concentration of the appropriate fractions (Rf = 0.7 in 7:3 v/v hexane/ethyl acetate) afforded 
the title compound 3.22 (392 mg, 51%) as an unstable, white solid, m.p. = 105-107 °C 
(decompose).  
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1H NMR (400 MHz, CDCl3) δH 7.50 (s, 1H), 6.82 (s, 1H), 6.22 (d, J = 10.2 Hz, 1H), 6.06 
(m, 2H), 6.00 (d, J = 10.2 Hz, 1H), 4.38 (m, 1H), 3.90 (broad d, J = 13.7 Hz, 1H), 3.81 (d, J 
= 18.5 Hz, 1H), 3.30 (d, J = 18.5 Hz, 1H), 2.21 (m, 1H), 1.64 (q, J = 12.2 Hz, 1H), 0.90 (s, 
9H), 0.09 (s, 3H), 0.08 (s, 3H); 
13C NMR (100 MHz, CDCl3) δC 208.8, 179.8, 153.8, 148.1, 139.6, 138.4, 121.4, 120.3, 
110.2, 104.1, 102.6, 67.7, 67.2, 53.9, 52.0, 34.4, 25.9, 18.3, −4.5, −4.7 (two signals 
obscured or overlapping); 
IR (KBr) vmax 2954, 2929, 2858, 1751, 1700, 1485, 1281, 1103, 1089, 1078, 1033, 934, 
871, 851, 838, 782 cm−1;  
MS (EI, 70 eV) m/z 413 (M+•, 15%), 356 (18), 329 (30), 328 (100), 298 (60), 253 (55), 225 
(99); 
HRMS (EI) Calculated for C22H27NO5Si: 413.1659. Found, 413.1660. 
 
(±)-(3R,4aS,6aS,13bS)-3-((tert-Butyldimethylsilyl)oxy)-5-tosyl-4a,5,6,6a-tetrahydro-
3H-[1,3]dioxolo[4',5':6,7]isochromeno[3,4-c]indol-8(4H)-one [(±)-3.27] 
 
 
 
A magnetically stirred solution of compound 3.18 (100 mg, 0.170 mmol) in methanol (10.0 
mL) maintained at 0 °C was treated with sodium borohydride (4.00 mg, 0.110 mmol). The 
ensuing mixture was stirred vigorously at 0 °C for 0.5 h before being diluted with ethyl 
acetate (20.0 mL) and water (10.0 mL). The seperated aqueous phase was extracted with 
ethyl acetate (3 × 10.0 mL ) and the combined organic phase then washed with brine (1 × 
10.0 mL) before being dried (MgSO4), filtered and concentrated under reduce pressure. 
The resulting yellow oil was subjected to flash chromatography (silica gel, 9:1 → 7:3 v/v 
hexane/ethyl acetate) and concentration of the appropriate fractions (Rf = 0.5 in 7:3 v/v 
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hexane/ethyl acetate) afforded the title compound 3.27 (83 mg, 86%) as a white, crystalline 
solid, m.p. = 166-168 °C.  
 
1H NMR (400 MHz, CDCl3) δH 7.58 (d, J = 8.1 Hz, 2H), 7.35 (s, 1H), 7.21 (d, J = 8.0 Hz, 
2H), 6.45 (s, 1H), 6.08 (dd, J = 10.1, 3.7 Hz, 1H), 6.02 (dd, J = 22.3, 1.2 Hz, 2H), 5.40 (dd, 
J = 10.1, 1.3 Hz, 1H), 4.75 (t, J = 4.4 Hz, 1H), 4.43 (m, 1H), 3.89 (m, 2H), 3.53 (dd, J = 
11.8, 4.1 Hz, 1H), 2.41 (s, 3H), 2.40-2.36 (complex m, 1H), 2.15-2.06 (complex m, 1H), 
0.95 (s, 9H), 0.16 (s, 3H), 0.13 (s, 3H); 
13C NMR (100 MHz, CDCl3) δC 161.43, 152.97, 147.91, 143.83, 136.75, 135.02, 133.95, 
129.62, 127.45, 126.56, 116.68, 109.91, 106.95, 102.38, 82.19, 63.69, 62.08, 52.87, 47.09, 
34.50, 25.98, 21.66, 18.31, –4.48, –4.58 (four signals obscured or overlapping); 
IR (KBr) vmax 2929, 2853, 1715, 1507, 1438, 1349, 1277, 1056, 1039, 1016, 837, 780, 733 
cm−1; 
MS (ESI, +ve) m/z 571 [(M+H)+, 100%]; 
HRMS (ESI, +ve) (M + H)+, calculated for C29H36NO7SSi: 570.1982. Found: 570.1982. 
 
(±)-(6-((3aR,6R,7aS,Z)-6-((tert-Butyldimethylsilyl)oxy)-3-ethylidene-1-((2-
nitrophenyl)sulfonyl)-2,3,3a,6,7,7a-hexahydro-1H-indol-3a-yl)benzo[d][1,3]dioxol-5-
yl)methanol [(±)-3.28] 
 
 
 
A magnetically stirred solution of compound 3.17 (500 mg, 0.780 mmol) in dry 
tetrahydrofuran (50.0 mL) maintained at −78 °C under a nitrogen atmosphere was treated 
with DIBAl-H (1.70 mL of 1.0 M solution in tetrahydrofuran, 1.70 mmol). The ensuing 
mixture was stirred vigorously at −78 °C for 0.5 h then quenched with tartaric acid (20.0 
mL of a 1.0 M aqueous solution). The resulting mixture was stirred for 1 h and the 
separated aqueous layer extracted with ethyl acetate (2 × 30.0 mL). The combined organic 
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phase then washed with brine (1 × 10.0 mL) before being dried (MgSO4), filtered and 
concentrated under reduce pressure. The resulting residue was subjected to flash 
chromatography (silica gel, 9:1 → 7:3 v/v hexane/ethyl acetate) and concentration of the 
appropriate fractions (Rf = 0.5 in 7:3 v/v hexane/ethyl acetate) afforded the title compound 
3.28 (436 mg, 91%) as a white, crystalline solid, m.p. = 174-175 °C.  
 
1H NMR (400 MHz, CDCl3) δH 7.63 (dd, J = 7.9, 1.4 Hz, 1H), 7.51 (td, J = 7.7, 1.4 Hz, 
1H), 7.41-7.32 (complex m, 2H), 6.83 (s, 1H), 6.46 (s, 1H), 5.86 (d, J = 1.4 Hz, 1H), 5.80 
(d, J = 1.4 Hz, 1H), 5.70 (d, J = 1.5 Hz, 2H), 5.51-5.43 (complex m, 1H), 4.68-4.50 
(complex m, 4H), 4.38-4.24 (complex m, 2H), 2.28 (m, 1H), 1.82 (m, 1H), 1.80-1.75 
(complex m, 3H), 0.91 (s, 9H), 0.13 (s, 3H), 0.11 (s, 3H) (signal due to O-H group proton 
not observed); 
13C NMR (100 MHz, CDCl3) δC 147.69, 146.82, 146.36, 141.65, 134.81, 133.55, 132.61, 
132.36, 131.39, 131.37, 130.40, 129.98, 123.84, 123.45, 111.05, 109.02, 101.21, 67.62, 
65.55, 62.23, 54.63, 48.64, 38.63, 26.01, 18.35, 14.95, –4.25, –4.48 (two signals obscured 
or overlapping); 
IR (KBr) vmax 2956, 2931, 2858, 1733, 1544, 1487, 1360, 1239, 1165, 1073, 1040, 932, 
871, 834, 734 cm−1; 
MS (ESI, +ve) m/z 637 [(M+Na)+, 100%]; 
HRMS (ESI, +ve) (M + Na)+, calculated for C30H38N2NaO8SSi: 637.2016. Found: 
637.2016. 
 
(±)-(3aR,6R,7aS,Z)-6-((tert-Butyldimethylsilyl)oxy)-3-ethylidene-3a-(6-
((methoxymethoxy)methyl)benzo[d][1,3]dioxol-5-yl)-1-((4-nitrophenyl)sulfonyl)-
2,3,3a,6,7,7a-hexahydro-1H-indole [(±)-3.29] 
 
 
 
DDDD
DDDDDDDDD
DDDDDN
O
ONs
CH2OHTBSO
3.28 3.29
N
O
ONs
CH2OMOMTBSOMOMCl
DIPEA
DMAP
DCM
0 - rt
2 h
94%
	 97 
A magnetically stirred solution of compound 3.28 (200 mg, 0.330 mmol) in dry 
dichloromethane (10.0 mL) maintained at 0 °C under a nitrogen atmosphere was treated 
with di-iso-propylethylamine (0.10.0 mL, 0.570 mmol), chloromethyl methyl ether (0.050 
mL, 0.560 mmol) followed by catalytic amount of 4-(N,N-dimethylamino)pyridine. The 
ensuing mixture was stirred vigorously at 22 °C for 2 h then quenched with cold water 
(5.00 mL). The separated aqueous phase was extracted with dichloromethane (2 × 10.0 mL) 
and the combined organic phases then washed with brine (1 × 10.0 mL) before being dried 
(MgSO4), filtered and concentrated under reduced pressure. The resulting residue was 
subjected to flash chromatography (silica gel, 9:1 → 8:2 v/v hexane/ethyl acetate) and 
concentration of the appropriate fractions (Rf = 0.7 in 7:3 v/v hexane/ethyl acetate) afforded 
the title compound 3.29 (204 mg, 94%) as colourless oil. 
1H NMR (400 MHz, CDCl3) δH 7.52-7.41 (complex m, 2H), 7.33 (d, J = 7.9 Hz, 1H), 7.20 
(t, J = 7.7 Hz, 1H), 6.77 (s, 1H), 6.46 (s, 1H), 5.83 (s, 1H), 5.78 (s, 1H), 5.68 (s, 2H), 5.47 
(m, 1H), 4.75-4.56 (complex m, 5H), 4.33-4.28 (complex m, 3H), 3.49 (s, 3H), 2.35 (m, 
1H), 1.83 (m, 1H), 1.78 (d, J = 7.3 Hz, 3H), 0.92 (s, 9H), 0.14 (s, 3H), 0.13 (s, 3H); 
13C NMR (100 MHz, CDCl3) δC 147.93, 146.73, 146.49, 141.60, 135.81, 132.17, 132.03, 
131.38, 131.21, 130.27, 130.14, 129.96, 123.91, 122.90, 111.87, 108.76, 101.21, 96.63, 
67.64, 66.60, 66.18, 56.08, 54.48, 48.06, 39.06, 26.00, 18.38, 14.93, –4.41, –4.60 (two 
signals obscured or overlapping); 
IR (KBr) vmax 2929, 2857, 2258, 1544, 1505, 1486, 1372, 1358, 1239, 1165, 1092, 1073, 
1040, 914, 871, 834, 776, 729 cm−1; 
MS (ESI, +ve) m/z 682 [(M+Na)+, 100%]; 
HRMS (ESI, +ve) (M + Na)+, calculated for C32H42N2NaO9SSi: 681.2278. Found: 
681.2281. 
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(±)-(3aS,6R,7aS)-6-((tert-Butyldimethylsilyl)oxy)-3a-(6-
((methoxymethoxy)methyl)benzo[d][1,3]dioxol-5-yl)-1-((4-nitrophenyl)sulfonyl)-
3a,6,7,7a-tetrahydro-1H-indol-3(2H)-one [(±)-3.30] 
 
 
 
Step i: A magnetically stirred solution of compound 3.29 (200 mg, 0.300 mmol) in 
acetonitrile/water (20.0 mL of a 4:1 v/v mixture) maintained at 22 °C was treated with citric 
acid (179 mg, 0.920 mmol), N-methylmorpholine N-oxide (103 mg, 0.600 mmol) and 
potassium osmate dihydrate (11.3 mg, 0.030 mmol). The ensuing mixture was stirred 
vigorously at 22 °C for 6 h before being diluted with ethyl acetate (20.0 mL) and water 
(20.0 mL). The separated aqueous phase was extracted with ethyl acetate (2 × 20 mL) and 
the combined organic phases then washed with brine (1 × 20.0 mL) before being dried 
(MgSO4), filtered and concentrated under reduced pressure. The resulting light-brown oil 
was used immediately in the next step as detailed immediately below. 
Step ii: A solution of the oil obtained as described above, in step i, in dichloromethane 
(15.0 mL) was treated with iodobenzene diacetate (116 mg, 0.360 mmol). The ensuing 
mixture was stirred vigorously at 22 °C for 2 h before being treated with TLC-grade silica 
gel (200 mg) then concentrated under reduced pressure. The resulting free-flowing solid 
was subjected to flash chromatography (silica gel, 10:0 → 4:1 v/v hexane/ethyl acetate) and 
concentration of the appropriate fractions (Rf = 0.6 in 7:3 v/v hexane/ethyl acetate) afforded 
the title compound 3.30 (105 mg, 54%) as white solid, m.p. = 183-185°C. 
 
1H NMR (400 MHz, CDCl3) δH 7.69 (dd, J = 7.8, 1.3 Hz, 1H), 7.52 (m, 1H), 7.42 (dd, J = 
8.0, 1.3 Hz, 1H), 7.31 (td, J = 7.7, 1.3 Hz, 1H), 6.80 (s, 1H), 6.20 (s, 1H), 5.89 (d, J = 10.3, 
1H), 5.83 (dd, J = 16.2, 1.3 Hz, 2H), 5.67 (dd, J = 10.1, 2.1 Hz, 1H), 4.96 (dd, J = 12.0, 5.0 
Hz, 1H), 4.71 (s, 2H), 4.62-4.52 (complex m, 3H), 4.21 (d, J = 11.5 Hz, 1H), 4.03 (d, J = 
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19.2 Hz, 1H), 3.50 (s, 3H), 2.46 (m, 1H), 1.79 (m, 1H), 0.91 (s, 9H), 0.13 (s, 3H), 0.12 (s, 
3H); 
13C NMR (100 MHz, CDCl3) δC 209.92, 147.77, 147.39, 146.85, 134.45, 132.76, 132.19, 
131.81, 130.97, 130.51, 130.41, 126.81, 123.32, 112.57, 107.50, 101.59, 96.47, 66.31, 
65.98, 64.41, 59.35, 56.16, 51.66, 38.46, 25.91, 18.27, –4.49, –4.67 (two signals obscured 
or overlapping); 
IR (KBr) vmax 2929, 2856, 1762, 1543, 1505, 1372, 1251, 1167, 1092, 1040, 871, 834, 782, 
598 cm−1; 
MS (ESI, +ve) m/z 669 [(M+Na)+, 100%]; 
HRMS (ESI, +ve) (M + Na)+, calculated for C32H42N2NaO9SSi: 669.1914. Found: 
669.1919. 
 
(±)-O-((3S,3aS,6R,7aS)-6-((tert-Butyldimethylsilyl)oxy)-3a-(6-
((methoxymethoxy)methyl)benzo[d][1,3]dioxol-5-yl)-1-((4-nitrophenyl)sulfonyl)-
2,3,3a,6,7,7a-hexahydro-1H-indol-3-yl) S-methyl carbonodithioate [(±)-3.31] 
 
 
 
Step i: A magnetically stirred solution of compound 3.30 (100 mg, 0.150 mmol) in 
methanol (10.0 mL) maintained at 0 °C was treated with sodium borohydride (5.00 mg, 
0.140 mmol). The ensuing mixture was stirred vigorously at 0 °C for 0.5 h before being 
diluted with ethyl acetate (20.0 mL) and water (10.0 mL). The seperated aqueous phase 
was extracted with ethyl acetate (3 × 10.0 mL) and the combined organic phase then 
washed with brine (1 × 10.0 mL) before being dried (MgSO4), filtered and concentrated 
under reduce pressure. The resulting residue was subjected to flash chromatography (silica 
gel, 9:1 → 7:3 v/v hexane/ethyl acetate) and concentration of the appropriate fractions (Rf = 
0.5 in 7:3 v/v hexane/ethyl acetate) afforded a clear, colourless oil. This material was 
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subjected, without further purification, to step ii of the reaction sequence as detailed 
immediately below. 
 
Step ii: A solution of the oil obtained as described above, in step i, in dry tetrahydrofuran 
(10.0 mL) was treated with sodium hydride (5.00 mg of a 60% dispersion in mineral oil, 
0.210 mmol) and stirred at 22 °C for 0.17 h. Carbon disulphide (0.120 mL, 2.00 mmol) was 
then added to the reaction mixture and refluxed for 0.5 h. The reaction mixture was allowed 
to cool to 22 °C and methyl iodide (0.0500 mL, 0.790 mmol) was added after and stirred 
vigorousely for another 0.5 h. The reaction mixture was cooled to 0 °C, quenched with iced 
water (5.00 mL) (CAUTION! EXOTHERMIC REACTION), and then diluted with ethyl 
acetate (10.0 mL). The separated aqueous phase was extracted with ethyl acetate (2 × 10.0 
mL) and the combined organic phase dried with MgSO4, filtered and concentrated under 
reduced pressure. The resulting residue was subjected to flash chromatography (silica gel, 
10:0 → 4:1 v/v hexane/ethyl acetate) and concentration of the appropriate fractions (Rf = 
0.7 in 7:3 v/v hexane/ethyl acetate) afforded the title compound 3.31 (95.0 mg, 86%) as 
colourless oil. 
 
1H NMR (400 MHz, CDCl3) δH 7.88 (d, J = 7.0 Hz, 1H), 7.57 (m, 2H), 7.48 (m, 1H), 6.90 
(s, 1H), 6.87 (s, 1H), 6.03 (d, J = 10.4 Hz, 1H), 5.99-5.89 (complex m, 3H), 5.12 (s, 1H), 
4.60 (s, 2H), 4.57 (d, J = 12.1 Hz, 1H), 4.45 (d, J = 11.9 Hz, 1H), 4.35 (t, J = 7.1 Hz, 1H), 
4.28 (m, 1H), 4.14 (d, J = 13.2 Hz, 1H), 4.03 (m, 1H), 3.38 (s, 3H), 2.69 (m, 1H), 2.50 (t, J 
= 8.2 Hz, 1H), 1.86 (s, 3H), 0.91 (s, 9H), 0.10 (s, 3H), 0.09 (s, 3H); 
13C NMR (100 MHz, CDCl3) δC 213.67, 148.50, 147.33, 146.45, 133.08, 133.01, 131.77, 
131.61, 130.83, 130.78, 129.73, 127.59, 123.47, 112.08, 108.19, 101.46, 95.48, 86.24, 
68.48, 67.27, 62.63, 59.99, 55.71, 53.85, 51.64, 34.18, 25.89, 18.22, –4.69, –4.80 (two 
signals obscured or overlapping); 
IR (KBr) vmax 2930, 2893, 2859, 1546, 1508, 1489, 1372, 1210, 1168, 1073, 1035, 836, 
776 cm−1; 
MS (ESI, +ve) m/z 762 [(M+Na)+, 100%]; 
HRMS (ESI, +ve) (M + Na)+, calculated for C32H42N2NaO10S3Si: 761.1669. Found: 
761.1670. 
	 101 
(±)-(3R,4aS,6aS,8R,13bS)-3-((tert-Butyldimethylsilyl)oxy)-8-methoxy-5-tosyl-
4,4a,5,6,6a,8-hexahydro-3H-[1,3]dioxolo[4',5':6,7]isochromeno[3,4-c]indol-6a-ol [(±)-
3.43] 
 
 
 
A magnetically stirred solution of compound 3.18 (100 mg, 0.170 mmol) in dry 
tetrahydrofuran (20.0 mL) maintained at −78 °C under a nitrogen atmosphere was treated 
with DIBAl-H (0.300 mL of 1.0 M solution in tetrahydrofuran, 0.300 mmol). The ensuing 
mixture was stirred vigorously at −78 °C for 2 h then quenched with tartaric acid (10.0 mL 
of a 1.0 M aqueous solution). The resulting mixture was stirred for 1 h and the separated 
aqueous layer extracted with ethyl acetate (2 × 30.0 mL). The combined organic phase then 
washed with brine (1 × 10.0 mL) before being dried (MgSO4), filtered and concentrated 
under reduce pressure. The resulting residue was subjected to flash chromatography (silica 
gel, 9:1 → 7:3 v/v hexane/ethyl acetate) and concentration of the appropriate fractions (Rf = 
0.6 in 7:3 v/v hexane/ethyl acetate) afforded the title compound 3.43 (74.0 mg, 72%) as a 
white solid, m.p. = 182-183 °C.  
 
1H NMR (400 MHz, CDCl3) δH 7.44 (d, J = 8.2 Hz, 2H), 7.06 (d, J = 8.0 Hz, 2H), 6.42 (s, 
1H), 6.16 (s, 1H), 6.02 (d, J = 10.1, 1H), 5.99 (d, J = 1.3 Hz, 1H), 5.83 (d, J = 1.3 Hz, 1H), 
5.38 (s, 1H), 5.24 (dd, J = 10.0, 1.9 Hz, 1H), 4.45 (m, 1H), 4.12 (dd, J = 10.7, 1.7 Hz, 1H), 
4.03 (dd, J = 11.6, 5.2 Hz, 1H), 3.67 (d, J = 10.7 Hz, 1H), 3.47 (s, 3H), 3.04 (d, J = 1.7 Hz, 
1H), 2.48-2.42 (complex m, 1H), 2.35 (s, 3H), 2.32-2.23 (complex m, 1H), 0.93 (s, 9H), 
0.14 (s, 6H); 
13C NMR (100 MHz, CDCl3) δC 148.22, 147.20, 142.92, 138.79, 133.91, 130.48, 129.20, 
127.55, 125.44, 124.40, 107.04, 106.67, 101.47, 101.35, 98.63, 66.66, 63.84, 55.88, 55.03, 
50.67, 38.32, 26.01, 21.49, 18.34, –4.26, –4.5 (four signals obscured or overlapping); 
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IR (KBr) vmax 3434, 2926, 1486, 1343, 1243, 1155, 1092, 1031, 932, 872, 835, 777, 662, 
548 cm−1; 
MS (ESI, +ve) m/z 624 [(M+Na)+, 100%]; 
HRMS (ESI, +ve) (M + Na)+, calculated for C30H39NNaO8SSi: 624.2063. Found: 
624.2064. 
 
(±)-Methyl 6-((3aS,6R,7aS)-6-((tert-Butyldimethylsilyl)oxy)-3-oxo-3a,6,7,7a-
tetrahydro-3H-indol-3a-yl)benzo[d][1,3]dioxole-5-carboxylate [(±)-3.44] 
 
 
 
A magnetically stirred solution of compound 3.18 (100 mg, 0.170 mmol) in dry methanol 
(10.0 mL) maintained at 22 °C under a nitrogen atmosphere was treated with L-selectride 
(0.200 mL of 1.0 M solution in tetrahydrofuran, 0.200 mmol). The ensuing mixture was 
stirred vigorously at 22 °C for 1 h before being diluted with ethyl acetate (10.0 mL) and 
water (10.0 mL). The seperated aqueous phase was extracted with ethyl acetate (3 × 10.0 
mL) and the combined organic phase then washed with brine (1 × 10.0 mL) before being 
dried (MgSO4), filtered and concentrated under reduce pressure. The resulting residue was 
subjected to flash chromatography (silica gel, 10:0 → 4:1 v/v hexane/ethyl acetate) and 
concentration of the appropriate fractions (Rf = 0.8 in 7:3 v/v hexane/ethyl acetate) afforded 
the title compound 3.44 (62.0 mg, 82%) as a white solid, m.p. = 175-177 °C.  
 
1H NMR (400 MHz, CDCl3) δH 7.76 (d, J = 3.1 Hz, 1H), 7.46 (s, 1H), 6.92 (s, 1H), 6.12 
(ddd, J = 9.9, 5.3, 1.1 Hz, 1H), 6.04 (s, 2H), 5.42 (d, J = 9.9, 1H), 4.67 (m, 1H), 4.28 (m, 
1H), 3.71 (s, 3H), 2.59 (m, 1H), 2.01 (dt, J = 15.0, 4.8 Hz, 1H), 0.89 (s, 9H), 0.10 (s, 3H), 
0.04 (s, 3H); 
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13C NMR (100 MHz, CDCl3) δC 200.25, 167.19, 160.76, 151.30, 146.85, 135.82, 133.57, 
127.39, 121.74, 112.08, 111.60, 102.33, 73.78, 62.19, 56.02, 52.38, 31.97, 25.88, 18.21, –
4.40, –4.55 (two signals obscured or overlapping); 
IR (KBr) vmax 2953, 2928, 2856, 1737, 1714, 1617, 1506, 1488, 1436, 1363, 1250, 1116, 
1073, 1037, 835, 775 cm−1; 
MS (ESI, +ve) m/z 466 [(M+Na)+, 100%]; 
HRMS (ESI, +ve) (M + H)+, calculated for C23H29NNaO6Si: 466.1662. Found: 466.1663. 
 
(±)-((1R,3aS,6R,7aS)-6-((tert-Butyldimethylsilyl)oxy)-3a-(6-
(methoxycarbonyl)benzo[d][1,3]dioxol-5-yl)-3-oxo-2,3,3a,6,7,7a-hexahydro-1H-indol-
1-ium-1-yl)trihydroborate [(±)-3.45] 
 
 
A magnetically stirred solution of compound 3.44 (50.0 mg, 0.110 mmol) in 
tetrahydrofuran (10.0 mL) maintained at 0 °C was treated with sodium borohydride (4.00 
mg, 0.110 mmol). The ensuing mixture was stirred vigorously at 0 °C for 1 h before being 
diluted with ethyl acetate (10.0 mL) and water (10.0 mL). The seperated aqueous phase 
was extracted with ethyl acetate (3 × 10.0 mL ) and the combined organic phase then 
washed with brine (1 × 10.0 mL) before being dried (MgSO4), filtered and concentrated 
under reduce pressure. The resulting brown oil was subjected to flash chromatography 
(silica gel, 19:1 v/v dichloromethane/ammonia-saturated methanol) and concentration of the 
appropriate fractions (Rf = 0.9 in 9:1 v/v dichloromethane/ammonia-saturated methanol) 
afforded the title compound 3.45 (34.0 mg, 68%) as a white, crystalline solid, m.p. = 102 
°C (decompose). 
  
1H NMR (400 MHz, CDCl3) δH 7.53 (s, 1H), 6.79 (s, 1H), 6.48-6.38 (complex m, 2H), 
6.04 (s, 2H), 5.52 (dd, J = 9.9, 1.7 Hz, 1H), 4.39 (t, J = 4.8 Hz, 1H), 4.11 (m, 1H), 3.97 (dd, 
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J = 18.0, 8.7 Hz, 1H), 3.84 (s, 3H), 3.72 (dd, J = 18.0, 8.6 Hz, 1H), 2.70 (m, 1H), 1.65-1.58 
(complex m, 1H), 0.94 (s, 9H), 0.21 (s, 3H), 0.16 (s, 3H);  
13C NMR (100 MHz, CDCl3) δC 206.64, 166.99, 151.37, 147.39, 134.09, 134.07, 126.90, 
121.62, 111.97, 111.63, 102.53, 66.79, 62.66, 59.63, 59.60, 52.79, 26.11, 25.91, 18.18, –
4.75, –4.79 (two signals obscured or overlapping); 
IR (KBr) vmax 3427, 2952, 2856, 1714, 1618, 1505, 1488, 1436, 1358, 1250, 1119, 1067, 
1034, 836, 840, 779 cm−1; 
MS (ESI, +ve) m/z 482 [(M + Na)+, 28%], 446 (100%);  
HRMS (ESI, +ve) (M + Na)+, calculated for C23H34BNNaO6Si: 482.2146. Found: 
482.2147. 
 
(±)-(3R,4aS,6aS,13bS)-3-((tert-Butyldimethylsilyl)oxy)-4a,5,6,6a-tetrahydro-3H-
[1,3]dioxolo[4',5':6,7]isochromeno[3,4-c]indol-8(4H)-one [(±)-3.48] and (±)-
(3R,5S,11bS,12R)-3-((tert-Butyldimethylsilyl)oxy)-12-hydroxy-4,4a-dihydro-11b,5-
ethano[1,3]dioxolo[4,5-j]phenanthridin-6(3H)-one [(±)-3.49] 
 
 
 
Step i: A magnetically stirred solution of compound 3.22 (240 mg, 0.580 mmol) in 
tetrahydrofuran was cooled to 0 °C then treated with chilled methanol (10.0 mL) followed 
by sodium borohydride (219 mg, 5.80 mmol). The ensuing mixture was warmed to 22 °C 
then stirred at this temperature for 0.25 h before being quenched with NH4Cl (5.00 mL of a 
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saturated aqueous solution) then diluted with ethyl acetate (30.0 mL) and water (30.0 mL). 
The separated aqueous phase was extracted with ethyl acetate (2 × 30.0 mL) and the 
combined organic phases then washed with brine (1 × 100 mL) before being dried (MgSO4), 
filtered and concentrated under reduced pressure. The ensuing light-brown oil was 
subjected to flash chromatography (silica gel, 10:0 → 95:5 v/v dichloromethane/ammonia-
saturated methanol) and concentration of the appropriate fractions (Rf = 0.5 in 95:5 v/v 
dichloromethane/ammonia-saturated methanol) afforded a ca. 3:2 mixture of compounds 
3.46 and 3.47 (181 mg) as a clear, colourless oil. 
 
Step ii: A vigorously stirred solution of a ca. 3:2 mixture of compounds 3.46 and 3.47 (181 
mg, 0.430 mmol) in dichloromethane (20.0 mL) was treated with manganese (IV) oxide 
(377 mg) and the ensuing mixture mainatined at 22 °C for 16 h then filtered through a pad 
of diatomaceous earth. The solids thus retained were washed with dichloromethane (40.0 
mL) and the combined organic filtrates concentrated under reduced pressure. The resulting 
light-brown oil was subjected to flash chromatography (silica gel, 10:0 → 95:5 v/v 
dichloromethane/ammonia-saturated methanol) to afford two fractions, A and B. 
 
Concentration of fraction A (Rf = 0.6 in 95:5 v/v dichloromethane/ammonia-saturated 
methanol) afforded compound 3.48 (108 mg, 45%) as a clear, colourless but rather unstable 
oil. 
 
1H NMR (400 MHz, CDCl3) δH 7.59 (s, 1H), 6.59 (s, 1H), 6.21 (m, 1H), 6.04 (ABq, J = 
6.2 Hz, 2H), 5.43 (d, J = 9.9 Hz, 1H), 4.85 (m, 1H), 4.35 (m, 1H), 3.46 (s, 1H), 3.41 (m, 
1H), 3.32 (m, 1H), 2.15 (d, J = 15.3 Hz, 1H), 1.84 (d, J = 15.3 Hz, 1H), 0.90 (s, 9H), 0.13 
(s, 3H), 0.12 (s, 3H) (signal due to N-H group proton not observed);  
13C NMR (100 MHz, CDCl3) δC 163.2, 152.7, 147.7, 136.7, 133.4, 127.2, 117.4, 110.2, 
107.3, 102.2, 87.4, 62.8, 61.5, 52.2, 48.3, 28.7, 25.9, 18.1, −4.6, −4.7 (two signals obscured 
or overlapping); 
IR (KBr) vmax 3366, 2928, 1710, 1617, 1481, 1385, 1273, 1056, 1038, 1017, 836, 778 cm−1; 
MS (ESI, +ve) m/z 416 [(M+H)+, 100%]; 
HRMS (ESI, +ve) (M+H)+, calculated for C22H30NO5Si: 416.1893. Found: 416.1890.  
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Concentration of the fraction B (Rf = 0.5 in 95:5 v/v dichloromethane/ammonium-saturated 
methanol) afforded a white powder, recrystallization (dichloromethane/hexane) of which 
gave compound 3.49 (71 mg, 29%) as a white, crystalline solid,  m.p. = 191-194 °C.  
 
1H NMR (400 MHz, CDCl3) δH 7.43 (s, 1H), 6.83 (s, 1H), 6.15 (ABq, J = 10.4 Hz, 2H), 
6.02 (s, 2H), 4.39 (m, 1H), 4.03 (m, 1H), 3.57 (m, 2H), 3.49 (m, 1H), 2.33-1.87 (complex 
m, 3H), 0.89 (s, 9H), 0.08 (s, 3H), 0.07 (s, 3H) (signal due to O-H group proton not 
observed); 
13C NMR (100 MHz, CDCl3) δC 181.1, 152.8, 147.0, 146.4, 140.9, 121.9, 121.0, 110.2, 
103.2, 102.2, 68.0, 67.7, 58.2, 52.1, 33.2, 26.0, 18.4, −4.4, −4.7 (three signals obscured or 
overlapping); 
IR (KBr) vmax 3467, 2929, 2857, 1683, 1613, 1480, 1264, 1254, 1050, 1029, 803, 772, 728 
cm−1; 
MS (ESI, +ve) m/z 416 [(M+H)+, 100]; 
HRMS (ESI, +ve) (M+H)+, calculated for C22H30NO5Si: 416.1893. Found: 416.1893.  
 
(±)-(3R,4aS,6aS,13bS)-3-Hydroxy-4a,5,6,6a-tetrahydro-3H-
[1,3]dioxolo[4',5':6,7]isochromeno[3,4-c]indol-8(4H)-one [(±)-3.50] 
 
 
 
A magnetically stirred solution of compound 3.48 (20.0 mg, 0.0480 mmol) in 
tetrahydrofuran (1.00 mL) maintained at 0 °C was treated with HF•pyridine (2.00 µL, 
0.0730 mmol,) and the ensuing mixture stirred at this temperature for 0.5 h before being 
concentrated under reduced pressure. The residue thus obtained was subjected to flash 
column chromatography (silica gel, 10:0 → 95:5 v/v dichloromethane/ammonia-saturated 
methanol) and concentration of the appropriate fractions (Rf = 0.4 in 95:5 v/v 
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dichloromethane/ammonia-saturated methanol) gave compound 3.50 (14.0 mg, 99%) as a 
clear, colourless oil.  
 
1H NMR (400 MHz, CDCl3) δH 7.55 (s, 1H), 6.64 (s, 1H), 6.49 (m, 1H), 6.04 (m, 2H), 5.46 
(d, J = 10.0 Hz, 1H), 4.78 (s, 1H), 4.18 (m, 1H), 3.79 (s, 1H), 3.33 (m, 2H), 2.16 (m, J = 
14.8 and 4.1 Hz, 1H), 1.75 (d, J = 14.8 Hz, 1H) (signals due to N-H and O-H group protons 
not observed); 
13C NMR (100 MHz, CDCl3) δC 163.3, 152.9, 147.9, 136.9, 136.0, 125.5, 116.8, 110.2, 
107.6, 102.3, 87.4, 63.2, 60.5, 51.0, 48.2, 29.1; 
IR (KBr) vmax 3329, 2919, 1705, 1616, 1480, 1440, 1383, 1272, 1243, 1115, 1057, 1035, 
931, 909, 728 cm−1; 
MS (ESI, +ve) m/z 324 (20%), 302 [(M+H)+, 100]; 
HRMS (ESI, +ve) (M+H)+ calculated for C16H16NO5: 302.1028. Found: 302.1026. 
 
(±)-(3R,4aS,6aS,13bS)-3-Hydroxy-5-methyl-4a,5,6,6a-tetrahydro-3H-
[1,3]dioxolo[4',5':6,7]isochromeno[3,4-c]indol-8(4H)-one [(±)-3.51] 
 
 
 
A magnetically stirred solution of compound 3.50 (10.0 mg, 0.0330 mmol) in 
tetrahydrofuran (1.00 mL) maintained under a nitrogen atmosphere at 0 °C was treated with 
potassium hydride (17.6 mg of a 30 wt % dispersion in mineral oil, 0.130 mmol) then 
methyl iodide (16.5 µL, 0.270 mmol). The ensuing mixture was stirred at 0 °C for 0.5 h 
then quenched with water (5.00 mL) (CAUTION: POSSIBILITY OF EVOLUTION OF 
HYDROGEN) before being extracted with ethyl acetate (3 × 10.0 mL). The combined 
organic phases were washed with brine (1 × 50.0 mL) then dried (Na2SO4), filtered, and 
concentrated under reduced pressure. The residue thus obtained was subjected to flash 
column chromatography (silica gel, 10:0 → 95:5 v/v dichloromethane/ammonia-saturated 
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methanol) and concentration of the appropriate fractions (Rf = 0.5 in 95:5 v/v 
dichloromethane/ammonia-saturated methanol) afforded compound 3.51 (10.0 mg, 99%) as 
a clear, colourless oil. 
 
1H NMR (400 MHz, CDCl3) δH 7.58 (s, 1H), 6.65 (s, 1H), 6.46 (m, 1H), 6.05 (ABq, J = 4.3 
Hz, 2H), 5.45 (d, J = 9.9 Hz, 1H), 4.73 (s, 1H), 4.15 (broad s, 1H), 3.59 (dd, J = 13.0 and 
3.2 Hz, 1H), 3.14 (s, 1H), 2.95 (d, J = 13.0 Hz, 1H), 2.58 (s, 3H), 2.20 (broad d, J = 14.9 
Hz, 1H), 1.73 (broad d, J = 14.9 Hz, 1H) (signal due to O-H group proton not observed); 
13C NMR (100 MHz, CDCl3) δC 163.1, 152.9, 147.9, 136.6, 135.4, 125.6, 117.1, 110.2, 
107.7, 102.4, 86.4, 68.9, 63.3, 59.9, 49.1, 42.7, 26.8; 
IR (KBr) vmax 3420, 2919, 1716, 1617, 1482, 1440, 1275, 1247, 1127, 1055, 1036, 932 
cm−1; 
MS (ESI, +ve) m/z 338 (69%), 316 [(M+H)+, 100]; 
HRMS (ESI, +ve) (M+H)+ calculated for C17H18NO5: 316.1185. Found: 316.1183. 
 
(±)-(3R,4aS,6aR,13bS)-3-Hydroxy-4a,5,6,6a-tetrahydro-3H-
[1,3]dioxolo[4',5':6,7]isochromeno[3,4-c]indol-8(4H)-one [(±)-3.52] 
 
 
 
A magnetically stirred solution of compound 3.49 (120 mg, 0.290 mmol) in toluene (5.00 
mL) was treated with p-toluenesulfonic acid monohydrate (54.9 mg, 0.330 mmol) and the 
resulting solution stirred at 90 °C for 1.5 h then cooled, quenched with NaHCO3 (10.0 mL 
of a saturated aqueous solution) and extracted with ethyl acetate (3 × 20.0 mL). The 
combined organic phases were washed with brine (1 × 100 mL) before being dried 
(Na2SO4), filtered, and concentrated under reduced pressure. The residue thus obtained was 
subject to flash column chromatography (silica gel, 10:0 → 95:5 v/v 
dichloromethane/ammonia-saturated methanol) and concentration of the appropriate 
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fractions (Rf = 0.4 in 95:5 v/v dichloromethane/ammonia-saturated methanol) afforded 
compound 3.52 (42.0 mg, 48%) as a white, crystalline solid, m.p. = 181-184 °C. 
 
1H NMR (400 MHz, CDCl3) δH 7.55 (s, 1H), 6.66 (s, 1H), 6.23 (m, 1H), 6.05 (ABq, J = 
8.0 Hz, 2H), 5.63 (d, J = 10.2 Hz, 1H), 4.56 (m, 1H), 4.20 (m, 1H), 4.00 (broad s, 1H), 3.28 
(m, 1H), 3.08 (t, J = 10.8 Hz, 1H), 2.46 (d, J = 15.1 Hz, 1H), 2.15 (dd, J = 15.1 and 4.8 Hz, 
1H) (signals due to O-H and N-H group protons not observed); 
13C NMR (100 MHz, CDCl3) δC 165.1, 152.7, 147.7, 140.9, 132.9, 125.7, 118.4, 111.4, 
103.7, 102.4, 82.9, 62.7, 55.6, 44.5, 44.0, 32.8; 
IR (KBr) vmax 3335, 2921, 1719, 1615, 1479, 1271, 1246, 1072, 1033, 907, 727 cm−1; 
MS (ESI, +ve) m/z 302 [(M+H)+, 100%]; 
HRMS (ESI, +ve) (M+H)+ calculated for C16H16NO5: 302.1028. Found: 302.1026. 
 
(±)-(3R,4aS,6aR,13bS)-3-Hydroxy-5-methyl-4a,5,6,6a-tetrahydro-3H-
[1,3]dioxolo[4',5':6,7]isochromeno[3,4-c]indol-8(4H)-one [(±)-1.68] 
 
 
 
A magnetically stirred solution of compound 3.52 (7.00 mg, 0.0230 mmol) acetonitrile 
(1.00 mL) maintained at 22 °C was treated, successively, with formalin (17.5 µL of a 37% 
aqueous solution, 0.210 mmol), acetic acid (5.00 µL, 0.0900 mmol) and NaBH3CN (5.70 
mg, 0.870 mmol). The ensuing mixture was stirred at ambient temperatures for 1 h then 
quenched with NaHCO3 (5.00 mL of a saturated aqueous solution) before being extracted 
with ethyl acetate (3 × 15.0 mL). The combined organic phases were washed with brine (1 
× 50.0 mL) then dried (Na2SO4) and filtered before being concentrated under reduced 
pressure. The residue thus obtained was subjected to flash column chromatography (silica 
gel, 10:0 → 95:5 v/v dichloromethane/ammonia-saturated methanol) and concentration of 
the appropriate fractions (Rf = 0.5 in 95:5 v/v dichloromethane/ammonia-saturated 
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methanol) afforded a powder that was recrystallized (methanol/water) to give compound 
1.68 (6.00 mg, 89%) as a white, crystalline solid, m.p. = 199-202 °C.  
 
1H NMR (400 MHz, CD3OD) δH 7.43 (s, 1H), 6.84 (s, 1H), 6.14 (dd, J ＝ 10.1 and 5.2 Hz, 
1H), 6.08 (ABq, J ＝ 1.0 Hz, 2H), 5.57 (dd, J = 10.2 and 1.4 Hz, 1H), 4.71 (m, 1H), 4.30 
(s, 1H), 4.12 (m, 1H), 3.37 (m, 1H), 3.25 (m, 1H), 2.90 (m, 1H), 2.58 (s, 3H), 2.44 (m, 1H), 
2.23 (m, 1H); 
13C NMR (100 MHz, CD3OD) δC 167.2, 154.3, 148.9, 143.1, 133.1, 127.2, 119.4, 111.3, 
104.9, 103.9, 82.0, 65.6, 64.4, 53.7, 47.5, 42.9, 31.1; 
IR (KBr) vmax 3267, 2920, 2877, 2852, 1723, 1615, 1480, 1276, 1247, 1026 cm-1; 
MS (ESI, +ve) m/z 316 [(M+H)+, 100%], 298 (80); 
HRMS (ESI, +ve) (M+H)+ calculated for C17H18NO5: 316.1185. Found: 316.1182. 
 
 
(±)-6-((3aR,6R,7aS,Z)-6-((tert-Butyldimethylsilyl)oxy)-3-ethylidene-1-tosyl-
2,3,3a,6,7,7a-hexahydro-1H-indol-3a-yl)benzo[d][1,3]dioxole-5-carbaldehyde [(±)-4.1] 
 
 
 
Step i: A magnetically stirred solution of compound 3.16 (500 mg, 0.820 mmol) in 
dichloromethane (35.0 mL) maintained under nitrogen was cooled to −78 °C then treated, 
dropwise, with DIBAl-H (2.05 mL of a solution 1 M in tetrahydrofuran, 2.05 mmol). The 
resulting mixture was stirred at −78 °C for 1 h then quenched with tartaric acid (20.0 mL of 
a 1 M aqueous solution) and the ensuing mixture stirred for 0.5 h while being allowed to 
warm to 22 °C. The separated aqueous phase was extracted with dichloromethane (2 × 30.0 
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mL) and the combined organic phases then dried (MgSO ), filtered and concentrated under 
reduced pressure. The resulting clear, colourless oil was subjected to flash chromatography 
(silica gel, 4:1 v/v hexane/ethyl acetate) to give, after concentration of the relevant fractions 
(Rf = 0.5 in 7:3 v/v hexane/ethyl acetate), a white solid. This material, assumed to be the 
anticipated benzyl alcohol, was subjected, without purification, to step ii of the reaction 
sequence as detailed immediately below. 
 
Step ii: The solid obtained from step i was dissolved in dry dichloromethane (20.0 mL) and 
the resulting solution cooled to 0 °C then treated with the Dess-Martin periodinane (345 
mg, 0.820 mmol). The ensuing mixture was stirred at 0 °C for 0.5 h then quenched with 
brine (10.0 mL). The separated aqueous phase was extracted with dichloromethane (2 × 
20.0 mL) and the organic phases then dried (Na2SO4), filtered and concentrated under 
reduced pressure. The resulting light-yellow oil was subjected to flash chromatography 
(silica gel, 4:1 v/v hexane/ethyl acetate) to afford, after concentration of the appropriate 
fractions (Rf = 0.6 in 7:3 v/v hexane/ethyl acetate), compound 4.1 (415 mg, 87%) as a 
white, crystalline solid, m.p. = 188-190 °C. 
 
1H NMR (400 MHz, CDCl3) δH 10.21 (s, 1H), 7.30 (d, J = 8.2 Hz, 2H), 7.22 (s, 1H), 6.99 
(d, J = 8.2 Hz, 2H), 6.41 (s, 1H), 5.99 (s, 1H), 5.91 (s, 1H), 5.72 (m, 2H), 5.50 (m, 1H), 
4.54 (m, 1H), 4.35 (m, 2H), 3.87 (dd, J = 14.2 and 1.2 Hz, 1H), 2.39 (m, 1H), 2.35 (s, 3H), 
1.80 (m, 4H), 0.91 (s, 9H), 0.13 (s, 3H), 0.11 (s, 3H); 
13C NMR (100 MHz, CDCl3) δC 188.6, 151.5, 147.2, 143.5, 142.8, 141.2, 135.5, 131.3, 
130.9, 129.4, 129.1, 126.6, 124.7, 109.6, 109.0, 102.1, 67.6, 67.4, 54.2, 48.1, 39.6, 26.0, 
21.5, 18.3, 14.9, –4.3, –4.5 (four signals obscured or overlapping); 
IR (KBr) νmax 2954, 2928, 2856, 1673, 1612, 1505, 1482, 1342, 1253, 1158, 1093, 1065, 
1038, 932, 872, 835, 664 cm–1; 
MS (ESI, +ve) m/z 604 [(M+Na)+, 100%]; 
HRMS (ESI, +ve) (M + Na)+, calculated for C31H39NNaO6SSi: 604.2165. Found: 
604.2169. 
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(±)-(3aS,5R,5aS,6R,7aS,12bR,Z)-Ethyl 5-((tert-Butyldimethylsilyl)oxy)-1-ethylidene-6-
isobutyl-3-tosyl-2,3,3a,4,5,5a,5a1,6,7,7a-decahydro-1H-
[1,3]dioxolo[4',5':5,6]indeno[1,2,3-cd]pyrrolo[3,2-e]isoindole-6-carboxylate [(±)-4.3]  
and (±)-(3S,4aS,6aS,7R,8R,9aR,14bR)-Ethyl 3-((tert-Butyldimethylsilyl)oxy)-8-
isobutyl-7-methyl-5-tosyl-4,4a,5,6,7,8,9,9a-octahydro-3H-
[1,3]dioxolo[4',5':5,6]pyrrolo[3',2':2,3]indeno[2,1-c]indole-8-carboxylate [(±)-4.4] 
 
 
 
A magnetically stirred solution of compound 4.1 (300 mg, 0.520 mmol, 1.0 equiv.) in 
dichloromethane (20.0 mL) maintained under a nitrogen atmosphere at 22 °C was treated 
with L-Leu-OEt•HCl (305 mg, 1.56 mmol), triethylamine (125 µL, 0.870 mmol) and 
anhydrous MgSO4 (300 mg, 7.82 mmol). The ensuing mixture was stirred at 22 °C for 18 h 
then concentrated under reduced pressure. The residue thus obtained was treated with 
toluene (20.0 mL) and the resulting suspension heated under reflux for 24 h before being 
cooled then concentrated under reduced pressure.  The residue was subjected to flash 
chromatography (silica gel, 9:1 → 4:1 v/v hexane/ethyl acetate) to afford two fractions, A 
and B.  
 
Concentration of fraction A (Rf = 0.6 in 7:3 v/v hexane/ethyl acetate) afforded compound 
4.3 (134 mg, 36%) as white, crystalline solid, m.p. = 210-212 °C. 
 
1H NMR (400 MHz, CDCl3) δH 7.79 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 8.2 Hz, 2H), 6.63 (s, 
1H), 5.83 (m, 2H), 5.29 (s, 1H), 5.05 (m, 1H), 4.70 (d, J = 7.9 Hz, 1H), 4.49 (m, 1H), 4.10 
(m, 2H), 3.86 (m, 1H), 3.74 (m, 1H), 3.67 (m, 1H), 3.24 (dd, J = 11.0 and 7.9 Hz, 1H), 2.45 
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(s, 3H), 2.35-2.33 (complex m, 1H), 2.11 (m, 1H), 1.97 (dd, J = 14.1 and 5.5 Hz, 1H), 1.62 
(m, 1H), 1.51 (d, J = 6.9 Hz, 3H), 1.49-1.40 (complex m, 2H), 1.14 (t, J = 7.2 Hz, 3H), 0.97 
(d, J = 6.6 Hz, 3H), 0.87 (s, 9H), 0.82 (d, J = 6.6 Hz, 3H), 0.08 (s, 3H), 0.06 (s, 3H) (signal 
due to N-H group proton not observed); 
13C NMR (400 MHz, CDCl3) δC	 174.3, 148.5, 147.5, 146.3, 144.0, 143.1, 136.3, 134.4, 
130.0, 127.4, 117.7, 104.7, 102.3, 101.3, 71.1, 66.4, 66.1, 64.6, 60.9, 58.4, 57.8, 51.5, 48.7, 
48.5, 37.8, 26.1, 25.4, 24.1(4), 24.0(7), 21.7, 18.2, 14.9, 14.0, –3.6, –4.2 (four signals 
obscured or overlapping); 
IR (KBr) νmax 2955, 2929, 2858, 1721, 1598, 1474, 1345, 1258, 1218, 1160, 1065, 1040, 
941, 834, 662 cm–1; 
MS (ESI, +ve) m/z 723 [(M+H)+, 100%]; 
HRMS (ESI, +ve) (M + H)+, calculated for C39H55N2O7SSi: 723.3499. Found: 723.3494. 
 
Concentration of fraction B (Rf = 0.5 in 7:3 v/v hexane/ethyl acetate) afforded compound 
4.4 (142 mg, 38%) as clear, colourless oil. 
 
1H NMR (400 MHz, CDCl3)	 δH 7.39 (d, J = 8.2 Hz, 2H), 7.07 (d, J = 8.2 Hz, 2H), 6.46 (s, 
1H), 6.21 (s, 1H), 5.97 (d, J = 1.3 Hz, 1H), 5.89 (d, J = 1.3 Hz, 1H), 5.77 (d, J = 10.2 Hz, 
1H), 5.20 (d, J = 10.2 Hz, 1H), 4.39 (m, 1H), 4.14 (ABq, J = 7.1 Hz, 2H), 3.99 (dd, J = 
12.8 and 4.6 Hz, 1H), 3.83 (s, 1H), 3.79 (d, J = 11.6 Hz, 1H), 3.41 (d, J = 11.6 Hz, 1H), 
2.36 (s, 3H), 2.26 (m, 1H), 2.17 (m, 1H), 1.74 (m, 3H), 1.45 (m, 1H), 1.25 (t, J = 7.4 Hz, 
3H), 1.20 (m, 1H), 1.04 (d, J = 7.4 Hz, 3H), 1.00 (d, J = 6.4 Hz, 3H), 0.90 (s, 9H), 0.81 (d, 
J = 6.4 Hz, 3H), 0.11 (s, 3H), 0.09 (s, 3H); 
13C NMR (100 MHz, CDCl3) δC 174.9, 148.9, 148.1, 143.1, 140.7, 136.7, 134.7, 134.3, 
129.3, 129.2, 126.8, 104.8, 104.4, 101.5, 76.6, 73.5, 67.8, 66.6, 64.0, 62.5, 61.3, 53.9, 48.9, 
38.2, 37.3, 26.0, 24.9, 24.7, 22.6, 21.5, 18.3, 14.2, 11.4, –4.4, –4.5 (four signals obscured or 
overlapping); 
IR (KBr) νmax 2953, 2927, 2865, 1727, 1475, 1331, 1246, 1162, 1090, 1041, 937, 878, 835, 
777, 664 cm–1; 
MS (ESI, +ve) m/z 745 (55%), 723 [(M+H)+, 100]; 
HRMS (ESI, +ve) (M + H)+, Calculated for C39H55N2O7SSi: 723.3499. Found: 723.3485. 
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(±)-(3aS,5R,5aS,6R,7aS,12bS)-Ethyl 5-((tert-Butyldimethylsilyl)oxy)-6-isobutyl-1-oxo-
3-tosyl-2,3,3a,4,5,5a,5a1,6,7,7a-decahydro-1H-[1,3]dioxolo[4',5':5,6]indeno[1,2,3-
cd]pyrrolo[3,2-e]isoindole-6-carboxylate [(±)-4.5] 
 
 
 
Step i: A magnetically stirred solution of compound 4.3 (150 mg, 0.210 mmol) in 
acetonitrile/water (15.0 mL of a 4:1 v/v mixture) maintained at 22 °C was treated with citric 
acid (99.0 mg, 0.510 mmol), N-methylmorpholine N-oxide (72.0 mg, 0.420 mmol) and 
potassium osmate dihydrate (8.00 mg, 0.0200 mmol). The ensuing mixture was stirred 
vigorously at 22 °C for 7 h then diluted with ethyl acetate (10.0 mL) and water (10.0 mL). 
The separated aqueous phase was extracted with ethyl acetate (2 × 10.0 mL) and the 
combined organic phases then washed with brine (1 × 20.0 mL) before being dried 
(MgSO4), filtered and concentrated under reduced pressure. The resulting light-brown oil 
was subject to flash chromatography (silica gel, 2% ammonia saturated methanol in 
dichloromethane) to afford, after concentration of the relevant fractions (Rf = 0.5 in 19:1 v/v 
dichloromethane/ammonia-saturated methanol), a clear, colourless oil. This material was 
subjected to step ii of the reaction sequence as detailed immediately below. 
 
Step ii: A solution of the oil obtained as described above in step i was dissolved in 
dichloromethane (1.50 mL) and the solution thus formed treated with iodobenzene 
diacetate (81.0 mg, 0.250 mmol). The ensuing mixture was stirred vigorously at 22 °C for 2 
h before being treated with TLC-grade silica gel (100 mg) then concentrated under reduced 
pressure. The resulting free-flowing solid was subjected to flash chromatography (silica 
gel, 4:1 v/v hexane/ethyl acetate) and concentration of the appropriate fractions (Rf = 0.6 in 
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7:3 v/v hexane/ethyl acetate) afforded the title compound 4.5 (119 mg, 79%) as white, 
crystalline solid, m.p. = 215-216 °C. 
1H NMR (400 MHz, CDCl3) δH 7.75 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 8.2 Hz, 2H), 6.69 (s, 
1H), 5.84 (m, 2H), 4.88 (s, 1H), 4.45 (d, J = 6.6 Hz, 1H), 4.32 (broadened s, 1H), 4.25-4.10 
(complex m, 1H), 4.11-3.97 (complex m, 2H), 3.93 (d, J = 1.7 Hz, 2H), 3.49 (m, 1H), 2.45 
(s, 3H), 2.32 (dd, J = 10.1 and 3.4 Hz, 1H), 2.05 (m, 1H), 1.91 (m, 1H), 1.87-1.72 (complex 
m, 3H), 1.67 (m, 1H), 1.27 (t, J = 7.2 Hz, 3H), 0.99 (d, J = 6.6 Hz, 3H), 0.88 (s, 9H), 0.82 
(d, J = 6.6 Hz, 3H), 0.99 (s, 3H), 0.97 (s, 3H); 
 13C NMR (100 MHz, CDCl3) δC 210.8, 174.2, 148.7, 147.7, 144.7, 140.0, 135.1, 134.7, 
130.3, 127.5, 105.6, 102.3, 101.5, 73.3, 65.6, 65.0, 63.0, 61.2, 60.2, 53.9, 52.9, 48.1, 47.7, 
34.4, 26.0, 24.8, 24.6, 23.1, 21.8, 18.6, 14.2, –4.6, –4.7 (four signals obscured or 
overlapping); 
 IR (KBr) νmax 2941, 2929, 2861, 1760, 1726, 1477, 1351, 1254, 1159, 1066, 1039, 941, 
834, 663, 586 cm–1; 
MS (ESI, +ve) m/z 733 (65%), 711 [(M+H)+, 100%]; 
HRMS (ESI, +ve) (M + H)+, Calculated for C37H51N2O8SSi: 711.3135. Found: 711.3127. 
 
(±)-(1S,3aS,5R,5aS,6R,7aS,12bS)-Ethyl 5-((tert-Butyldimethylsilyl)oxy)-1-hydroxy-6-
isobutyl-3-tosyl-2,3,3a,4,5,5a,5a1,6,7,7a-decahydro-1H-
[1,3]dioxolo[4',5':5,6]indeno[1,2,3-cd]pyrrolo[3,2-e]isoindole-6-carboxylate [(±)-4.6] 
 
 
 
A magnetically stirred solution of compound 4.5 (150 mg, 0.211 mmol) in methanol (10.0 
mL) maintained at 22 °C was treated with sodium borohydride (8.50 mg, 0.230 mmol) and 
the ensuing mixture stirred for 0.5 h then diluted with ethyl acetate (10.0 mL) and water 
(5.00 mL). The separated aqueous phase was extracted with ethyl acetate (2 × 10.0 mL) and 
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the combined organic phases were washed with brine (1 × 20.0 mL) before being dried 
(MgSO4), filtered and concentrated under reduced pressure. The resulting clear, colourless 
oil was subjected to flash chromatography (silica gel, 4:1 v/v hexane/ethyl acetate) and 
concentration of the appropriate fractions (Rf = 0.3 in 7:3 v/v hexane/ethyl acetate) afforded 
the title compound 4.6 (134 mg, 89%) as white, crystalline solid, m.p. = 218-219 °C. 
 
1H NMR (400 MHz, CDCl3) δH 7.77 (d, J = 8.2 Hz, 2H), 7.37 (d, J = 8.2 Hz, 2H), 6.68 (s, 
1H), 5.85 (m, 2H), 4.93 (s, 1H), 4.60 (d, J = 7.7 Hz, 1H), 4.39 (m, 1H), 4.20 (m, 1H), 3.85-
3.78 (complex m, 1H), 3.78-3.70 (complex m, 1H), 3.70-3.61 (complex m, 1H), 3.54 (m, 
1H), 3.11 (dd, J = 10.8 and 7.8 Hz, 1H), 2.97 (t, J = 9.2 Hz, 1H), 2.46 (s, 3H), 2.38-2.32 
(complex m, 2H), 1.98 (dd, J = 14.1 and 5.4 Hz, 1H), 1.69 (m, 1H), 1.60 (m, 1H), 1.43 (m, 
1H), 1.13 (t, J = 7.2 Hz, 3H), 0.95 (d, J = 6.6 Hz, 3H), 0.90 (s, 9H), 0.82 (d, J = 6.6 Hz, 
3H), 0.12 (s, 3H), 0.09 (s, 3H) (signal due to N-H and O-H protons not observed); 
 13C NMR (100 MHz, CDCl3) δC 174.2, 148.4, 148.3, 144.5, 138.9, 134.7, 133.9, 130.1, 
127.8, 105.5, 103.3, 101.5, 78.6, 71.0, 66.5, 65.7, 62.9, 60.8, 58.3, 57.8, 51.9, 50.7, 48.3, 
39.3, 26.2, 25.4, 24.2, 24.1, 21.8, 18.3, 14.0, –3.5, –3.9 (four signals obscured or 
overlapping); 
 IR (KBr) νmax 3499, 2953, 2929, 2858, 1720, 1598, 1474, 1347, 1256, 1159, 1067, 1039, 
940, 833, 665 cm–1; 
MS (ESI, +ve) m/z 735 (51%), 713 [(M+H)+, 100]; 
HRMS (ESI, +ve) (M + H)+, Calculated for C37H53N2O8SSi: 713.3292. Found: 713.3291. 
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(±)-(1S,3aS,5R,5aS,6R,7aS,12bS)-Ethyl 5-((tert-Butyldimethylsilyl)oxy)-6-isobutyl-1-
(((methylthio)carbonothioyl)oxy)-3-tosyl-2,3,3a,4,5,5a,5a1,6,7,7a-decahydro-1H-
[1,3]dioxolo[4',5':5,6]indeno[1,2,3-cd]pyrrolo[3,2-e]isoindole-6-carboxylate [(±)-4.7] 
 
 
 
A magnetically stirred solution of alcohol 4.6 (50.0 mg, 0.0700 mmol) in dry 
tetrahydrofuran (10.0 mL) maintained at 0 °C under a nitrogen atmosphere was treated with 
sodium hydride (2.00 mg of a 60% dispersion in mineral oil, 0.0830 mmol). After 0.25 h 
carbon disulfide (100 µL, 1.70 mmol) then methyl iodide (110 µL, 1.70 mmol) were added 
to the reaction mixture. The ensuing mixture was allowed to warm to 22 °C and stirred for 
1 h at this temperature before being treated with water (10.0 mL) then extracted with ethyl 
acetate (3 × 10.0 mL). The combined organic phases were washed with brine (1 × 20.0 mL) 
then dried (MgSO4), filtered and concentrated under reduced pressure. The resulting yellow 
oil was subjected to flash chromatography (silica gel, 4:1 v/v hexane/ethyl acetate) and 
concentration of the appropriate fractions (Rf = 0.7 in 7:3 v/v hexane/ethyl acetate) afforded 
the title compound 4.7 (52.0 mg, 92%) as colourless oil.  
 
1H NMR (400 MHz, CDCl3) δH 7.75 (d, J = 8.2 Hz, 2H), 7.36 (d, J = 8.0 Hz, 2H), 6.65 (s, 
1H), 5.85 (dd, J = 9.4, 1.4 Hz, 2H), 5.76 (t, J = 5.9 Hz, 1H), 5.38 (s, 1H), 4.59 (d, J = 7.5 
Hz, 1H), 4.36 (dt, J = 8.3, 4.2 Hz, 1H), 4.08 (dd, J = 11.1, 6.0 Hz, 1H), 3.93-3.84 (complex 
m, 1H), 3.76-3.66 (complex m, 2H), 3.36 (dd, J = 11.1, 5.9 Hz, 1H), 3.07 (dd, J = 10.9, 7.5 
Hz, 1H), 2.45 (s, 3H), 2.39 (dd, J = 10.9, 4.8 Hz, 1H), 2.13 (s, 3H), 2.08-1.92 (complex m, 
3H), 1.60 (dt, J = 12.8, 6.5 Hz, 1H), 1.52-1.41 (complex m, 1H), 1.14 (t, J = 7.2 Hz, 3H), 
0.96 (d, J = 6.6 Hz, 3H), 0.91 (s, 9H), 0.82 (d, J = 6.6 Hz, 3H), 0.14 (s, 3H), 0.11 (s, 3H) 
(signal due to N-H group proton not observed); 
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 13C NMR (100 MHz, CDCl3) δC 214.62, 174.06, 147.87, 147.83, 144.15, 137.46, 135.71, 
134.04, 129.98, 127.60, 104.94, 103.87, 101.21, 86.86, 71.22, 65.68, 65.64, 61.64, 60.65, 
57.04, 56.23, 49.96, 49.41, 48.84, 36.11, 26.07, 25.16, 24.08, 23.82, 21.63, 18.44, 18.23, 
13.86, –3.99, –4.39 (four signals obscured or overlapping); 
IR (KBr) νmax 3499, 2953, 2929, 2858, 1720, 1598, 1474, 1347, 1256, 1159, 1067, 1039, 
940, 833, 665 cm–1; 
MS (ESI, +ve) m/z 735 (51%), 713 [(M+H)+, 100]; 
HRMS (ESI, +ve) (M + H)+, Calculated for C37H53N2O8SSi: 713.3292. Found: 713.3291. 
 
(±)-(3aS,5R,5aS,6R,7aS,12bR)-Ethyl 5-((tert-Butyldimethylsilyl)oxy)-6-isobutyl-3-
tosyl-2,3,3a,4,5,5a,5a1,6,7,7a-decahydro-1H-[1,3]dioxolo[4',5':5,6]indeno[1,2,3-
cd]pyrrolo[3,2-e]isoindole-6-carboxylate [(±)-4.8] 
 
 
 
A magnetically stirred solution of xanthate 4.7 (52.0 mg, 0.0650 mmol) in benzene (5.00 
mL) and the resulting solution deoxygenated using nitrogen then treated with 2,2’-
azobis(iso-butyronitrile) (3.50 mg, 0.0200 mmol), tri-n-butyltin hydride (37.0 µL, 0.140 
mmol) before being heated under reflux for 1 h. The cooled reaction mixture was 
concentrated under reduced pressure and the residue thus obtained subjected to flash 
chromatography (silica, 4:1 v/v hexane/ethyl acetate). Concentration of the appropriate 
fractions (Rf = 0.4 in 7:3 v/v hexane/ethyl acetate) gave compound 4.8 (33.0 mg, 73%) as 
clear, colourless oil.  
 
1H NMR (400 MHz, CDCl3) δH 7.79 (d, J = 8.2 Hz, 2H), 7.37 (d, J = 8.2 Hz, 2H), 6.64 (s, 
1H), 5.82 (m, 2H), 4.88 (s, 1H), 4.61 (d, J = 7.5 Hz, 1H), 4.40 (m, 1H), 3.90-3.79 (complex 
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m, 1H), 3.67 (m, 1H), 3.58 (m, 1H), 3.42 (dd, J = 10.4 and 4.6 Hz, 1H), 3.23 (m, 1H), 3.00 
(dd, J = 10.8 and 7.9 Hz, 1H), 2.47 (s, 3H), 2.35 (m, 2H), 2.14 (m, 1H), 1.99 (dd, J = 14.1 
and 5.4 Hz, 1H), 1.72-1.56 (complex m, 3H), 1.44 (m, 1H), 1.13 (t, J = 7.2 Hz, 3H), 0.97 
(d, J = 6.6 Hz, 3H), 0.90 (s, 9H), 0.83 (d, J = 6.6 Hz, 3H), 0.13 (s, 3H), 0.11 (s, 3H) (signal 
due to N-H group proton not observed); 
13C NMR (100 MHz, CDCl3) δC 174.1, 148.1, 147.3, 144.1, 142.0, 135.2, 134.3, 129.9, 
127.5, 104.9, 102.0, 101.1, 70.9, 66.5, 65.7, 63.5, 60.6, 58.0, 54.5, 51.9, 48.2, 46.7, 41.9, 
39.3, 26.0, 25.3, 24.0(4), 23.9(9), 21.6, 18.2, 13.8, –3.6, –4.1 (four signals obscured or 
overlapping); 
IR (KBr) νmax 2951, 2928, 2860, 1721, 1474, 1347, 1258, 1162, 1040, 862, 836, 665 cm-1; 
MS (ESI, +ve) m/z 697 [(M+H)+, 72%,], 245 (100); 
HRMS (ESI, +ve)  (M + H)+, Calculated for C37H53N2O7SSi: 697.3343. Found: 697.3345. 
 
(±)-(3aS,5R,5aS,6R,7aS,12bR)-Ethyl 5-Hydroxy-6-isobutyl-2,3,3a,4,5,5a,5a1,6,7,7a-
decahydro-1H-[1,3]dioxolo[4',5':5,6]indeno[1,2,3-cd]pyrrolo[3,2-e]isoindole-6-
carboxylate [(±)-4.9] 
 
 
 
A solution of compound 4.8 (50.0 mg, 0.0700 mmol) in methanol (10.0 mL) maintained at 
22 °C under a nitrogen atmosphere was treated with magnesium metal (20.0 mg, 0.820 
mmol). The ensuing mixture was subject to sonication for 0.5 h in an ultrasonic cleaning 
bath operating at 50 kHz bath then quenched with hydrochloric acid (5.00 mL of a 3 M 
aqueous solution) before being stirred magnetically for 0.25 h then partitioned between 
water (10.0 mL) and ethyl acetate (10.0 mL). The separated aqueous phase was extracted 
with ethyl acetate (3 × 10 mL) and the combined organic phases were washed with brine (1 
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× 10.0 mL) then dried (MgSO4), filtered and concentrated under reduced pressure. The 
resulting yellow oil was subjected to flash chromatography (silica, 19:1 v/v 
dichloromethane/ammonia-saturated methanol) and concentration of the appropriate 
fractions (Rf = 0.2 in 9:1 v/v dichloromethane/ammonia-saturated methanol) afforded the 
title compound 4.9 (23.0 mg, 75%) as clear, colourless oil.  
 
1H NMR (400 MHz, CDCl3) δH 6.78 (s, 1H), 6.52 (s, 1H), 5.93 (m, 2H), 4.76 (d, J = 7.8 
Hz, 1H), 3.95-3.80 (complex m, 3H), 3.57 (t, J = 4.6 Hz, 1H), 3.17-3.06 (complex m, 2H), 
3.01 (dd, J = 10.9 and 7.8 Hz, 1H), 2.52 (dd, J = 11.0 and 4.0 Hz, 1H), 2.04 (dd, J = 13.8 
and 5.8 Hz, 1H), 1.94 (t, J = 7.0 Hz, 2H), 1.82 (m, 1H), 1.68-1.51 (complex m, 3H), 1.16 (t, 
J = 7.2 Hz, 3H), 1.00 (d, J = 6.6 Hz, 3H), 0.87 (m, 1H), 0.83 (d, J = 6.4 Hz, 3H) (signals 
due to O-H and N-H group protons not observed); 
13C NMR (100 MHz, CDCl3) δC 175.0, 148.4, 147.5, 141.4, 136.4, 105.4, 102.3, 101.3, 
72.8, 67.0, 66.4, 61.5, 60.9, 57.2, 52.9, 50.2, 49.7, 46.1, 44.5, 31.6, 25.4, 24.3, 23.7, 14.0; 
 IR (KBr) νmax 3319, 2943, 2862, 1719, 1476, 1368, 1319, 1252, 1229, 1147, 1039, 939, 
862, 731 cm–1; 
MS (ESI, +ve) m/z 429 [(M+H)+, 100%]; 
HRMS (ESI, +ve)  (M + H)+, Calculated for C24H33N2O5: 429.2389. Found: 429.2389. 
 
(±)-Gracilamine [(±)-1.1] 
 
 
 
A magnetically stirred solution of compound 4.9 (23.0 mg, 0.0540 mmol) in acetonitrile 
(10.0 mL) was treated with formaldehyde (4.50 µL of a 35% w/w aqueous solution, 0.0500 
mmol) and sodium cyanoborohydride (3.30 mg, 0.0500 mmol). The resulting mixture was 
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stirred at room temperature for 0.25 h then quenched with NaHCO3 (10.0 mL of a saturated 
aqueous solution). The separated aqueous phase was extracted with ethyl acetate (3 × 20.0 
mL) and the combined organic phases were washed with brine (1 × 20.0 mL) before being 
dried (MgSO4), filtered and concentrated under reduced pressure. The resulting brown oil 
was subjected to flash chromatography (silica gel, 98:2 v/v dichloromethane/ammonia-
saturated methanol) and concentration of the appropriate fractions (Rf = 0.7 in 9:1 v/v 
dichloromethane/ammonia-saturated methanol) afforded compound (±)-1.1 (15.1 mg, 63%) 
as a colourless, crystalline solid, m.p. = 212-213 °C (lit.22 m.p. = 188-191 °C). 
 
1H NMR (700 MHz, CD3OD) δH 6.85 (s, 1H), 6.67 (s, 1H), 5.93 (m, 2H), 4.65 (d, J = 8.0 
Hz, 1H), 4.00-3.95 (complex m, 2H), 3.41 (m, 1H), 3.15 (dd, J = 9.9 and 8.0 Hz, 1H), 3.11 
(m, 1H), 2.81 (broadened s, 1H), 2.56 (m, 1H), 2.48 (s, 3H), 2.27 (dd, J = 9.9 and 8.8 Hz, 
1H), 2.03 (m, 1H), 1.96 (m, 2H), 1.84 (m, 1H), 1.73 (m, 1H), 1.65 (dd, J = 14.1 and 5.4 Hz, 
1H), 1.54 (m, 1H), 1.21 (t, J = 7.2 Hz, 3H), 1.01 (d, J = 6.7 Hz, 3H), 0.86 (d, J = 6.7 Hz, 
3H) (signals due to hydroxyl and amine group protons not observed); 
 13C NMR (175 MHz, CD3OD) δC 175.8, 150.1, 149.1, 144.4, 136.4, 105.8, 103.7, 102.7, 
74.2, 71.3, 67.7, 66.5, 62.1, 58.8, 56.6, 55.6, 54.7, 47.7, 45.3, 40.8, 35.5, 26.3, 24.9, 23.6, 
14.1; 
 IR (KBr) νmax 3331, 2947, 2865, 2784, 1721, 1501, 1476, 1368, 1232, 1145, 1038, 940, 
861 cm–1; 
MS (ESI, +ve) m/z 465 (15%), 443 [(M+H)+, 100]; 
HRMS (ESI, +ve)  (M + H)+, calculated for C25H35N2O5: 443.2546. Found: 443.2547. 
 
 
 
 
 
 
 
 
	 122 
																																								 																				 	
1 N. Ünver, G. İ. Kaya, Turk. J. Chem., 2005, 29, 547. 
  
2 S. Tian, W. Zi, D. Ma,  Angew. Chem. Int. Ed., 2012, 51, 10141. 
  
3 For recent reviews, see: a) M. Kitajima, H. Takayama, Top. Curr. Chem., 2012, 309, 1; b) 
Z. Jin, Nat. Prod. Rep., 2007, 24, 886; c) N. Unver, Phytochem. Rev., 2007, 6, 125; d) Z. 
Jin, Nat. Prod. Rep., 2005, 22, 111; e) A. Evidente, A. Kornienko, Phytochem. Rev., 2009, 
8, 449. 
 
4 For useful points-of-entry into the literature on the history, chemistry and pharmacology 
of galanthamine, see: a) M. Heinrich, H. L. Teoh, J. Ethnopharmacol., 2004, 92, 147; b) J. 
Marco-Contelles, M. do Carmo Carreiras, C. Rodríguez, M. Villarroya, A. G. García, 
Chem. Rev., 2006, 106, 116; c) L. Marco, M. do Carmo Carreiras, Recent Pat., CNS Drug 
Discovery, 2006, 1, 105; d) M. Heinrich, Alkaloids, 2010, 68, 157. 
 
5 a) A. Mclachlan, N. Kekre, J. McNulty and S. Pandey, Apoptosis., 2005, 10, 619-630. 
b) N. Kekre, C.Griffin, J. McNulty and S. Pandey, Cancer Chemother. Pharmacol., 2005, 
56, 29-38.  
 
6 G. R. Pettit, N. Melody, J. Nat. Prod., 2005, 68, 207-211.  
 
7 S. Kodama, H. Takita, T. Kajimoto, K. Nishide and M. Node, Tetrahedron, 2004, 60, 
4901. 
 
8 I. Coldham, R.Hufton, Chem. Rev., 2005, 105, 2765. 
 
9 Y. Shi, B. Yang, S. Cai, S. Gao, Angew. Chem., Int. Ed., 2014, 53, 9539. 
 
10 H.W. Sünnemann, A. Hofmeister, J. Magull, Chem. Eur. J., 2007, 13, 3739. 
 
11 S. Cai, Z. Xiao, Y. Shi, S. Gao, Chem. Eur. J., 2014, 20, 8677. 
 
12 Y. Ito, T. Hirao, and T. Saegusa, J. Org. Chem., 1978, 43, 1011. 
 
13 S. Bose, J. Yang, Z.-X. Yu, J. Org. Chem., 2016, 81, 6757 
 
14 L. Jiao, M. Lin, L.-G. Zhuo, Z.-X.Yu, Org. Lett., 2010, 12, 2528. 
 
15 J.-C. Hsieh, A.-Y. Cheng, J.-H. Fu, T.-W. Kang, Org. Biomol. Chem., 2012, 10, 6404. 
 
16 R. V. Stevens, L. E. Dupree, P. L. Loewenstein, J. Org. Chem., 1972, 37, 977. 
 
17 Z. Elkhayat, I. Safir, I. Castellote, P. Retailleau, S. Arseniyadis, Org. Lett., 2008, 10, 
2219. 
 
	 123 
																																								 																																								 																																								 																																								 																								 	
18 E. J. Corey, C. J. Helal, Angew. Chem., Int. Ed., 1998, 37, 1986. 
19 P. Gan, M. W. Smith, N. R. Braffman, S. A. Snyder, Angew.Chem., Int. Ed., 2016, 55, 
3625. 
 
20 K. Afarinkia, M. J. Bearpark, A. Ndibwami, J. Org. Chem., 2003, 68, 7158. 
 
21 For details, see supporting information of reference 19. 
 
22 J. H. Rigby, A. Cavezza, M. J. Heeg, J. Am. Chem. Soc., 1998, 120, 3664. 
 
23 W. G. Salmond, M. A. Barta, J. L. Havens, J. Org. Chem., 1978, 43, 2057. 
 
24 J. E. Toth, P. L. Fuchs, J. Org. Chem., 1987, 52, 473. 
 
25 M. González-Esguevillas, A. Pascual-Escudero, J. Adrio, J. C. Carretero, Chem. Eur. J., 
2015, 21, 4561. 
 
26 G. Pandey, P. Banerjee, R. S. Gadre, Chem. Rev., 2006, 106, 4484. 
 
27 N. Gao, X. Ma, L. Petit, B. Z. Schwartz, M. G. Banwell, A. C. Will, I. A. Cade, A. D. 
Rae, Aust. J. Chem., 2013, 66, 30. 
  
28 A. L. Lehmann, A. C. Willis, M. G. Banwell, Aust. J. Chem., 2010, 63, 1665. 
  
29 M. G. Banwell, D. A. S. Beck, P. C. Stanislawski, M. O. Sydnes, R. M. Taylor, Curr. 
Org. Chem., 2005, 9, 1589. 
 
30 N. Miyaura, T. Yanagi, A. Suzuki, Synth. Commun., 1981, 11, 513. 
 
31 For a review see: A. L. Crisp, J. Li, P. Lan, J. Nugent, E. Matoušová, M. G. Banwell, 
Aust. J. Chem., 2015, 68, 1183. 
 
32 (a) L. Petit, M. G. Banwell, A. C. Willis, Org. Lett., 2011, 13, 5800.  (b) J. Nugent, E. 
Matoušová, M. G. Banwell, Eur. J. Org. Chem., 2015, 3771. 
 
33 B. M. Trost, Acc. Chem. Res.,1990, 23, 34. 
 
34 C.-K. Sha, S.-J. Huang, Z.-P. Zhan, J. Org. Chem., 2002, 67,831. 
 
35 R. K. Crossland, K. L. Servis, J. Org. Chem., 1970, 35, 3195. 
 
36 B. D. Schwartz, M. G. Banwell, I. A. Cade, Tetrahedron Lett., 2011, 52, 4526. 
 
37 P. C. Conrad, P. L. Kawiatkowski, P. L. Fuchs, J. Org. Chem., 1987, 52, 586. 
 
	 124 
																																								 																																								 																																								 																																								 																								 	
38 A. E. Håkansson, A. Palmelund, H. Holm and R. Madsen, Chem. Eur. J., 2006, 12, 3243. 
 
39 B. M. Trost, C. Pedregal, J. Am. Chem. Soc., 1992, 114, 7292. 
 
40 J. P. Schaefer, J. C. Lark, C. A. Flegal, L. M. Honig, J. Org. Chem., 1967, 32, 1967. 
 
41 T. K. M. Shing, Y.-Y. Yeung, P. L. Su, Org. Lett., 2006,8, 3149. 
 
42 K. A. B. Austin, M. G. Banwell, A. C. Willis, Org. Lett., 2008, 10, 4465. 
 
43 (a) T. M. Trnka, R. H. Grubbs, Acc. Chem. Res., 2001, 34, 18. (b) A. Fürstner, Angew. 
Chem., Int. Ed., 2000, 39, 3012. (c) S. J. Connon, S. Blechert, Angew. Chem., Int. Ed., 
2003, 42, 1900. (d) K. C. Nicolaou, P. G. Bulger, D. Sarlah, Angew. Chem., Int. Ed., 2005, 
44, 4490. 
 
44 P. Schwab, R. H. Grubbs, J. W. Ziller, J. Am. Chem. Soc., 1996, 118, 100. 
 
45 M. Makosza, Pure Appl. Chem., 1975, 43, 439. 
 
46 (a) P. Dupau, R. Epple, A. A. Thomas, V. V. Fokin, K. B. Sharpless, Adv. Synth. Catal., 
2002, 344, 421. (b) A. Ell, A. Closson, H. Adolfsson, J.-E. Bäckvall, Adv. Synth. Catal., 
2003, 345, 1012. 
 
47 K. C. Nicolaou, V. A. Adsool, C. R. H. Hale, Org. Lett., 2010, 12, 1552. 
 
48 E. Mosettig, R. Mozingo, Org. React., 2011, 362-377. 
 
49 D. H. R. Barton, D. A. J. Ives, and B. R. Thomas, J. Am. Chem. Soc (Resumed)., 1955, 
2056. 
 
50 L. Caglioti, M. Magi, Tetrahedron, 1963, 19, 1127-1131.  
 
51 R. Schwarz, H. Hering, Org. Synth, 1953, 33, 17. 
 
52 T. Fukuyama, C.-K. Jow, M. Cheung, Tetrahedron Lett., 1995, 36, 6373. 
 
53 H. Hauth, D. Stauffacher, Helv. Chim. Acta., 1964, 47, 185. 
 
54 (a) C. F. Murphy, W. C. Wildman, Tetrahedron Lett., 1964, 5, 3857. (b) W. C. Wildman, 
D. T. Bailey, J. Org. Chem., 1968, 33, 3749. 
 
55 N. Unver, S. Noyan, T. Gözler, M. A. Onur, B. Gözler, M. Hesse, Planta Med. 1999, 65, 
347. 
 
	 125 
																																								 																																								 																																								 																																								 																								 	
56 (a) L.-Z. Lin, S.-F. Hu, H.-B. Chai, T. Pengsuparp, J. M. Pezzuto, G. A. Cordell, N. 
Ruangrungsi, Phytochemistry., 1995, 40, 1295. (b) S. Berkov, J. Bastida, B. Sidjimova, F. 
Viladomat, C. Codina, Biochem. Syst. Ecol., 2008, 36, 638. (c) S. Berkov, J. Bastida, B. 
Sidjimova, F. Viladomat, C. Codina, Chem. Biodiversity., 2011, 8, 115. (d) C. Iannello, J. 
Bastida, F. Bonvicini, F. Antognoni, G. A. Gentilomi, F. Poli, Nat. Prod. Res., 2014, 28, 
704. (e) N. Cortes, R. A. Posada- Duque, R. Alvarez, F. Alzate, S. Berkov, G. P. Cardona-
Gómez, E. Osorio, Life Sci., 2015, 122, 42. (f) C. G. Guerrieri, N. B. Pigni, J. P. de 
Andrade, V. D. dos Santos, F. Binns, W. de Souza Borges, F. Viladomat, J.  Bastida, 
Arabian J. Chem., 2016, 9, 688. 
 
57 K. Isobe, J. Taga, Y. Tsuda, Tetrahedron Lett., 1976, 17, 2331. 
 
58 K. B. Sharpless, R. F. Lauer, J. Org. Chem., 1974, 39, 427. 
 
59 Y. Tsuda, T. Sano, H. Watanabe, Synthesis, 1977, 652-654. 
 
60 R. G. Kalkhambkar, H. M. Savanur, RSC Adv. 2015, 5, 60106. 
 
61 H. B. Bürgi, J. D. Dunitz, J. M. Lehn, G. Wipff, Tetrahedron., 1974, 30, 1563. 
 
62 For a useful review on the chemistry of bridged lactams and related heterocycles, see: M. 
Szostak, J. Aubé, Chem. Rev., 2013, 113, 5701. 
 
63  The following reagent/solvent combinations were used in attempts to effect this O-
methylation: (i) MeI, NaH, THF; (ii) MeI, NaH, DMF; (iii) MeI, Ag2O, THF; (iv) 
(MeO)2SO2, K2CO3, THF. Either no reaction or decomposition of the substrate was 
observed in each instance. 
 
64 D. Crich, L. Quintero, Chem. Rev., 1989, 89, 1413. 
 
65  A. B. Pangaborn, M. A. Giardello, R. H. Grubbs, R. K. Rosen, F. J. Timmers, 
Organometallics., 1996, 15, 1518. 
 
66 W. C. Still, M. Kahn, A. Mitra, J. Org. Chem. 1978, 43, 2923. 
 
67 C.-K. Sha, S.-J. Huang, Z.-P. Zhan, J. Org. Chem. 2002, 67, 831. 
 
68 L. Zhao, X. Lu, W. Xu, J. Org. Chem., 2005, 70, 4059. 
 
69 (a) P. Dupau, R. Epple, A. A. Thomas, V. V. Fokin, K. B. Sharpless, Adv. Synth. Catal., 
2002, 344, 421. (b) A. Ell, A. Closson, H. Adolfsson, J.-E. Bäckvall, Adv. Synth. Catal., 
2003, 345, 1012. 
	
